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ABSTRACT 
Modern healthcare research demands collaboration across disciplines to build 
preventive measures and innovate predictive capabilities for curing diseases. Along with 
the emergence of cutting-edge computational and statistical methodologies, data 
generation and analysis has become cheaper in the last ten years. However, the 
complexity of big data due to its variety, volume, and velocity creates new challenges for 
biologists, physicians, bioinformaticians, statisticians, and computer scientists. 
Combining data from complex multiple profiles is useful to better understand cellular 
functions and pathways that regulates cell function to provide insights that could not 
have been obtained using the individual profiles alone. However, current normalization 
and artifact correction methods are platform and data type specific, and may require 
both the training and test sets for any application (e.g. biomarker development). This 
often leads to over-fitting and reduces the reproducibility of genomic findings across 
studies. In addition, many bias correction and integration approaches require 
renormalization or reanalysis if additional samples are later introduced. The motivation 
behind this research was to develop and evaluate strategies for addressing data 
integration issues across data types and profiling platforms, which should improve 
healthcare-informatics research and its application in personalized medicine. We have 
	  	   vii	  
demonstrated a comprehensive and coordinated framework for data standardization 
across tissue types and profiling platforms.  This allows easy integration of data from 
multiple data generating consortiums. The main goal of this research was to identify 
regions of genetic-epigenetic co-ordination that are independent of tissue type and 
consistent across epigenomics profiling data platforms. We developed multi-‘omic’ 
therapeutic biomarkers for epigenetic drug efficacy by combining our biomarker regions 
with drug perturbation data generated in our previous studies. We used an adaptive 
Bayesian factor analysis approach to develop biomarkers for multiple HDACs 
simultaneously, allowing for predictions of comparative efficacy between the drugs. We 
showed that this approach leads to different predictions across breast cancer subtypes 
compared to profiling the drugs separately. We extended this approach on patient 
samples from multiple public data resources containing epigenetic profiling data from 
cancer and normal tissues (The Cancer Genome Atlas, TCGA; NIH Roadmap 
epigenomics data). 
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Chapter 0 Introduction 
0.A Big data challenges in biomedical research 	  
Modern healthcare infrastructure and research approaches encourage collaboration 
across disciplines to address predictive and preventive measures towards curing 
disease. Example of this multi-disciplinary approach can be seen in recent progress and 
achievements in bioinformatics, clinical informatics and big data applications in 
biomedical research. Along with the emergence of cutting-edge computational and 
statistical methodologies, data generation and analysis has become cheaper over the 
last ten years. However, the complexity of big data due to its variety, volume, and 
velocity has led to new challenges that are now faced by biologists, physicians, 
bioinformaticians, statisticians, and computer scientists [1]. For example, integrating data 
across different profiling platforms is difficult due to the fact that they introduce different 
technological biases and produce data with different shapes and scales. Specifically, 
gene expression microarrays typically measure transcription levels on a continuous (log) 
intensity scale, whereas RNA sequencing measures the same biological phenomena 
using over-dispersed and zero-inflated count data. Data from genome-wide DNA 
methylation studies experience even broader variation, due to the combination of next-
generation sequencing or tiling array profiling with techniques such as bisulfite 
conversion (e.g. BS-seq or BeadChip Arrays), enrichment of methylated DNA using 
immunoprecipitation (MeDIP) or restriction digestion (MRE), or using a combination of 
these approaches (e.g. RRBS). Although these profiling combinations generate 
heterogeneous data, the goal of these approaches is the same— to estimate the level of 
DNA methylation across the genome. Furthermore, due to the high cost of these 
experiments in both personnel and monetary expense, these datasets are often 
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processed in small batches, at different times, and in different facilities. This proves to be 
a challenge to researchers trying to take advantage of massive data resources, as the 
data generated across different profiling platforms require standardized preprocessing, 
platform-specific bias correction, and downstream analysis approaches that handle 
heterogeneous profiling data from these different approaches. 
0.B Big Data Consortiums: 
 
Big data consortiums, such as The Cancer Genome Atlas (TCGA) [2], NIH Roadmap 
Epigenomics Data [3], and International Human Epigenomics Consortium (IHEC) [4], 
have generated and continue to generate large volumes of genomics, epigenomics, and 
complex patient data across a variety of profiling platforms. These massive data sets 
can be used for many purposes, including understanding basic biological functions, 
classifying molecular subtype of disease, characterizing disease etiology, predicting 
disease prognosis and severity. Initially, the majority of these studies have been 
completed using microarray platforms, but sequencing platforms are now common for 
many applications. 
Combining data from these complex multiple profiles is useful to better understand 
cellular functions and pathways that regulate cell function, and gain additional insights 
that could not be obtained using the individual profiles alone. Furthermore, using multiple 
data types can help to filter out false positive findings that arise due to anecdotes in one 
particular profiling data set or due to platform-specific limitations. However, current 
normalization and artifact correction methods are platform and data type specific, and 
may require both the training and test sets for application (e.g. biomarker development). 
This often leads to over-fitting and reduces the reproducibility of genomic findings across 
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studies. In addition, many bias correction and integration approaches require 
renormalization or reanalysis if additional samples are later introduced. The motivation 
behind this research is to develop and evaluate strategies for biomedical data integration 
issues across different data types and profiling platforms with emphasis on improving 
healthcare-informatics research and their application in personalized medicine. To 
resolve these issues, we have demonstrated a comprehensive and coordinated 
framework for data standardization across tissue types, and profiling platforms, and for 
the integration of data from multiple large-data generating consortiums. 
The end goal of this project is to identify regions of genetic-epigenetic co-regulation that 
are independent of tissue type and consistent across epigenomic profiling data 
platforms. Our particular focus is across epithelial cell types to identify core epigenetic 
“biomarker regions” that consistently co-regulate across these and other tissue types. 
The identification of these biomarker regions will enable the development and 
application of uniform biomarkers that are independent of genomic data platform and cell 
type. To test the robustness of these core biomarker regions in a clinically relevant 
application, we developed multi-‘omic’ therapeutic biomarkers for epigenetic drug 
efficacy by combining our biomarker regions with drug perturbation data generated in 
our previous studies. We extended this approach on patient samples from multiple public 
data resources containing epigenetic profiling data from cancer and normal tissues (The 
Cancer Genome Atlas, TCGA and NIH Roadmap epigenomics data). 
0.C. Standardizing data across platform and data type: 
In prior work in our lab, we developed a novel genomic ‘barcoding’ approach: Universal 
ExPression Code (UPC) that classifies genomic features as ‘active/present’ or 
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‘inactive/absent’ and improves researchers’ ability to integrate data across data types, 
genomic profiling platforms, and across multiple studies [5]. Our barcoding approach can 
support data from any array or sequencing based high-throughput profiling platform, 
including applications profiling mRNA and miRNA expression. However, it has only been 
thoroughly tested for mRNA applications. In a previous comparison in gene expression 
analysis, we were able to identify a large subset of genes for which our barcode values 
are ~98% concordant across replicate samples profiled on microarray and sequencing 
platforms [5]. In this research, we extend this idea to chromatin immunoprecipitation 
(ChIP, MeDIP), restriction enzyme digestion (MRE, DNase), and bisulfite conversion 
(BeadChip arrays). Our barcoding approach provides the powerful advantage of being 
interpreted consistently, irrespective of profiling technology, thus enabling platform-
agnostic downstream analysis pipelines to be developed. This approach will not only 
benefit the proposed work, but also will be advantageous to individuals trying to combine 
data across multiple studies, to large-scale data projects where data are being 
generated on multiple platforms, or where researchers are transitioning to newer 
technologies. 
0.D. Platform and data type independent ‘biomarker regions: 	  
Complex diseases such as cancer are typically associated with altered or deregulated 
pathways and many modern cancer drugs are designed to target specific molecules or 
signaling pathways involved in tumor growth and metastasis. Even with the recent 
accumulation of high-throughput genomic data, profiling disease-causing pathway 
activity in patients remains a challenge due to the lack of cell- or tissue- independent 
pathway annotation and efficient computational tools. Addressing this challenge can 
provide guidance for the development of more personalized therapeutic regimes. We 
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leveraged the reference maps from the Epigenetics Roadmap project to identify 
‘biomarker regions’ of coordinate regulation across multiple genome profiling data types. 
We identified these regions across all tissue types and also targeted subtypes (lung, 
breast, brain, heart, lung, liver, small intestine). Because UPCs standardize all data 
types to the same (0,1) scale with the same interpretation (probability that a feature is 
‘active/present’), barcoding provides a straightforward platform to determine epigenetic 
modifiers and their co-regulation across multiple cell types and diverse data platforms. 
This approach further allows for the development of downstream visualization, 
classification, and analysis tools that are data type and platform independent. 
 
0.E Robust multi-‘omic’ signatures of epigenetic drug responsiveness: 
We build off our previous success in developing biomarkers using multiple genomic data 
types as well as our experience in developing biomarkers for epigenetic drug efficacy [6, 
7] to develop robust tissue and data type independent biomarkers for drugs that target 
epigenetic pathways. We will combine these regions with data from our own 
experimental perturbations to develop robust multi-‘omic’ biomarkers of epigenomic drug 
efficacy. We focused our efforts valproic acid (VPA), an HDAC inhibitor, which is of 
considerable interest because it is oral, already FDA-approved for treatment of epilepsy, 
and well tolerated over the long term. The low toxicity of VPA makes it an ideal 
candidate to its potential in the treatment of selected patients most likely to respond. 
VPA is currently being studied in clinical trials against breast, lung, ovarian, thyroid, 
melanoma, prostate, and cervical cancers [8]. The fact that this drug is being tested 
against so many different cancers without a clear indication of potential efficacy 
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highlights the need for a more targeted approach to finding the populations of patients 
who will respond. We validated our biomarker and predict individual drug efficacy on 
samples from existing data resources (TCGA, ICBP). 
Summary of upcoming chapters in this thesis: 
In chapter 1, we developed signatures of HDAC efficacy using both gene expression and 
DNA methylation, and validated them in mouse xenograft samples. We also identified a 
40-gene multi-omic biomarker that works for both methylation and gene expression; our 
biomarker produces highly concordant efficacy predictions between these datatypes 
(correlation 0.93) in an independent validation in TCGA samples. Profiling the drugs 
simultaneously allows for more accurate profiling of the individual and comparative 
effects of the efficacy of each drug. We used an adaptive Bayesian factor analysis 
approach to develop biomarkers for multiple HDACs simultaneously, allowing for 
predictions of comparative efficacy between the drugs. We observed that this approach 
leads to different predictions across breast cancer subtypes compared to profiling the 
drugs separately. 
Chapter 2 is focused on the development of a software package for an efficient and fast 
bulk data download of NIH roadmap epigenomics data consortium. The NIH Roadmap 
Epigenomics Mapping Consortium has released next generation sequencing data, DNA 
methylation, chromatin accessibility in stem cells and normal tissues across multiple 
platforms and tissue-experiment types. All the data resources are publically available for 
downloading from the FTP website 
(ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/roadmapepigenomics/). To facilitate the 
process of data downloading with customized features, we have built software in python 
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programming language, ‘downloadNIH.py’. This python script provides the user with 
multiple customized features for fast data download from NIH FTP website to local 
directory. We used this package to download data for mRNA expression, bisulfite-
sequencing, and four different histone marks (H3K4me3, H3K36me3, H3K27ac, 
H3K9me3) for genetic- epigenetic co-regulation regulation across brain, breast, heart, 
liver, lung, and small-intestine. 
Chapter 3 is focused on exploratory analysis to identify biomarker regions of genetic-
epigenetic co-ordination independent of platform and tissue types comparing expression 
and methylation profiles across different tissue types. We plan to use these regions to 
develop VPA biomarkers, similar as those derived in Chapter 1, that can cross validate 
across multiple different data types. 
This research will have a broad impact on the development, validation, and application 
of genomic biomarkers for drug efficacy and repositioning in the following ways: 1) the 
integration of robust orthogonal biomarkers from multiple genomic data types, 2) the 
development of data type independent biomarker tools for integration across platforms, 
and 3) outlining a framework for reproducible biomarker derivation and validation across 
multiple cell lines, experiments and databases, and patient tumor samples. 
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Chapter 1 Multi-component signature for predicting epigenomic treatment efficacy 
1.1.A Introduction 	  
Aberrant epigenetic alterations like DNA methylation and histone modifications can 
inactivate tumor suppressors, activate oncogenes, and contribute to cancer 
development. Recent research in targeted epigenetic therapy for cancer focuses on 
development of histone deacetylase (HDAC) inhibitors and DNA demethylating drugs. 
An efficient strategy for targeted therapies for such drugs would be to identify the subset 
of cancer patients that will most effectively respond to these epigenetic enzymatic drugs. 
In this work, we have developed an unbiased, multi-component approach, which profiles 
DNA methylation and gene expression signatures across breast cancer subtypes. The 
goal of this study is to predict drug sensitivity for HDAC inhibitors in breast cancer cell 
lines, mouse xenografts, and tumor samples from the Cancer Genome Atlas (TCGA). 
1.1.B Targeted epigenetic therapy: HDAC inhibitors and DNA demethylating drugs 
 
Many clinical trials focus on randomly selected patient populations for drug response, 
thus evaluating drug efficacy on the entire group and may fail to accurately identify 
subsets of patients that are the most responsive to the drug [11]. Strategic 
personalization of patient treatment allocation in clinical trials can better identify and 
specifically target the correct patient subpopulation for better drug efficacy and 
combination therapy. This in turn will prevent side effects, promote more effective 
utilization of time and resources on treating patients, and minimize non-responsiveness 
to a specific therapy. We describe the use of a signature-based approach for drug 
response prediction that integrates gene expression and methylation response data from 
the same patient, and profiles multiple drugs simultaneously to understand which 
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therapies will be most effective. The drugs used in the study are histone deacetylase 
(HDAC) inhibitors, which are known to control gene expression by epigenetic 
modification. The reversible nature of epigenetic modifications makes them a potential 
therapeutic target for personalized cancer therapy. Recent research has also shown 
association of HDAC with regulation of transcription, cancer initiation, growth, and 
metastasis [12]. Increased expression and recruitment of HDAC to the nucleus has been 
reported in various cancers such as breast, prostate, and colon cancer [13,14,15].  
 
The major focus of this study is to predict efficacy of three HDAC inhibitors: 
Trichostatin-A (TSA), Suberanilohydroxamic acid (SAHA), and Valproic Acid (VPA) for 
breast cancer cell line perturbations, mouse xenografts, and in TCGA breast cancer 
samples. VPA, also known as 2-propylpentanoic acids, is an attractive choice as it is an 
FDA approved epilepsy drug with relatively low toxicity and is readily available. From a 
statistical informatics perspective, these HDAC inhibitors are useful in that they can be 
easily tested on cancer cell lines in vitro, without metabolic activation [12]. 
1.1.C Multi-omic signature based approach to design adaptive and effective 
clinical trial. 
 
We applied our novel pathway profiling approach, Adaptive Signature Selection 
and Integration (ASSIGN) [16] to generate multi-component signature for drug efficacy 
prediction. ASSIGN has been used to characterize growth factor receptor network 
(GFRN) activation of EGFR, AKT, BAD, HER2, KRAS in breast cancer patient samples 
from TCGA [7]. ASSIGN robustly adapts pathway activity signatures into a specific 
disease context. In this high throughput profiling approach, we used ASSIGN to 
generate multi-component signature for characterizing breast cancer xenograft, cell line, 
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and TCGA patient samples for drug sensitivity. We used in vitro drug screens to 
generate both gene expression and DNA methylation primary signatures extracted from 
perturbation experiments of breast cancer cell lines treated with VPA.  
 
 In this work, we generated both multi-omic (expression and methylation 
combined) and single-omic (expression-only and methylation-only) gene signatures. This 
study also represents a novel approach to integrate and analyze breast cancer cell lines, 
mouse xenografts, and patient samples (TCGA) across a diverse variety of profiling 
platforms, which include Affymetrix expression, Agilent expression, and the Infinium 
human methylation 450k Beadchip. See Table 1 for a detailed summary of these 
studies. Multidrug and multi-omic signature generation is based on the ASSIGN 
Bayesian adaptive modeling approach, which calculates a score ranging from 0 to 1 for 
each sample to predict the likelihood of drug response (0 = low likelihood of response, 1 
= high likelihood). Based on these scores, a list of genes with a difference in gene 
expression and methylation level as a result of drug treatment are selected and defined 
as “drug response signature”. Web based tools: DAVID [18] and PANTHER [19] were 
used to explore and study differentially expressed and methylated genes and their 
association with biological functional categories and pathways. 
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1.2 Methods  
1.2.A Drug dose-response assay, expression and methylation response signature 
generation  
 
 
 
 
Table 1: Data analyzed in the multi-component study across a diverse array of platforms 
in breast cancer cell lines (treated with VPA, SAHA and TSA), mouse xenograft, and 
The Cancer Genome Atlas (TCGA) breast carcinoma patient samples.   
 
 
Category Platform Parameter 
Breast Cancer Signature Cell 
lines (32 cell lines) 
Affymetrix 
Infinum 450k Bead ChIP 
Expression 
Methylation 
Mouse Xenograft (2 models)  Infinum 450k Bead ChIP Methylation 
TCGA (248 samples)  Agilent Expression and 
Methylation 
Damaen et al., Cell Line Panel 
(35 cell lines) 
Affymetrix U133A Expression 
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Three different HDAC inhibitors: VPA, SAHA, and TSA were used in the study to treat 
the following ATCC (https://www.atcc.org) breast cancer cell lines: HCC1806, HCC1428, 
HCC1143, BT549, BT474, MDA-MB-361, MDA-MB-435s, MDA-MB-231, MDA-MB-453, 
SKBR3, ZR75, CAMA I, MCF7, Hs578t, T47D. To prepare above cell lines for drug 
response experiment, cells were seeded in 384 plates (NUNC). The media used for cell  
culture was mammary epithelial growth medium, MEBM (Lonza), with 5% fetal bovine 
serum (GIBCO). After 24 hours of seeding, VPA was added at 10 different doses 
ranging from 0.25 to 64 mM. SAHA was treated at doses of 100 uM to 30nM and TSA 
was used at 16.1 uM to 62.8 nM. For seeding the cells and for dispensing drug a 
BIOMEK 3000 (Beckman Coulter) robot was used. All points were set up in triplicates. 
After 72 hours of incubation at 37C, cell viability was evaluated by Cell 65Titer-Blue 
Reagent from Promega followed by 2 hours of incubation at 37°C. A Victor3V 1420 
Multilabel Counter (Perkin-Elmer) plate reader was used to record the fluorescence. 
RNA was extracted with RNeasy midi Kit (Qiagen, Valencia, CA, USA) according to 
manufacturer’s protocol. Briefly, breast cancer cell lines were seeded in 100 mm plates 
(Constar). When they reached 70% confluency, 5 mM VPA, 1.5 uM of SAHA and 100 
nM of TSA were added in RPMI medium containing 10% FBS without antibiotics. After 6 
hours at 37C, the cells were harvested and RNA was isolated according the 
manufacturer’s procedure. RNA concentration was measured by Nanodrop (Thermo 
Scientific, Wilmington, DE, USA) and the quality assessed by Experion RNA StdSens 
Analysis kit (Bio-RAD). Approximately 2 ug of RNA was used for the microarray analysis. 
For methylation assay, breast cancer cell lines were seeded in 100 mm plates (Constar). 
When they reached 70% confluency, 5 mM VPA, 1.5 uM of SAHA and 100 nM of TSA 
were added in RPMI medium containing 10% FBS without antibiotics. Cells were 
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harvested at 6, 12 and 24 hours and genomic DNA was isolated from the lysate using 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). DNA concentration was measured 
by Nanodrop (Thermo Scientific, Wilmington, DE, USA). 500 ng DNA from each 
xenograft samples and cell line samples were used for bisulfite conversion using EZ 
DNA methylation kit (ZYMO research, Irvine, CA, USA) according to the manufacturer’s 
instruction. The methylation assays were performed at the core facility of UCSF using 
Infinium Human Methylation 450 BeadChip kit, Illumina, San Diego, CA. 
 
1.2.B Expression Array Normalization 
Affymetrix expression data from the cell line perturbation experiments with the treatment 
of VPA, SAHA and TSA and the TCGA breast carcinoma samples were normalized 
through the use of Single-Channel Array Normalization (SCAN) [20]. SCAN uses a 
mixture model to adjust for probe biases and standardizes of variances across arrays on 
each sample individually. Expression levels for genes with multiple probes were 
estimated using a trimmed-mean approach (trim margin = top and bottom 10%). 
 
1.2.C Methylation Array Normalization 
For both the VPA signature and mouse xenograft samples, the ‘methylumi’ Bioconductor 
package [21] using default parameters was used to extract fluorescence values for the 
‘methylated’ and ‘unmethylated’ probes directly from the raw ‘.idat’ files [GSE94943 
series]. We then used ‘beta value normalization’ to estimate methylation levels across 
the genome. To calculate the beta values, we use the approach described previously 
[22]. To formally describe this approach, we let i=1...383,452 index the features on the 
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array, and let yi,methy and yi,unmethy represent the probe intensities from the methylated and 
unmethylated probes, respectively. The beta values for feature i is then calculated using 
the formula: 
 
Where α =100 as recommended previously.  This approach was used so that our 
methylation data processing closely matching the TCGA pipeline. 
 
We observed noise in the methylation data with normalized beta values. And as a result 
of the noise, we were able to see any signal in VPA efficacy prediction signatures in 
xenograft and TCGA dataset (Supplementary Tables 1 and 2). To combat the noise that 
lone probes could produce, the beta values of each probe were smoothed by averaging 
the beta values of other probes that targeted proximal loci on the same chromosome. To 
do this, we first begin with a set that initially includes only a single probe. We then 
expanded the probe set to include all probes that target a genomic locus within 500 base 
pairs up or downstream of the initial probe. If the resulting set includes at least 10 
probes, we drop the probes that are in the bottom and top 10th distance percentile. 
Finally, a smoothed beta value for the initial probe was calculated by averaging the non-
smoothed beta values of all probes in the remaining set. By applying this procedure to 
each probe, we were able to compute a smoothed beta value for each probe in our 
dataset. Thus, the smoothed data resulted in better predictions in xenograft 
Betai = 
max (Yi,methy,0) 
max (Yi, methy,0) + max ( Yi, unmethy,0) + α 
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(Supplementary Table 3) and TCGA (Supplementary Table 4) predictions than the 
unsmoothed data. 
 
1.2.D Mouse xenograft experiment (DNA methylation) 
Patient-derived orthotopic xenograft tumors were implanted and passaged in the 
mammary fat pads of female NOD-SCID mice (5-7 weeks old) for in vivo drug treatment 
as previously described [23]. The two xenograft mice models, SUTI 110 and SUTI 320, 
which were derived from two breast cancer patients with triple negative tumor using 
primary tumor or lung metastasis samples respectively, were used for in vivo time point 
drug treatment experiments. SUTI 110 and SUTI 320 mice were randomized into 4 
groups with 3 mice in each group. VPA (Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in PBS for drug treatment. They were treated via intraperitoneal injection. 
Injection with (1) Control vehicle (PBS) for 2 hours; (2) Control vehicle for 6 hours; (3) 
VPA, 400 mg/kg for 2 hours; (4) VPA, 400 mg/kg for 6 hours. At the end of treatment (2 
hours or 6 hours), mice were humanely euthanized, and tumors were excised and frozen 
immediately on dry ice. DNA was isolated from the frozen tumor samples. 
  
In a separate experiment, after tumor xenografts SUTI 110 and SUTI 320 grew to an 
average between 50 to 100 mm3 in tumor volume, mice were stratified and randomized 
by tumor volume into treatment groups of 6-9 mice each. The treatment groups included: 
1) VPA group, receiving intraperitoneal (IP) administration of 400 mg/kg VPA every day 
for up to four weeks; and 2) control group, receiving IP administration of control vehicle 
(sterile PBS) everyday for up to four weeks. Tumors were measured twice a week with a 
caliper in two dimensions. Tumor volume was calculated by the following formula:  tumor 
	  	   16	  
volume = (l x w2) / 2, where l is the longest diameter of the tumor, w is the shortest 
diameter of the tumor. Mean tumor volumes were calculated, and growth curves were 
established as a function of time (Supplementary Table 5). 
Frozen xenograft tissues were cut into small pieces and homogenized using Talboys 
High Throughput homogenizer (Troemner, Thorofare, NJ). Genomic DNA was isolated 
from the lysate using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). DNA 
concentration was measured using Nanodrop (Thermo Scientific, Wilmington, DE, USA). 
500-nano gram DNA from each xenograft samples and cell line samples were used for 
bisulfite conversion using EZ DNA methylation kit (ZYMO research, Irvine, CA, USA) 
according to the manufacturer’s instruction. The methylation assays were performed at 
the core facility of UCSF using Infinium Human Methylation 450K BeadChip kit, Illumina, 
San Diego, CA. The resulting methylation data were normalized using the same 
procedure as the signature data. 
  
1.2.E The Cancer Genome Atlas samples (TCGA) 
We downloaded genome-profiling data (gene expression and methylation data) from 
247-breast cancer or matched adjacent normal samples from The Cancer Genome Atlas 
(TCGA), Breast Carcinoma Dataset. These samples were selected based on the 
availability of both AgilentG4502A_07 array gene expression and Infinium Human 
Methylation 450k Beadchip Arrays on the same samples. These samples consisted of 
genomic data for 215 cancer samples as well as matched normal adjacent breast tissue 
for 32 of these of these samples. We also obtained breast cancer molecular subtype 
information for each of these samples based on classifications defined previously [28]. 
For these 212 samples with available subtype information, 39 of the samples were 
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classified as basal, 14 as HER2, 108 as luminal-A, 46 as luminal-B, and 5 as normal-like 
complete list of the samples used in this study and their subtypes are given in 
Supplementary Tables 4 and 6. For both the expression and methylation data we 
downloaded preprocessed ‘Level 3’ normalized data. The TCGA consortium 
preprocessed/normalized the Agilent array data using the LOWESS log ratio of cy5:cy3 
dyes. The 450k methylation array data was preprocessed by TCGA using the ratio of the 
intensity of methylated probes to the total probe intensity to produce ‘beta’ values, which 
correspond to an alpha value of 0. To maintain consistency between the mouse 
xenograft array data and the TCGA dataset, only features existing in both datasets were 
kept. Features with missing values for any samples were removed entirely, resulting in a 
final count of 383,452 features. PCA Analysis was conducted on the expression profiles 
and methylation profiles to evaluate the data for batch effects. The first two principal 
components were plotted on a two-dimensional plot for the TCGA samples 
(Supplementary Figures S2 and S3). Samples were colored by their batch groups (i.e., 
the 96-well plate on which the samples were prepared for the high throughput profiling). 
No obvious clustering patterns by batches were observed. Therefore, batch correction 
within the TCGA samples was not required. 
  
1.2.F Batch correction and prior drug signature selection 
Although no obvious batch effects were observed within the xenografts / TCGA samples, 
batch effects existed between the cell line perturbation samples (training samples) and 
the xenografts/TCGA samples (test samples) due to the sample preparation procedures, 
profiling platforms, etc. Therefore, batch correction was required prior to the signature 
selection and prediction steps. We applied the ComBat [24] to adjust for these effects 
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underlying the training samples and test samples in the expression and methylation 
profiling datasets. The datasets after the batch correction [25] were then used in the 
downstream analyses.  
 
The drug signature genes/probes were selected based on the differentially 
expressed/methylated status between the treatment group and non-treatment group 
using LIMMA [26]. The top 500 genes from the VPA, SAHA, and TSA gene expression 
samples were selected as the prior drug signatures (expression-only) for the prediction 
of the drug responsiveness in the TCGA samples. For the methylation data, we used a 
signature list of gene list of 500 differentially methylated genes to profile methylation 
individually, but then used the processing described approach below to identify our multi-
omic profiling set.  
 
1.2.G Drug response signature generation in breast cancer cell lines  
Molecular signatures are important tools to explore gene expression and methylation 
profiles of cancer cell lines, after drug treatment. We applied the Bayesian adaptive 
modeling approach, ASSIGN [16] for gene expression and methylation signature 
generation in breast cancer cell lines (training set). The rationale for the molecular 
signature-based drug efficacy prediction is that test samples with the presence of a 
molecular signature for the drug are more likely to be responsive to that drug than those 
with the absence of a molecular signature. The molecular signatures used for drug 
efficacy prediction such as gene expression signature or DNA methylation (epigenomic) 
signature are experimentally profiled in the breast cancer cell lines. The whole genome 
gene expression and methylation status are measured in the breast cancer cell lines 
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known to be responsive to a certain drug before and after the drug treatment. A list of 
genes or genomic loci with substantial change of expression and methylation level due 
to the drug treatment are selected and defined as “drug response signature” 
(Supplementary Tables 5 and 6). 
  
The ASSIGN model estimates for each individual test sample a score ranging from 0 to 
1, which represents the likelihood of the responsiveness to the drug. One challenge of 
drug efficacy prediction is the heterogeneity of the baseline and signatures between the 
cancer cell lines samples from which the drug response signatures are generated and 
the test samples. The misspecification of the baseline and signature negatively impacts 
the prediction accuracy. The advantage of our ASSIGN Bayesian adaptive model is that 
it jointly estimates the context-specific baseline gene-expression/methylation level and 
molecular signatures along with the drug response score in test samples, thus yielding 
more robust and accurate prediction of drug efficacy in the cancer samples. Specifically, 
we used assign.wrapper function from the ASSIGN package. The details on all 
functions, parameters, and code are available on https://github.com/supriya-
sharma/drugsignature_prediction. 
 
1.2.H Multi-drug biomarker signatures 
ASSIGN allows the context-specific baseline and signature in terms of both gene list and 
magnitude. Some genes that are significantly differentially expressed in the cancer cell 
lines are not necessarily differentially expressed in cancer tissues. We initially selected 
500 differentially expressed genes from the breast cancer cell lines as drug signatures. 
ASSIGN uses the cancer cell-derived drug signatures as the prior information and adapt 
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them to be breast tissue specific drug signatures. The TCGA samples were clustered by 
the posterior gene expression with a clear distinction of the signature profile between 
tumor and normal tissues. For gene enrichment analysis using web-based tools, we 
used LIMMA selected 500 differentially expressed genes from cell lines treated with 
VPA, SAHA, and TSA.  
 
1.2.I Multi-omic feature selection of biomarker genes: independent correlation 
analysis 
Identification of biomarker genes in cancer is crucial, however robustness is always 
challenging and depends on diverse biological validations. This study identified a robust 
biomarker gene set and its application from cell lines to mouse models to patient 
samples across different -omic platforms. We found genes in which the methylation and 
gene expression were highly concordant (or discordant) across samples, and in which 
both the methylation and gene expression were significantly changed in response the 
drug treatment. We used the multi-omic biomarker genes extracted from breast cancer 
cell lines for VPA efficacy signature prediction. Since these methylation sites in a 
Illumina 450K beadchip array 
(https://www.illumina.com/products/methylation_450_beadchip_kits.html) covers 99% of 
refseq genes with 17 CpG sites per gene across promoter, which are known to affect 
gene expression. 
 We extracted the 500 most differentially expressed genes and the 500 most methylated 
genes from the breast cancer cell lines treated with VPA (Supplementary Tables 7 and 
8, using LIMMA as described above. For the genes that were significant in both lists, we 
calculated the correlation between the raw expression and raw methylation values 
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across the cell line samples.  Because we expect that the methylation of DNA directly 
inhibit gene expression at that site, we focused our efforts on genes with a strong 
negative Pearson’s correlation coefficient (with cutoff at -0.5). This selection generated 
robust list of 40 multi-omic biomarker genes based on their differential methylation and 
expression profiles after drug treatment that was used as a consistent biomarker gene 
set for both expression and methylation. The positively correlated, and uncorrelated 
genes were also retained for control sets. The 40 genes were used as a multi-omic 
biomarker set in our ASSIGN [16] model to predict drug efficacy in mouse xenograft and 
TCGA samples. We also compared the performance of the multi-omic biomarkers 
(expression and methylation) with the single-omic (independent 500 gene expression-
only and methylation-only) biomarker described in the previous sections. 
 
1.3 Results 
In this study, we explored VPA’s effect on altering chromatin network by histone 
acetylation and DNA methylation. Histone acetylation induces gene expression adding 
acetyl groups to histone tails, thus resulting in chromatin modeling. VPA has been 
reported not only for its histone deacetylase properties by hyper acetylating histones but 
has been observed to play an important role in altering DNA methylation profiles across 
a variety of cell types. The VPA effects on DNA methylation at global level have been 
reported in MCF-7 breast cancer cells, lung cancer cells, neuroblastoma [17, 27]. In this 
analysis, we explored VPA impacts on global DNA-methylation in breast cancer cell lines 
and mouse xenograft. We extracted differentially methylated genes in breast cancer cell 
lines and mouse xenograft after VPA treatment. In breast cancer cell lines, we extracted 
500 genes (FDR < 0.05) showed differential methylation after treatment with VPA. 
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Examples of these genes include MITF, GMEB2, KEAP1, RAB11FIP1, MEPCE, MAX 
(Supplementary Table 8 has the complete list). Similarly, we identified top 500 
differentially methylated genes in mouse xenograft (FDR < 0.05), which include genes 
like TP63, ZNF490, SHCBP1L, REEP5, ADCY9, ATP2A2 (Supplementary Table 9 has 
the complete list). We used these differentially methylated genes to generate our multi-
omic biomarker in a correlation analysis between differentially expressed genes from cell 
lines treated with VPA.  
 
Figure 1 represents signature prediction model to identify target patient population, 
sensitive to drug prior to treatment. We present two different multi-component 
approaches: multidrug and multi-omic. The multidrug signature features an expression-
only signature selection of differentially expressed genes from breast cancer cell lines 
treated with VPA, SAHA, and TSA for simultaneous, multi-drug prediction in the TCGA 
expression samples. The multidrug signature was validated in gene expression data 
from a panel of breast cancer cell lines [28] and evaluated by cancer subtype and drug 
response measured as –logEC50. The multi-omic model features differentially 
expressed and methylated biomarker genes from cell lines treated with VPA only, as 
signature selection for prediction in TCGA samples. For multi-omic signature extraction, 
we did an independent correlation analysis between differentially expressed and 
differentially methylated genes from VPA treated breast cancer cell lines and identified 
top negatively correlated 40 genes (Pearson’s coefficient -0.5). Our general approach for 
both multidrug and multi-omic biomarkers consists of three major steps: 1) signature 
generation using gene expression and DNA-methylation data from breast cancer cell 
lines treated with the drug, 2) multi-omic signature prediction in mouse xenograft for and 
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validation in tumor volume experiment for VPA efficacy and 3) application for signature 
strength prediction in gene expression and methylation data patient tumor samples such 
as those available from the TCGA. In Step 1, we generated gene expression and/or 
methylation signatures from breast cancer cell lines, treated with drug and control.  We 
treated the cell lines with three HDAC inhibitors: VPA, SAHA, TSA to generate 
signatures using genomic or epigenomics (i.e. ‘-omic’) profiling. To better understand 
what these genomic signatures represents from a biological or mechanistic perspective, 
we performed functional annotation analysis on the differentially expressed and 
methylated genes extracted from -omic profiling. In Step 2, we validated methylation 
signatures in mouse xenograft treated with VPA. Here, where we used multi-omic genes 
extracted from cell lines treated with as training set to predict VPA efficacy in xenograft. 
Step 3 of this approach is to apply these signatures in TCGA breast cancer samples 
expression and methylation datasets to predict drug response.  
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Figure 1: Flowchart of proposed multi-component signature prediction framework to 
identify target population for a drug or combination therapy using single omic and multi-
omic biomarker genes. Multi-omic feature selection includes methylation and expression 
signatures from cell lines treated with VPA only.  For multi-drug signatures predictions 
on TCGA, we used multi-drug signatures generated from cell lines treated with VPA, 
SAHA, and TSA. 
 
1.3.A Multi-omic Signature Prediction and Validation in Mouse Xenograft Models 
In our previous work, VPA expression signatures were validated patient-derived 
orthotopic mouse xenograft (PDOX) models, including our SUTI 110 xenograft model 
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[17]. We projected the VPA epigenomic (methylation) response signature in the mouse 
xenografts using our 40 gene multi-omic signature (see methods). We used these 
results to validate our VPA methylation signatures generated from the breast cancer cell 
lines in this xenograft model as follows. There were two different experiments performed 
on each of two xenograft models:  SUTI 110 and SUTI 320, engrafted with tumors 
freshly derived from breast cancer patients. The first experiment (epigenomic profiling) 
tested the VPA efficacy signatures, using both xenografts at both two hour and six hours 
after VPA treatment. At each time point the methylation VPA response signature was 
applied to predict drug response. The second experiment (tumor volume) monitored both 
the xenografts after treatment with VPA for a period of four weeks, and tumor volume 
was measured at different time points. The control mice were treated with a placebo 
containing phosphate buffer saline (PBS) in both sets of experiments. 
 
In epigenomic profiling experiment, we observed a decrease in the methylation signature 
strength in the mouse xenograft models after VPA treatment. In the SUTI110 xenografts, 
our VPA prediction response signature strength was significantly reduced after 
treatment, suggesting that SUTI110 xenografts responsive to VPA. The prediction mean 
for SUTI110 before VPA treatment was 0.57, and then reduced to 0.18 after VPA (p-
value=0.0131, Figure 2 top left panel). Similarly, the SUTI 320, xenografts also showed 
a mean decrease in methylation signature, although this result was not statistically 
significant. The predicted mean for SUTI 320, was 0.35 before VPA treatment and 
reduced to 0.22 after VPA treatment (p-value=0.221; Figure 2 bottom left panel, 
Supplementary Table 3).  
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Figure 2: VPA methylation signature validation in two different mouse xenograft models: 
SUTI 110 and SUTI 320. Left top panel has ASSIGN signature prediction in 110 
xenograft treated with VPA and right top panel shows tumor volume measured in a 
separate experiment over time in the same 110 xenograft model treated with VPA. Left 
bottom panel has ASSIGN signature prediction in 320 xenograft treated with VPA and 
right bottom panel shows tumor volume measured in a separate experiment over time in 
the same 320 xenograft model treated with VPA. 
 
In our validation in tumor volume experiment, two mouse PDOX models (different 
animals implanted with different tumors) were treated with VPA over four weeks and 
were evaluated for VPA response with respect to the size of tumor growth. The SUTI110 
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mouse showed earlier response with decrease in tumor volume right after second day of 
VPA treatment, with an average decrease in tumor size 313.5 mm3 (48.6% reduction, 
Figure 2 top right panel) from the PBS treated SUTI110 mice that measured mean tumor 
size 644.5 mm3 after four weeks (Supplementary Table 5. The SUTI 320, model also 
showed a response, but not until after the seventh day compared to the control mouse 
(Figure 2, top right panel), with an average decrease in tumor size 895.2 mm3 (54.2% 
reduction, Figure 2 bottom right panel) from the PBS treated SUTI 320, mice that 
measured mean tumor size 1650.5 mm3 after four weeks (Supplementary Table 5).  
 
Overall, we observed a similar pattern of VPA response in both signature prediction and 
validation experiments. The SUTI110 mouse model was more sensitive to VPA 
treatment than SUTI 320, both in signature prediction and validation experiments, 
although both mice showed evidence of VPA responsiveness.  	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1.3.B Multi-omic VPA methylation and expression signature prediction in TCGA 
data 
 
Figure 3: VPA methylation signature sensitivity predictions by ASSIGN to evaluate VPA 
efficacy in TCGA breast samples, with single-omic (left) feature selection and multi-omic 
(right) biomarker genes selection as two different training sets. Breast carcinoma tissues 
overall carry a higher drug signature than their adjacent normal tissues for VPA 
 
We projected the VPA epigenomic (methylation) response signature into the TCGA 
breast carcinoma expression and methylation samples. In this analysis, we wanted to 
compare performance of single-omic with multi-omic biomarker genes for VPA efficacy 
in TCGA methylation and expression signature predictions. For gene expression 
signature prediction, both the single-omic and multi-omic biomarker genes gave 
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equivalent predictions (Figure 4). For methylation, however, we found that the multi-omic 
gene selection approach yielded better prediction in TCGA methylation-only predictions. 
For example, we observed strong effective VPA methylation response signatures for 
breast cancer subtypes with the multi-omic biomarker genes with better separation 
between normal and tumor samples over the single-omic. More specifically, with multi-
omic feature selection (CD58, TP53, TSPYL5, SOBP, PTK6 etc.) the average VPA 
methylation response signature in the 32 normal samples was 0.14 compared to an 
average of 0.70 in the 215 tumor samples (fold change 5.0, p-value= 0.0003, Figure 3, 
right panel). Basal, Her2, and Luminal-B showed relatively strong signatures compared 
to Luminal-A and normal-like (Figure 3, Supplementary Table 4. With single-omic 
methylation-only feature selection (ZNF490, SCHBP1L, REEP5, ADCY9 etc.), VPA 
average methylation response signature in the 32 normal samples was 0.38 compared 
to an average of 0.61 in the 215 tumor samples (fold change 1.6; p-value= 0.0007, 
Figure 3, left panel). Thus, the multi-omic biomarker resulted in stronger signature 
differences between cancer/normal than single-omic (methylation-only) feature selection 
(fold change 5.0 in multi-omic vs. 1.6 in single-omic). The differences between breast 
cancer subtypes in the multi-omic signature were also stronger than the single-omic 
signature. 
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Figure 4: VPA expression signature sensitivity predictions by ASSIGN to evaluate VPA 
efficacy in TCGA breast samples, with single-omic feature selection (left) and multi-omic 
biomarker genes selection as two different training sets. Breast carcinoma tissues 
overall carry a higher drug signature than their adjacent normal tissues for VPA. 
 
The expression signature prediction in TCGA with both the multi-omic and single-omic 
(expression-only) feature selection gave equivalent results for VPA response in TCGA 
expression dataset. The average VPA response signature with multi-omic genes in the 
32 normal samples was 0.01 compared to an average of 0.72 for the tumor samples (p-
value=0.00019, Figure 4 right panel).  With single-omic (expression-only) biomarker 
genes, the average VPA response signature in the 32 normal samples was 0.01 
compared to a 0.61 average in the tumor samples 0.61 (p-value=0.00027, Figure 4 left 
panel). VPA expression response signatures for breast cancer subtypes with multi-omic 
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biomarker genes gave relatively better subtype signatures for Basal, Her-2 and Luminal-
B than Luminal-A, and Normal-like (Figure 4, Supplementary Table 6). 
 
1.3.C Correlation Analysis between VPA Expression and Methylation 
We compared and analyzed the performance of DNA methylation based and RNA-
based expression biomarker genes for signature predictions. Because RNA is inherently 
unstable and degrades rapidly, a DNA-based biomarker would have significant 
advantages in regard to specimen collection and processing. However, based on our 
results above, it is clear that RNA-based signatures are more effective than their 
DNA/methylation counterparts even for epigenetic drugs such as HDAC inhibitors. 
However, by using a multi-omic feature selection approach as described in the Methods, 
we can select a set of biomarker genes for our methylation signatures that perform 
nearly identically to an RNA expression-based approach.  
As shown in Figure 5 (Supplementary Tables 10 and 11, the single-omic expression-only 
and methylation-only gene signatures applied to the same 247 TCGA breast cancer 
samples showed only a weak correlation across samples (Pearson coefficient of 0.30). 
However, the multi-omic biomarker gene panel, selected from genes with strong 
negatively correlated methylation and expression in the cell lines, showed a high 
correlation between VPA expression and methylation ASSIGN signatures (Pearson’s 
coefficient of 0.93). As an additional control, we considered a panel of 55 genes with 
positively correlated methylation and expression values, which had a correlation of only 
Pearson’s coefficient of 0.33, which is similar to the overall single-omic correlations (p-
value difference for correlation using multi-omic and single-omic biomarker genes p-
value= 0.000002).  
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Figure 5: Correlation between VPA expression and methylation ASSIGN signatures from 
TCGA samples, with single-omic feature selection (left) and with multi-omic biomarker 
genes (right) as training set. Multi-omic signature selection gave a strong correlation of 
0.93 than single-omic feature selection correlation of 0.33 (Pearson’s correlation 
coefficient). Each dot in the plots represents one sample. 
 
These multi-omic biomarkers had much better consistency and concordance compared 
to the single-omic: expression-only and methylation-only biomarker genes in VPA 
methylation and expression signatures prediction in TCGA. This data integration from 
cell lines to TCGA patient samples, add to robustness of multi-omic biomarker in a 
platform independent, and data independent approach. Furthermore, and most 
importantly, our approach begins to examine how to develop of platform and data type 
independent biomarker gene sets; it does not matter which data type (methylation or 
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expression) or platform (Affymetrix, Agilent) is used to collect data, our 40-gene 
biomarker panel will give similar results regardless of the input profiling data.  
 
1.3. D Enrichment analysis of Multi-Drug response signatures  
 
Enrichment analysis using web-based tools was performed on two sets of differentially 
expressed genes: first set of genes include overlapping genes that fell with the top 500 
most differentially expressed genes for all three drugs, while the second set includes 
only genes that were significant in only one of the drugs, e.g. VPA-only, SAHA-only, and 
TSA-only genes. The rationale behind above gene selection in two sets was to 
understand action mechanism of the VPA, SAHA, and TSA by exploring biological 
processes and pathway associated with these genes as their drug response signatures. 
For the first set of genes (genes in common for all drugs), functional annotation analysis 
was performed using the web-based tool DAVID. In this gene list, we observed 
significant functional annotation categories including phosphoprotein, nucleus, cell 
cycle, and transcription (Figure 6). These biological processes are known to be 
associated with the activities of HDAC inhibitor action mechanism on cancer 
(Supplementary Figure S1 and Supplementary Tables 12, 13, and 14) suggesting the 
common action mechanisms across these drugs. These three HDAC inhibitors are 
known for inhibition of cell proliferation and promoting cell death in MCF7 breast cancer 
cell lines (29).  
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Figure 6: Functional annotation analysis differentially expressed overlapping genes from 
breast cancer cell lines treated with VPA, SAHA, and TSA and their association with 
molecular processes and mechanisms. 
 
The second set of enrichment analysis was done with VPA-only, SAHA-only, and TSA-
only genes separately to compare gene enrichment for a specific drug with respect to 
other HDAC inhibitors. Because we observed strong VPA response specifically for 
luminal subtypes in TCGA expression samples (Figure 7) and ICBP cell lines (Figure 8), 
we looked more specifically into biological processes associated with VPA-only genes 
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contributing to strong VPA response. DAVID [18] analysis resulted in significant 
annotations in enzyme binding, protein kinase activity, nucleoside binding for SAHA-
only, microtubule nuclear localization signal, kinesin for TSA-only, and transition metal 
ion binding, nucleotide binding for VPA-only. To further compare-contrast VPA gene 
signatures from SAHA and TSA gene signatures, we also use the web-based tool, 
PANTHER [19]. In the VPA-only gene list, we observed a higher proportion of genes 
associated with catalytic activity and binding than with the other drug gene lists 
(Supplementary Figure S5, S6, S7). Specifically, genes involved in catalytic activity 
include 57 genes (39.0%) for VPA, 44 (28.6%) for SAHA and 43 (28.9%) for TSA. Out of 
the 57 enriched VPA genes for catalytic activitygenes linked to transferase (kinase, 
methyltransferase, acyltransferase) and 25 linked to hydrolase (ATPase, GTPase, 
Peptidase, Phosphatase). While we observed fewer genes enriched for SAHA and TSA 
for above categories, 14 SAHA genes and 13 TSA genes linked to transferase, 15 SAHA 
genes and 10 TSA genes linked to hydrolase. We hypothesize that the stronger 
presence of catalytic activity genes in the VPA-only signature might be responsible for 
stronger response in luminal subtypes in the TCGA and cell line datasets compared to 
the SAHA-only and TSA-only genes.  
 
We also evaluated the molecular profile of luminal breast cancer subtypes, which are 
typically categorized with higher gene expression of estrogen receptor (ER) positive 
genes [30, 31, 32]. We observed more differentially expressed VPA-only genes than for 
SAHA-only and TSA-only. VPA-only genes associated with higher ER positivity in 
luminal subtypes include ATP9A, ATP6V1B1, BCL3, C1orf134, EAF2, FOXA1, FZD8, 
LYST, PEX11B, SLC9A3R1, ZNF14, and ZNF167. While the genes associated with 
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SAHA-only are BUB3, C14orf132, RYPB, and WAC and for TSA-only are CCDC47, 
CEP68, CPD, and RAB22A. 
 
1.3.E Multi-Drug response signature prediction in TCGA Breast Cancer Expression 
data  
We generated expression signatures for multiple HDAC inhibitor drugs, including VPA, 
SAHA and TSA. We used these signatures to analyze patient samples from TCGA in the 
same platform we used above. We projected the gene expression-only drug signatures 
identified from the breast cancer cell lines to the TCGA breast carcinoma tissue 
samples. The goal was to predict the extent to which each TCGA sample carries the 
drug response signatures (i.e., the similarity between a breast tissue sample and breast 
cancer cell lines before treated with drug). The underlying assumption here is that 
samples predicted with high likelihood of possessing the drug signature are more likely 
to be responsive to the treatment of drug.  
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Figure 7: Boxplot for gene expression signature sensitivity predictions by ASSIGN to 
evaluate VPA, SAHA, and TSA efficacy in the 247 TCGA breast samples and their 
subtypes (32 normal tissues and 215 carcinoma tissues). Breast carcinoma tissues 
overall carry a higher drug signature than their adjacent normal tissues for VPA, SAHA, 
and TSA. 
 
We applied ASSIGN to simultaneously evaluate the VPA, SAHA, TSA combined drug 
signature in each of the 247 TCGA breast samples including 215 carcinoma tissues and 
32 matched controls. Profiling the drugs simultaneously in ASSIGN can lead to more 
accurate profiling of the individual and comparative effects of the efficacy of each drug.. 
Effectively, this works in the same manner as a linear regression—predicting the efficacy 
of each drug in the presence of the other drugs. In this manner, if one-drug scores 
highly, while the others score poorly, it implies that the highest scoring drug is likely most 
effective and the others do not provide significant additional benefit. If multiple drugs 
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score well, it implies that the drugs may have complementary effects and a combination 
of the drugs may be appropriate.  
 
The results from TCGA profiling show that the breast carcinoma tissues overall carry a 
higher drug efficacy signature than their adjacent normal tissues for all the three drugs 
respectively (Figure 7 and Supplementary Table 6). We also observed effective 
signatures in breast cancer subtypes for multidrug expression signatures in TCGA 
samples. As previously shown [7], these profiles were highest in aggressive breast 
cancer subtypes, including basal, Luminal-B and Her2.  
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Figure 8: Multi-drug signature validation in ICBP breast cancer cell lines (categorized 
into their subtypes), where Luminal subtype showed sensitivity for VPA while TSA 
response was observed higher in Basal and Normal-Like subtype. Multidrug expression 
signatures from cell lines treated with VPA, SAHA, and TSA were used as training set. 
 
 To further validate our expression-based multidrug signature profiling approach, we 
applied our signature to a breast cancer cell line data set from a previous study [28]. The 
panel include 1 control cell line, 10 cell lines for basal, 19 cell lines for luminal, and 3 cell 
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lines for normal-like (Supplementary Table 15).  For the multidrug expression signature 
validation using differentially expressed genes, we compared different cancer lines 
breast cancer cell lines categorized in the following subtypes as basal, luminal, and 
normal-like with controls. We observed a similar pattern of multidrug signature validation 
in these cell lines as in TCGA breast cancer subtypes predictions (Figures 7 and 8, 
Supplementary Table 15).  EC50 or IC50 is the half maximal effective concentration of 
drug required to induce a drug response halfway between the first and maximum dose 
given. EC50 values are used to measure potency of a drug. That means lower the value 
of –log EC50 more effective is the drug. The IC50 range for VPA for all the cell lines is 
from 2.16 - 3.45, for SAHA are 3.08 - 5.03, and for TSA are 4.22 - 6.40. Overall, VPA 
was observed with lowest range (more effective) of -logEC50 among all three drugs, 
showed higher response than TSA and SAHA. In our signature prediction in TCGA and 
validation in ICBP, we observed VPA to be most effective for the breast cancer samples 
with luminal subtypes. For example: ASSIGN signature for MDAMB361 (luminal) cell line 
was 0.98 with –logEC50 of 2.82 for VPA, 4.26 for SAHA, and 5.09 for TSA 
(Supplementary Table 15). 
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Chapter 2: Accessing NIH Roadmap Epigenomics Data  
 
2.1.A	  Introduction	  
 
Regulation of gene expression is controlled not only by activation of genes 
present on the sequence but by a variety of factors that surrounds the gene itself [10]. 
Epigenetics is an emerging field of molecular science that combines role of various 
chemical modifications resulting in change of phenotype without causing any change in 
the genotype. Epigenetic changes are stable modifications in genes like DNA 
methylation and histone modifications regulate gene expression by modulating the 
packaging of the chromatin inside the nucleus while epigenomics includes modification 
at global level across the whole genome. In 2008, the NIH invested in an exploration of 
the epigenome across different data types and platform and launched NIH Roadmap 
Epigenomics [3] program’s mission is to explore mechanisms and process that controls 
epigenetic regulation in normal adult tissue, fetal and adult stem cell differentiation, and 
their role in disease occurrence.  
 
The primary goal behind NIH Roadmap Epigenomics Consortium was to provide 
an extensive public resource of human epigenomic data for normal fetal, and adult 
tissues, stem cells across a variety of data types and data profiling platforms. The 
consortium aims to initiate and expand molecular-translational research from basic 
science to clinical-disease oriented research. In addition to this, the consortium also 
aims to strengthen experimental pipelines and data analysis tools/algorithms based on 
cutting-edge next generation sequencing platforms. These platforms are focused to 
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analyze and map a variety of histone modifications, DNA methylation, chromatin 
accessibility across normal adult tissues and stems cells from brain, lung, liver, heart, 
kidney, skin, spleen, etc., contributing the normal counterparts of the organ systems 
involved in disease occurrence and progression. The consortium provides an excellent 
platform to integrate data across diverse protocols, experiments and studies that are still 
adding data from ongoing research projects. It also provides raw sequencing data and 
epigenomic maps. The consortium is encouraging scientific community to build methods 
and tools for a standard pipeline that features reference for comparative analysis across 
data types and tissues. The consortium represents a diverse resource of cell and tissue 
models, which includes human embryonic stem cells; adult stem cells and their 
differentiated progeny; induced pluripotent stem cells; and primary ex vivo human fetal 
and adult tissues. There are nine data generation/mapping centers contributing in the 
consortium. These include the University of Washington: northwest reference 
epigenome mapping center; UCSF University of California, San Francisco: integrated 
epigenetic maps of human embryonic and adult cells; BCGSC Vancouver British 
Columbia Genome Sciences Center; UC Davis Genome Center; UCSD Ludwig Institute 
for Cancer Research the San Diego Epigenome Center; La Jolla Salke institute for 
biological studies; UW Madison: Morgridge Institute for research; MGH/Broad: Broad 
Institute of MIT and Harvard production sequencing of reference human epigenomics; 
EDACC Baylor/Houston, Baylor College of Medicine: Epigenomics data analysis and 
coordination center. The long-term goal of the consortium is to leverage epigenomics 
landscape with better understanding and resolution to further explore how epigenetic 
modifications contribute to pathways and mechanisms associated with diseases. 
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2.1.B Software package of NIH Roadmap Epigenomics consortium data download 
 
The NIH Roadmap Epigenomics Mapping Consortium has released epigenomics 
data for mapping chromatin accessibility, DNA methylation, and histone modifications for 
cell and tissue models, including hESCs and adult stem cells and their differentiated 
progeny; induced pluripotent stem cells; and primary ex vivo human fetal and adult 
tissues across multiple platforms and experiment types. All the data resources are 
publically available for downloading from the FTP website. 
To facilitate the data download with customized features, we have built software 
in the Python programming language,  ‘downloadNIH.py’ (https://github.com/supriya-
sharma/nih-roadmap). This software requires anaconda version 2.2.0 and the 
robobrowser library (https://github.com/xxinfinityxx/robobrowser) for its successful 
installation and execution (Figure 9). Robobrowser is a simple library to browse the web, 
download data, to click on links, and to fill out and submit forms. 
Installation steps: 
This Python script provides user with multiple customized features for fast data 
download from NIH FTP website to local directory.  The main script is written with the “--
help” option for user to explore different features (Figure 10). These features include 
Figure: 9 Installation steps for software package ‘download.py’ written in Python.  
The initial steps include loading anaconda 2.2.0 with Robobrowser library.   
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following four commands to list all experiments to view, list all the samples to view, and 
to download one specific tissue for a specific data type or download all data types for a 
one tissue type and vice versa. 
 
1) listexp: to view all available experiments for respective sample cells and tissue 
on the consortium website. Figure 11 describes the use of listexp command and 
the output from FTP website which displays all the experiments available on NIH 
Roadmap Epigenomics consortium. 
Figure: 10 Usage and arguments in the ‘downloadNIH.py’ package for NIH 
Roadmap Epigenomics data download. The program features following four 
arguments: a) getexp: get + download an experiment for respective samples, 
b) getsamp: get + download sample for respective experiments, c) listexp: list 
all experiments for a sample, d) listsamp: list all samples for an experiment. 
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2) listsamp: to view all available sample cells and tissue on the consortium 
website. Figure 12 describes the use of listsamp command and the output all the 
Figure: 11 Usage details for the arguments ‘listexp’, which basically 
displays / outputs all the experiments available on NIH Roadmap 
Epigenomics consortium. 
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samples available from NIH Roadmap Epigenomics consortium FTP website.
 
 
3) getsamp: to download specific sample or all samples on a specific data platform. 
Figure 13 describes the use of ‘getsamp’ command and the output from NIH Roadmap 
Epigenomics consortium FTP website for downloading all data types for breast stem 
Figure: 12 Usage details for the arguments ‘listsamp’, which basically 
displays / outputs all the samples available on NIH Roadmap Epigenomics 
consortium. 
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cells only.
 
 
Figure 14 describes the usage if we want to download all samples for breast stem cells 
for a specific data type, for example for MeDIP-Seq specifically. 
Figure: 13 Usage details for the arguments ‘getsamp’, which displays / outputs all the 11 
files available for breast stem cells on the NIH Roadmap Epigenomics consortium. 
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4) getexp: to download specific experiment on a specific data platform. For example, if 
we want to download bisulfite-sequencing data for lung tissue, then we can use ‘getexp’ 
command. Figure 15 has the usage details for downloading all files from the experiment 
MeDIP-Seq. 
Figure: 14 Usage details for the arguments ‘getsamp’, which displays / outputs all 
the 4 files available for breast stem cells specifically for MeDIP-Seq experiment on 
the NIH Roadmap Epigenomics consortium. 
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Figure 16 describes the usage if we want to download all files for mRNA-Seq data for 
lung tissue only. 
 
Figure: 15 Usage details for the arguments ‘getsamp’, which displays / 
outputs all the 162 files available for mRNA-Seq on the NIH Roadmap 
Epigenomics consortium. 
Figure: 16 Usage details for the arguments ‘getexp’, which displays / outputs 
both the 2 files available for mRNA-Seq experiemnt specifically for lung 
tissue on the NIH Roadmap Epigenomics consortium. 
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This toolkit served as an efficient source for fast and bulk data download from NIH ftp 
website to local computers. We downloaded and analyzed a variety of samples across 
different data types and platforms. The following section provides details on data 
downloaded using this software package across different tissues. 
 
2.1.C NIH data download for six data types across six different tissues. 
 
NIH roadmap epigenome consortium is a great public resource for a variety of normal 
reference tissues and their counterparts. This consortium now contains a total of 2,804 
genome-wide datasets, including 1,821 histone modification datasets, 360 DNase 
datasets, 277 DNA methylation datasets, and 166 RNA-Seq datasets, encompassing a 
total of 150.21 billion mapped sequencing reads corresponding to 3,174-fold coverage of 
the human genome.  The table below describes the details on all data availability across 
diverse tissues and data types on the NIH Roadmap Epigenomics consortium. The table 
in Figure 17 has blue-colored boxes that represent data availability for that particular 
tissue for the respective data type. Since the consortium is currently active and data 
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submission is still an ongoing process from different mapping centers. 
 
In this research, we specifically downloaded samples for six specific tissues: brain, 
breast, heart, liver, lung, and small intestine for following six data types: mRNA 
sequencing, bisulfite sequencing, H3K4me3, H3K36me3, H3K27ac, H3K9me3. Table 2 
below summarizes the details for all tissues and data types used in this study with their 
geo enquiry omnibus (GEO) accession numbers. The first column summarizes the tissue 
names and first row has the data type (mRNA sequencing, bisulfite sequencing and 
ChIP sequencing data) for respective tissues. 
 
 
Figure: 17 Details on data available for different normal tissues across different 
data types on NIH Roadmap Epigenomics Consortium data. 
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Conclusion 
 
We successfully used the software package to download data from NIH Roadmap 
Epigenomics Consortium across different data types mRNA-Seq, bisulfite Seq, ChIP 
sequencing for H3K4me3, H3K27ac, H3K36me3, and H3K9me3. The next steps for the 
data pre-processing includes normalization using Universal expression code (UPC) 
toolkit.  
 
 
 
 
Table: 2 GEO accession numbers for all the data downloaded from NIH Roadmap 
Epigenomics Consortium across different data types (mRNA-Seq, bisulfite Seq, ChIP 
seq data for H3K4me3, H3K27ac, H3K36me3, H3K9me3) 
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Chapter: 3 Multi-omic biomarker regions of genetic-epigenetic coordination 
across different tissue types in NIH Roadmap Epigenomics Consortium 
 
3.1.A Role of DNA methylation in regulation of gene expression 
 
 Recent research in epigenomics has contributed extensively on the role of 
epigenetics in the regulation of gene expression required for normal cellular growth, cell 
division, and other cellular functions. Epigenetic regulation is crucial to study and explore 
tissue-specific gene expression profiles, X-inactivation, gene silencing etc. Aberrant 
gene regulation as a result of epigenetic modifications like DNA methylation, gain or loss 
in chromatin structure, and histone modifications has been reported in a variety of 
diseases including cancer [11,12]. DNA methylation the addition of a methyl group (CH3) 
covalently to the base cytosine (C) in the dinucleotide 5´-CpG-3´. When a cytosine (C) is 
linked by a phosphate bond to guanine on the DNA sequence it is called CpG. A majority 
of CpGs is methylated in human genome and methylation of CpG islands in promoter 
regions play a crucial role in regulation of gene expression. Methylated CpGs have been 
reported to occur specifically in promoter regions of housekeeping genes of cancer.  
DNA methylation plays a crucial role is regulation of gene expression, most often 
resulting in the loss of gene expression. The detailed mechanism behind how DNA 
methylation affects gene expression has been the topic of extensive research over the 
last decade. The importance of DNA methylation extends from normal development and 
regulation during embryogenesis, X-inactivation, genomic imprinting, from cancer 
initiation to metastasis [11].  
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In this chapter, we focused our efforts on exploring whole genome-wide DNA 
methylation patterns across six different tissues: brain, breast, heart, liver, lung, and 
small intestine from the NIH roadmap epigenomics consortium using bisulfite-
sequencing data. The goal of this approach was to identify genomic locations with 
epigenetic coordination by exploring methylated and unmethylated status across 
different tissues. Increased DNA methylation has mostly been reported associated with 
decreased gene expression profiles, so we performed correlation analysis on data sets 
for bisulfite sequencing and mRNA sequencing. We extracted genomic locations from 
different chromosome with negative correlation between gene expression and DNA 
methylation across different tissues. We observed regions with higher methylation 
activity with no gene expression signal and vice versa. We also observed tissue-specific 
gene expression and methylation profiles for specific genomic locations across tissues.  
 
3.2 Methods, pipeline and analysis report on multi-omic biomarker discovery in 
NIH roadmap epigenomics consortium 
 
3.2.A Introduction: Universal exPression Code (UPC) approach to barcode NIH 
epigenomics roadmap data. 
 
High throughput data profiling platforms sometimes are associated data integration due 
to technology-specific biases and produces distinct raw-data distributions. To address 
better data integration across newer profiling platforms and consortiums, The Universal 
ExPression Codes (UPC) was developed in our lab, which basically corrects platform-
specific background noise. UPC uses a mixture model to estimate whether a gene or a 
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signal is active in a particular profiling sample. UPC ‘barcodes’ the final output on a zero-
to-one scale, so that they can be interpreted consistently, irrespective of profiling 
platform [5].  
 
UPC approach assumes that each gene or genomic feature comes from one of two 
distinct populations. For example, UPC values for gene expression represents the 
assignment probabilities of each gene to one of the following populations: genes that are 
not expressed / inactive (background variation) and genes that are expressed / active 
(background variation plus biological signal).  The UPC normalization approach is based 
on a mixture model where UPC output approximates the probability of signal (gene 
expression, histone modification peak etc.) with priors that are uniform over their 
appropriate parameter space. Since UPC values are represented on the same scale and 
have an identical interpretation for each platform, they can be used for cross-platform 
data integration analysis across profiling platforms, combining samples across 
experiments, and tissues [5]. Software for calculating UPCs is available at 
www.bioconductor.org/packages/release/bioc/html/ SCAN.UPC.html.  
Our group’s previous publications applied UPC to gene expression experiments. Here 
we extended the UPC approach to process not only mRNA sequencing, but also histone 
modification sequencing data (CHIP sequencing) for H3K4me3, H3K36me3, H3K27ac 
and H3K9me3 across brain, breast, heart, liver, lung, and small intestine. We also 
extended the UPC pipeline to follow three steps from data download, conversion of .wig 
files to bigWig files, and the final UPC run. We used UCSC genome browser 
(https://genome.ucsc.edu) to visualize the normalized data across all data types and 
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tissues. The following section describes the details of the pipeline with examples on how 
to run UPC on multiple samples at the same time. 
 
UPC pipeline on mRNA sequencing, bisulfite sequencing, and ChIP sequencing 
data 
This is a pipeline to run UPC on sequence data available from GEO. The pipeline has 3 
basic steps: 
1. Download .wig files from GEO and convert to bigWig files (.bw). 
2. Find average signal within bins specified by separate annotation file. 
3. Run UPC using this average signal and size of region. 
 
Support files (Example) 
 
Annotation File 
This pipeline currently uses an annotation file of proximal promoter regions from the 
Ensemble Regulatory Build. These files were adapted from tables downloaded from the 
UCSC genome browser (hg19). Here the proximal promoter regions used are shown as 
thick red bars. These regions flank the transcription start site of about half of annotated 
protein coding genes. The annotation file must have 4 columns as demonstrated in 
Figure 18. 
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Genome Builds File 
In order to convert a .wig file to a bigWig file, the user needs to specify the genome 
build. On local machines this can be handled using the seqinfo() function from the 
GenomeInfoDb package. However, on the SCC the user must currently manually include 
genome build object as class “Seqinfo”. The “GenomBuilds.RData” file includes this 
information for human genome builds: hg19, hg18, and hg38 (Figure 19). 
Figure: 18 Annotation table for the genome “Promoters_EnsReg_hg19.txt” with four  
columns: chromosome number, start, end, and name of the transcription start site. 
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Submitting Jobs 
UPC can be run on an array of GEO accession numbers (GSM#) by editing the 
“UPCops.sh” file (Figure 20). Here the user specifies the GSM#’s (separated by a 
space), an email address to send notifications when the job is finished, file path and 
name of the annotation file, the build of the annotation file, the directory to write files, and 
the file path and name of the genome build RData file. 
Figure: 19 Genome build specification 
 to convert a .wig file to a bigWig file.   
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3.2.B Barcoded data visualization on UCSC browser 	  
The next step in this pipeline is to take UPC output and convert it into bed graph format 
and upload them on the UCSC genome browser for visualization. The bed graph format 
!/bin/bash 
#To Run 
chmod u+x UPCops.sh 
./UPCops.sh 
 
#List of GSM#'s to run 
# # # Space separated! 
GEOacc=(GSM1127053 GSM1127093) 
 
#Set e-mail address to alert when job is finished 
email=supriya7@bu.edu 
 
#Set Annotation File 
annotFile="Promoters_EnsReg_hg19.txt" 
 
#Specify the build of the annotation file 
build="hg19" 
 
#Set Directory for writing files 
baseDir="/Users/supriyasharma/Desktop/nih/new” 
 
#Set file that has the genome build information 
seqInfo="GenomBuilds.RData” 
 
for i in ${GEOacc[@]}; do runMult="qsub -P combat -M $email  
-pe single_node 8 -v GSM=$i -v annot=$annotFile -v  
build=$build -v baseDir=$baseDir -v Seq=$seqInfo  
RunUPC.sh"; eval $runMult; done 
Figure: 20 Submitting jobs using UPCops.sh where UPC can 
be run on an array of GEO accession numbers (GSM#) 
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is used to display continuous-valued data, probability scores in a track format and useful 
for exploring transcriptome data, epigenome data etc.  
 
The graphs in Figures 21-23 are examples from UCSC browser visualization of bed 
graph files uploaded for bisulfite- sequencing, mRNA sequencing, and chIP-sequencing 
data for barcoded data across different genomic locations. The data visualization on the 
UCSC browser can be done for multiple samples (tracks) at the same time for the whole 
genome. Figure 21 captures the entire Chromosome 17 at 2 mega (1 mega = 1000000) 
base resolution for two tracks: bisulfite sequencing and H4K27ac data for breast, while 
Figure 22 shows entire chromosome 1 for breast at 100 mega (1000000) base resolution 
for bisulfite sequencing and mRNA sequencing data. Figure 23 describes a comparison 
between barcoded and non-barcoded data for H3K27ac for gene JUN on chromosome 1 
in breast tissue. 
 
Figure 21: UPC barcoded data visualization of entire chromosome 17 (2 Mega base 
resolution) on UCSC browser for breast bisulfite sequencing data (blue) and breast 
H3K27ac (green). 
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Figure 22: UPC barcoded data visualization of entire chromosome 1 (100 Mega base 
resolution) on UCSC browser for breast bisulfite sequencing data (blue) and breast 
mRNA sequencing (red) data. 
 
Figure 23: UPC barcoded data visualization of gene ‘JUN’ on chromosome (1kilo base 
pair resolution) on UCSC browser for breast bisulfite sequencing data (blue), breast 
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mRNA sequencing (red) data, and H3K27ac histone (green) data. The last row with 
H3K27ac data is raw data (non-barcoded) on UCSC browser. 
 
3.3.  Gene expression and methylation profiles for multi-omic biomarker discovery 
across different tissues. 
 
This section summarizes the negative co-ordination between mRNA expression and 
methylation signal across different genomic locations different tissues. Following 
examples specifically describe for single gene location and for the entire chromosome. A 
gene location on a chromosome is defined with respect to base pair, which basically is a 
unit that consists of two nucleobases bound to each other by a hydrogen bond.  Figure 
24 details methylation signal peaks across the entire chromosome 1 at 100-mega base 
resolutions with lower mRNA expression signal. Figure 25 is covers the breast tissue for 
active expression signal for gene MCL1 for myeloid cell leukemia at location 
150,574,551 base pair from 150,579,738 base pair on chromosome 1 (5 kilo base = 
1,000 base pairs resolution) with no methylation signal. Similarly, Figure 26 covers 
active expression signals for gene EIF1 for eukaryotic translation initiation factor 1 at 
location 41,688,875 base pair from 41,692,668 base pair on chromosome 17 (5 kilo 
base resolution) and ACTG1 for actin gamma 1 at location 81,509,971 base pair from 
81,523,847 base pair on chromosome 17 (10 kilo base resolution) with no methylation 
signal. While Figure 27 shows an opposite scenario with no gene expression signal but 
active signal peak for methylation the gene SOCS3, suppressor of cytokine signaling 3 
at location 78,356,777 base pair from 78,360,079 base pair on chromosome 17. 
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Figure 24: UCSC browser coverage for entire chromosome 1, at 100-mega base pairs 
resolution for breast tissue for bisulfite and mRNA sequencing data tracks. 
 
 
Figure 25: UCSC browser coverage for the gene MCL1 on chromosome 1, at 5 kilo base 
pairs resolution for breast tissue for bisulfite and mRNA (active signal) sequencing data 
tracks. 
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Figure 26: UCSC browser coverage for the gene EIF1 and ACTG1 on 
chromosome 17, at 5 kilo base pair and 10 kilo base pair resolution respectively, 
for breast tissue for bisulfite and mRNA (active signal) sequencing data tracks. 
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Figure 27: UCSC browser coverage for the SOCS3 and UBB on chromosome 
17, at 2 kilo base pairs and 1 kilo base resolution respectively, for breast tissue 
for bisulfite and mRNA sequencing data tracks. UBB gene is expressed 
whileSOCS3 shoes no expression.
 
Figure 28: UCSC browser coverage for the gene DHRS3 on chromosome 1 
across different tissue: brain, breast, liver, lung, and small intestine for bisulfite 
and mRNA (active signal) sequencing data tracks. The gene is exclusively 
expressed in liver tissue. 
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Figure 29: UCSC browser coverage for the gene SDHB and FNDC4 on chromosome 1 
and 2 respectively, across different tissue: brain, breast, liver, lung, and small intestine 
for bisulfite and mRNA (active signal) sequencing data tracks. The gene is exclusively 
expressed in liver tissue. 
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Figure 30: UCSC browser coverage for the gene DHRS3 on chromosome 11, 
across different tissue: brain, breast, liver, lung, and small intestine for bisulfite 
and mRNA (active signal) sequencing data tracks. The gene is exclusively 
expressed in liver tissue. 
 
We observed tissue-specific expression profiles for a variety of genes where 
specific genes expressed in a specific tissue. In Figures 28 and 29, genes like 
DHRS3: dehydrogenase/reductase 3, SDHB: Succinate Dehydrogenase 
Complex Iron Sulfur Subunit B, are exclusively expressed in liver and involved in 
oxidation / reduction in a variety of substrates. While gene CXC4: C-X-C motif 
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chemokine ligand 2 (Figure 30) on chromosome 4 was observed with active 
expression signal in liver and lung. Overall, we observed negative coordination 
between active gene expression and DNA methylation across different genomic 
locations and tissues. Table: 3 summarize all the genomic regions with active 
signal for mRNA expression across brain, breast, heart, liver, and lung. 
 
Tissue/ Data           mRNA (>0.5)             Bisulfite (<0.5) Overlap 
Brain 880 1904 104 
Breast 840 1692 53 
Heart 2019 3100 243 
Liver 1175 16803 1149 
Lung 681 16742 616 
 
 
Table 3: Genomic regions with active signal for RNA expression, measured as UPC > 
0.5 across five tissues. The last column with overlap represents common chromosome 
locations with active signal (UPC > 0.5) for mRNA sequencing and inactive signal for 
bisulfite sequencing data. 
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3.3. B Exploratory analysis on co-occurrence of different histone marks (alone or 
in combination) with mRNA gene expression across different tissues (H3K4me3, 
H3K36me3, H3K27ac, H3K9me3). 
 
Figure 31: Pipeline for the exploratory data analysis for biomarker regions for genetic - 
epigenetic co-ordination in NIH Roadmap Epigenomics Consortium and breast cancer 
cell lines data. 
Epigenetic modifications and its regulation is tightly controlled by a variety of 
mechanisms in nucleus that involve DNA methylation; histone modifications such as 
methylation and acetylation. These changes can be short-term or may represent a 
permanent mark on histones that contribute to gene expression profile in a specific 
tissue. In the nucleus, DNA is associated with a variety of proteins and together they 
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form a complex structure of chromatin. Nucleosome is the complex chromatin network 
composed of DNA packaged around histone proteins. A single core unit of nucleosome 
has 147 base pairs of DNA associated with an octameric core made up of histone 
proteins, with two H3-H4 histone dimers surrounded by two H2A-H2B dimers.  There are 
also N-terminal histones tails protrude from nucleosomes into the nuclear lumen. There 
is a specific histone H1, which is associated with the linker DNA that connects two 
different nucleosomes. The position and distance between different nucleosomes is 
crucial in defining and determining chromatin structure as euchromatin and 
heterochromatin. Euchromatin is lightly packed network of chromatin with genes actively 
involved in transcription, contributing to major part enriched with active genes of the 
entire genome. While the heterochromatin represents packed and dense chromatin 
complex composed of genetically inactive genes and other DNA sequences. 
Heterochromatin is also composed of non-coding DNA and is present in telomeres, 
centromeres etc. Epigenetic changes in chromatin structure are controlled and regulated 
both by DNA and histone modifications that target the gene expression. Different histone 
marks and DNA methylation tags are responsible for specific functions, for example: 
acetylation of specific lysine residues on histone regulates opening of chromatin 
structure, hence enabling activation of transcription. Histone code hypothesis suggests 
that histone modifications in different combinations also regulate transcription of genes 
in a tissue specific regulation [11]. And most commonly studied histone modifications 
have been observed occurring on H3 and H4 tails. 
 In this chapter, we specifically focused on exploring four different histone 
modifications (alone or in combination) and their role in regulation of gene expression. 
These four histone marks include HeK4me3, H3K36me3, H3K27ac, and H3K9me3; out 
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of these first three are activation marks for gene expression while H3K9me3 has been 
reported to occur in heterochromatin. 
H3K4me3 has been reported at sites of active transcription. Trimethylation of 
lysine 4 is also known as a universal chromatin modification present in active genes from 
yeast to human [11]. H3K36me3 represent trimethylation of lysine 36 activation marks 
for gene expression and has been associated with transcriptional activity. In terms of 
their occurrence, H3K4me has been observed in promoter regions while H3K36me3 
tags occur at the core of 3’ end of active genes. We studied another activation mark 
involved in acetylation of histone H3, H3K27ac. This active enhancer mark has been 
reported with higher activity of transcription associated with both the proximal and distal 
regions of transcription start site. We included another histone modification H3K9me3 in 
the study, which is known for its repressive activity. H3K9me3 specifically characterized 
as a repressive mark and binds heterochromatin protein 1 (HP1), which is required for 
maintenance of heterochromatin. 
 
We compared presence of these histone marks with gene expressions profiles in the 
UPC barcoded samples for brain, breast, heart, liver, lung, and small intestine. We 
observed co-occurrence of specifically two histone marks H3K4me3 and H3K27ac with 
mRNA expression signal across all tissues. We also observed presence of repressive 
histone signal H3K9me3. Following examples below focuses on presence of these 
histone marks (alone or in combination) with gene expression for respective genes. 
Figure 32 covers UPC barcoded data on UCSC browser gene UBB: Ubiquitin B on 
chromosome 17 with active signal for bisulfite sequencing (blue), mRNA expression 
(red) and for H3K27ac (green) activation histone mark together. The fourth row in the F 
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Figure 32 raw data (non-barcoded) for H3K27ac histone mark for comparison with UPC 
barcoded data. Figure 33 shows opposite situation for gene FOXA1: Forkhead Box A1 
on chromosome 14, where in presence of methylation signal we saw no signal for mRNA 
expression and H3K27ac (both in UPC barcoded and raw data). Figures 34 and 35 are 
for two different genes: CD68 and TACSTD2 respectively across six different tissues.  
We observed expression of CD68 gene (Figure 34) on chromosome 17 along with co-
occurrence of H3K27ac and H3K4me3 histone marks in brain, lung, and liver. While in 
breast tissue we saw absence of H3K4me3 signal along with mRNA expression. 
H3K9me3, a heterochromatin mark was observed in small intestine, with no expression 
of CD68. In Figure 35 for the gene TACSTD2 on chromosome 1, we observed tissue-
specific expression in lung only, while H3K9me3 repressive mark was observed small 
intestine only. To summarize, we observed two histone marks: H3K27ac and H3K4me3 
together with mRNA expression signal across all tissues. Table 4 details all the 
genomics locations for mRNA, bisulfite, H3K4me3, H3K27ac, H3K36me3, and 
H3K9me3 across all six tissues: brain, breast, heart, liver, lung, and small intestine. 
Overall we observed co-occurrence of activation (for gene expression) histone marks 
H3K27ac and H3K4me3 across all six tissues. Interestingly in small intestine, H3K9me3 
repressive mark was seen in highest with 17,247 locations while only 60 locations for 
gene expression was observed. Table 5 summarizes the overlap present between 
histone marks along with mRNA expression and intersection across tissues. For 
instance, in breast, we observed 82% overlap of genomic locations where we saw active 
signal for both the histone marks H3K27ac and H3K4me3 overlapping with active mRNA 
expression signal. 
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Figure 32: UCSC browser coverage for the gene UBB on chromosome 17, for bisulfite, 
mRNA (active signal) sequencing, and H3K27ac (active signal) data tracks.  
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Figure 33: UCSC browser coverage for the gene FOXA1 on chromosome 14 for bisulfite 
(active signal), mRNA sequencing, and H3K27ac data tracks. 
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Figure 34: UCSC browser coverage for the gene CD68 on chromosome 17, across 
different tissue: brain, breast, liver, lung, and small intestine for bisulfite, mRNA 
sequencing, and histone marks (H3K27ac, H3K4me3, H3K36me3, H3K9me3) data 
tracks. The gene is exclusively expressed in brain, liver, and lung tissue. 
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Figure 35: UCSC browser coverage for the gene TACSTD2 on chromosome 1, across 
different tissue: brain, breast, liver, lung, and small intestine for bisulfite, mRNA 
sequencing, and histone marks (H3K27ac, H3K4me3, H3K36me3, H3K9me3) data 
tracks. The gene is exclusively expressed in lung tissue. 
Platform / Tissue type Brain Breast Heart Liver Lung Small Intestine 
mRNA Expression 890 840 2092 1176 682 60 
H3K27ac 13715 11931 11455 11309 12884 13350 
H3K4me3 14435 13468 12945 11380 13493 12484 
H3K36me3 116 407 227 609 501 81 
H3K9me3 95 128 73 176 86 17247 
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Table 4: Summary table for genomics locations for mRNA, bisulfite, H3K4me3, 
H3K27ac, H3K36me3, and H3K9me3 across all six tissues: brain, breast, heart, liver, 
lung, and small intestine. 
 
Overlap mRNA : 
H3K4me3 
mRNA : 
H3K27ac 
H3K4me3 : 
H3K27ac 
Intersection co-occurrence 
H3K27ac & 
H3K4me3 with 
mRNA 
Brain 751 815 12580 743 83% 
Breast 766 727 10801 694 82% 
Heart 2095 1924 11458 1921 91% 
Liver 1178 1090 10110 1045 88% 
Lung 602 640 12921 585 85% 
Table 5: Summary table with overlapping genomics locations for mRNA, bisulfite, 
H3K4me3, H3K27ac, and for the co-occurrence H3K27ac and H3K4me3, across all six 
tissues: brain, breast, heart, liver, lung, and small intestine. 
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3.4 Pipeline for gene expression and DNA methylation-based multi-omic 
biomarker discovery across different tissues in NIH roadmap epigenomics 
consortium 
This section describes the use of UPC pipeline described above to explore gene 
expression and DNA methylation profiles across different tissues: brain, breast, heart, 
liver, lung, and small intestine. Specifically, we used UPC to barcode and analyze mRNA 
sequencing and bisulfite sequencing data across different tissues to identify 
chromosome locations at whole genome-wide scale (Aim-3B). After normalization (UPC 
run), we pulled all chromosome locations with active signal (UPC above 0.5) and no 
signal (UPC below 0.5) for mRNA sequencing while for bisulfite sequencing data, we 
focused on raw values (already normalized from the NIH roadmap website) across 
different tissues. The goal here was to identify genomic regions where we observed 
active signal for gene expression but no signal for DNA methylation in at least more than 
one tissue. The motivation behind this search was to explore different chromosome 
locations where DNA methylation regulates gene expression (gene activation or 
repression) across tissues (discussed in Section 3.1.A). We extracted a list of 353 
genome locations (Supplementary Table 16) overlapping across six different tissues and 
converted them into their respective gene names using the UCSC table browser 
(https://genome.ucsc.edu/cgi-bin/hgTables).  This gene list represents a range of 
dynamic genomic regions with active gene expression and no signal for DNA 
methylation present in one tissue or two and absent in others, at the same time.  
 
In the next step, we looked for expression and methylation profile for these 353 
genes in the VPA cell line perturbation experiment (methods 1.2.A), where five different 
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breast cancer cell lines were treated with VPA. These breast cell lines are MCF7, T4D, 
MDAMB453, CAMA-1, and SKBR3. In first part of this analysis, we focused on the 
comparison between expression and methylation profiles for 353 genes in control breast 
cancer cells. The reason behind this approach was to identify regions of genetic and 
epigenetic co-regulation independent of tissue type (six tissues from NIH or breast cell 
lines). Out of 353 genes, only 103 genes were present in the expression and methylation 
data sets for the breast cancer cell line perturbation experiment. A variety of miRNA 
genes, uncategorized genes, and multiple genes from one family were present, as a 
result of which we lost 250 genes (Supplementary Table 17). 103 genes overlapped both 
in the VPA cell line expression and methylation datasets. We performed a correlation 
analysis between expression and methylation profiles for each of above five cell lines, 
which resulted in 47 negatively correlated (22 genes had Pearson coefficient -0.98 to -
0.5) and and 56 positively correlated (15 genes with Pearson coefficient 0.5 to 0.9) 
genes. We then went back in the NIH roadmap epigenomics data and found following 18 
genes negatively correlated for their expression and methylation profile: SDF4, NOCL2, 
PLOD1, CCNL2, DNAJC16, SLC35E2, PEX10, NOL9, NBPF1, SLC2A5, ALDH4A1, 
H6PD, TARDBP, NECAP2, EPHA2, C1orf174, PDPN, ISG15. 
 
In the second part of this analysis, we explored the 103 genes that overlapped 
between NIH roadmap epigenomics consortium and VPA treated breast cancer cell lines 
for VPA efficacy. We performed correlation analysis on differentially expressed and 
methylated genes from the breast cancer cell lines before and after treatment with VPA. 
The heat map (Figure 36) describes the expression and methylation profiles for 103 
genes in control and VPA treated cell line data. We wanted to use these gene lists as 
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our training genes in ASSIGN model for VPA efficacy predictions in TCGA expression 
(Figure 37) and TCGA methylation (Figure 38) datasets. But we observed no differential 
expression and differential methylation for 103 genes identified from NIH roadmap 
epigenomics consortium.  
 
Figure 36: Differential expression and differential methylation status of 103 genes from 
NIH Roadmap Epigenomics Consortium that overlapped in the breast cancer cell lines 
data treated with VPA.  We observed no difference in before and after treatment with 
VPA for the 103 genes. 
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Figure 37: VPA efficacy prediction in TCGA expression data using 103 multi-omic 
biomarker genes from expression and methylation profiles in VPA treated breast 
cancer cell lines. 
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Figure 38: VPA efficacy prediction for TCGA methylation dataset using 103 multi-omic 
biomarker genes from expression and methylation profiles in VPA treated breast cancer 
cell lines. 
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Chapter 4 Discussion and conclusion 
 
The purpose behind this research was to address a variety of challenges in data 
integration for different data types across different profiling platforms with end goal to 
identify multi-omic biomarker regions of genetic-epigenetic coordination. These diverse 
data included gene expression microarrays, RNA sequencing, DNA sequencing, and 
ChIP sequencing on Affymetrix microarrays, Agilent microarray, and 450K BeadChip 
profiling platforms. We successfully integrated data from a multiple public data resources 
like TCGA, NIH Roadmap Epigenomics Consortium, cMAP, ICBP, etc. We integrated 
data from different platforms and also from different experimental systems like breast 
cancer cell lines, mouse xenograft, and patient data from TCGA. In the methylation 
studies, we observed variation across array profiling techniques with respect to next 
generation sequencing. We focused our efforts on DNA methylation and gene 
expression profiles (multi-omics signature generation in Chapter 1). Combining data 
across multi-omic profiles helped to better understand behind cellular functions and 
pathways associated with diseases. We identified multi-omic biomarker genes for VPA 
efficacy from breast cancer cell lines and applied them on patient data TCGA for efficacy 
predictions. Since the data came from different experiments, source, and platforms, we 
filtered the false positives outcome associated with platform-specific limitations. One 
step in this approach was to apply both training set and test sets to avoid data type 
specific and platform specific artifacts during normalization and downstream analysis. To 
summarize the big picture motivation behind this research was to develop a platform to 
evaluate approaches for NGS genomic data integration challenges across different data 
types and profiling platforms with emphasis on improving healthcare-informatics 
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research and their application in personalized medicine. To address these challenges, 
we developed a comprehensive strategy for data standardization across tissue types, 
and profiling platforms, and for the integration of data from multiple large-data generating 
consortiums. 
The end goal of Chapter 1 was to identify genomics regions of genetic-epigenetic co-
regulation that are independent of tissue type and consistent across epigenomic profiling 
data platforms. We specifically focused our efforts to epithelial cells to identify core 
epigenetic “biomarker regions” that consistently co-regulate across these and other 
tissue types.  The analysis done and results obtained in Chapter 1 is an example of 
a novel approach to integrate and analyzing next-generation genomic sequencing data 
for gene expression and DNA methylation drug response across multiple array 
platforms. In addition, we extended our RNA expression based biomarker platform to a 
DNA methylation signature biomarker analysis. Our multi-omic biomarker includes genes 
selected from DNA based methylation profiling combined with genes extracted 
expression experiments. We predicted VPA efficacy for mouse xenografts and TCGA 
samples. Although the single-omic biomarker genes performed well in TCGA 
methylation prediction analysis, the multi-omic biomarker genes performed better and 
gave stronger prediction in the TCGA samples. 
In this innovative study, we also generated for the first time, multidrug efficacy profiles of 
cell lines and TCGA samples for VPA, SAHA, and TSA. In our previous work, we 
performed gene expression data analysis of VPA treated breast tumor subtypes, to 
identify genes sensitive to VPA [7]. With this study, we extended this signature-based 
approach to consider multiple drugs at the same time. Our multi-drug profiling results 
suggest that luminal subtypes would achieve the best benefit from VPA-only treatment, 
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whereas a combination approach using all three drugs is predicted to be most effective 
in basal subtypes.  
Although our multicomponent approach generates cell line derived genomic signatures 
for drug response, it requires more substantial clinical validation across a variety of 
systems in vitro as well as in vivo. Dose requirements may be different for respective 
drugs in different environment, so validation is challenging and hence needed across a 
variety of systems. We are using drug response to identify subset of patient that might 
respond to drug, but these models do not provide effectively model the impact of side 
effects for a drug.  Additional -omic features might provide more depth in understanding 
drug performance from cell lines to animal models. Overall, the drug response data 
generated in our unbiased, multi-component study leverages gene expression and DNA 
methylation analysis in one platform. These integrative drug response signatures will 
contribute to efficient design of combination therapy for new drugs entering clinical trial. 
This approach will also contribute to an adaptive effective therapy choice for subset of 
patient population that actually respond to a specific drug. 
Overall, the research from Chapter 1 represents an unbiased, multi-drug, multi-omic 
approach that leverages effective experimental design to predict drug response and 
sensitivity. This work will further the goals of precision medicine to help target the right 
patients with the right combination of drugs. Also, this study involves data integration of 
breast cancer cell lines, mouse xenografts, patient samples (TCGA), and ICBP breast 
cancer drug response data across a multiple –omic-profiling platforms. Our signature 
prediction approach will contribute to the field by effectively predicting drug response for 
a specific therapy or combinations prior to research application in the clinic or 
assignment in a clinical trial, without actual prior knowledge on drug mechanism. 
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Signatures sensitive to specific drugs can also help predict efficacy for less toxic or more 
effective therapy choices with the right drug combination, thus targeting the right 
populations prior to initiating a clinical trial. The unbiased multi-component framework 
proposed in this study will aid in evaluating drug efficacy prior to clinical drug trials, 
contributing an important step in precision medicine applications.  
We developed an efficient toolkit in Chapter 2 that served as source for fast and bulk 
data download from NIH Roadmap Epigenomics Consortium ftp website to local 
computers. We downloaded and analyzed a variety of samples across different data 
types (brain, breast, heart, liver, lung, small intestine) and profiling platforms. 
We focused our efforts on exploring whole genome-wide expression and DNA 
methylation patterns across six different tissues: brain, breast, heart, liver, lung, and 
small intestine from the NIH roadmap epigenomics consortium using bisulfite-
sequencing data. Using our UPC barcoded approach, we extended the pipeline from 
gene expression and DNA methylation to chromatin immunoprecipitation (ChIP, MeDIP), 
restriction enzyme digestion (MRE, DNase), and bisulfite conversion (BeadChip arrays). 
UPCs have the advantage of being interpreted consistently, irrespective of profiling 
technology, thus enabling platform-agnostic downstream analysis pipelines to be 
developed.  In Chapter 3, we identified 103 genomic locations with genetic-epigenetics 
coordination by exploring methylated and unmethylated status across different tissues 
with respect to gene expression profiles. Increased DNA methylation has mostly been 
reported associated with decreased gene expression profiles, so we performed 
correlation analysis on data sets for bisulfite sequencing and mRNA sequencing. We 
extracted genomic locations from different chromosome with negative correlation 
between gene expression and DNA methylation across different tissues. We observed 
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regions with higher methylation activity with no gene expression signal and vice versa. 
We also observed tissue-specific gene expression and methylation profiles for specific 
genomic locations across tissues. Although these 103 genes actually resulted in weak 
signal prediction in patient data as we saw no differential expression and differential 
methylation between control and VPA treated breast cancer cell lines data (training 
set) for 103 genes. Due to technical limitations, we lost a large number of overlapping 
genes coming from NIH Roadmap data in drug treated cell line data, which also 
summarizes the challenges in biomarker discovery not only associated with technical 
limitations but behind the regulated mechanism controlling omic profiles across cell 
types. 
Availability of data 
The methylation data generated in the study from breast cancer cell lines and xenograft, 
treated with VPA are available on GEO GSE94943. This series include raw data files for 
all 72 samples generated on 450K-methylation beadchip platform. The code used in the 
data analysis is available in the following gitHub repository link: 
https://github.com/supriya-sharma/drugsignature_prediction. 
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SUPPLEMENTARY FIGURES 
 
Figure S1: DAVID analysis functional annotations for breast cancer cell lines signature. 
The top 500 differentially expressed and methylated genes were extracted (using 
LIMMA) from breast cancer cell lines by ASSIGN signature prediction Functional 
annotation clustering analysis on above 500 genes was performed by DAVID. 
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Figure S2: PCA analysis on the gene expression profiling data of the TCGA breast 
carcinoma samples. 
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Figure S3: PCA analysis on the methylation profiling data of the TCGA breast carcinoma 
samples.  
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Figure S4: PCA analysis to visualize different data sets from three different experiments 
of methylation data combined for breast cancer cell lines, mouse xenograft SUTI110 and 
SUTI 320, and TCGA samples. We observed a complete separation between two 
experimental mouse models (mouse SUTI110 and SUTI 320) and between cell lines and 
TCGA data. Control and drug treated cell lines showed separation, while TCGA samples 
were processed in same batch are clustered together. 
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Figure S5: Gene enrichment analysis on SAHA-only genes on PANTHER, 55 genes 
enriched for binding, 44 genes enriched for catalytic activity. 
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Figure S6: Gene enrichment analysis on TSA-only genes on PANTHER, 50 genes 
enriched for binding, 43 genes enriched for catalytic activity. 
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Figure S7: Gene enrichment analysis on VPA-only genes on PANTHER, 34 genes 
enriched for binding, 57 genes enriched for catalytic activity. 
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SUPPLEMENTARY TABLES 
VPA  predictions in TCGA using unsmoothened data 
TCGA.BH.A0DQ.11A.12D.A10Q.05 0.007481728 
TCGA.BH.A0B3.11B.21D.A10Q.05 0.006983382 
TCGA.BH.A0DK.11A.13D.A10Q.05 0.004207568 
TCGA.BH.A1EO.11A.31D.A138.05 0.003661098 
TCGA.BH.A0BA.11A.22D.A10Q.05 0.005104458 
TCGA.BH.A0E0.11A.13D.A10Q.05 0.003565261 
TCGA.A7.A0D9.11A.53D.A10Q.05 0.005377114 
TCGA.BH.A0DV.11A.22D.A12R.05 0.005985656 
TCGA.BH.A0BM.11A.12D.A093.05 0.005670439 
TCGA.E2.A15I.11A.32D.A138.05 0.006081028 
TCGA.A7.A13E.11A.61D.A12R.05 0.004408454 
TCGA.BH.A1ET.11B.23D.A138.05 0.002130031 
TCGA.BH.A0BS.11A.11D.A12R.05 0.006083888 
TCGA.BH.A1EU.11A.23D.A138.05 0.004561236 
TCGA.BH.A0BZ.11A.61D.A12R.05 0.005661247 
TCGA.BH.A0AU.11A.11D.A12R.05 0.004481851 
TCGA.BH.A0DH.11A.31D.A10Q.05 0.004047366 
TCGA.BH.A0C3.11A.23D.A12R.05 0.003462363 
TCGA.BH.A0BC.11A.22D.A093.05 0.008734918 
TCGA.BH.A0HK.11A.11D.A10Q.05 0.005122856 
TCGA.BH.A0H9.11A.22D.A093.05 0.005791317 
TCGA.BH.A0HA.11A.31D.A12R.05 0.007183573 
TCGA.BH.A1EW.11B.33D.A138.05 0.004822702 
TCGA.BH.A0BJ.11A.23D.A10Q.05 0.002256012 
TCGA.BH.A0E1.11A.13D.A10Q.05 0.006745223 
TCGA.A7.A13F.11A.42D.A12R.05 0.006561593 
TCGA.BH.A0H7.11A.13D.A10Q.05 0.005102925 
TCGA.BH.A1F0.11B.23D.A138.05 0.00434898 
TCGA.BH.A0DP.11A.12D.A10Q.05 0.005451564 
TCGA.BH.A0B8.11A.41D.A093.05 0.007176098 
TCGA.E2.A1BC.11A.32D.A12R.05 0.005502357 
TCGA.BH.A0C0.11A.21D.A10Q.05 0.002843289 
TCGA.BH.A0H3.01A.11D.A12R.05 0.004137387 
TCGA.AR.A1AY.01A.21D.A12R.05 0.003030671 
TCGA.A1.A0SM.01A.11D.A10P.05 0.003719745 
TCGA.AN.A0XS.01A.22D.A10A.05 0.002234065 
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TCGA.AO.A0JG.01A.31D.A10P.05 0.003112895 
TCGA.B6.A0IK.01A.12D.A10P.05 0.004646606 
TCGA.A2.A0SV.01A.11D.A10P.05 0.005059275 
TCGA.BH.A0HK.01A.11D.A10P.05 0.006052707 
TCGA.E2.A10C.01A.21D.A10N.05 0.004177912 
TCGA.E2.A1B0.01A.11D.A12R.05 0.003586686 
TCGA.E2.A105.01A.11D.A10N.05 0.006633551 
TCGA.AN.A0XW.01A.11D.A10A.05 0.003894584 
TCGA.AO.A0JA.01A.11D.A10P.05 0.002856309 
TCGA.BH.A0HA.01A.11D.A12R.05 0.004014768 
TCGA.AN.A0XO.01A.11D.A10A.05 0.002198003 
TCGA.B6.A0WV.01A.11D.A10A.05 0.005411057 
TCGA.E2.A1BC.01A.11D.A12R.05 0.004071702 
TCGA.AO.A0JE.01A.11D.A10P.05 0.00222716 
TCGA.BH.A0H6.01A.21D.A10P.05 0.005509679 
TCGA.C8.A1HL.01A.11D.A138.05 0.002349998 
TCGA.AR.A1AU.01A.11D.A12R.05 0.003939572 
TCGA.E2.A15K.06A.11D.A12R.05 0.005976479 
TCGA.B6.A0RN.01A.12D.A10P.05 0.0035807 
TCGA.A2.A0SU.01A.11D.A10P.05 0.005575257 
TCGA.E2.A106.01A.11D.A10N.05 0.003708666 
TCGA.E2.A10F.01A.11D.A10N.05 0.007670503 
TCGA.BH.A0W3.01A.11D.A10A.05 0.00518 148 
TCGA.BH.A1F0.01A.11D.A138.05 0.005551899 
TCGA.A2.A0YE.01A.11D.A10A.05 0.003228078 
TCGA.A7.A13E.01A.11D.A12R.05 0.005233268 
TCGA.BH.A0AW.01A.11D.A10P.05 0.003093219 
TCGA.AR.A0TR.01A.11D.A10P.05 0.007590065 
TCGA.BH.A0DI.01A.21D.A12R.05 0.006613896 
TCGA.A2.A0T6.01A.11D.A10P.05 0.004627554 
TCGA.A1.A0SO.01A.22D.A10P.05 0.003221583 
TCGA.BH.A0BJ.01A.11D.A10P.05 0.005579227 
TCGA.A2.A0EU.01A.22D.A10P.05 0.002621183 
TCGA.B6.A0WZ.01A.11D.A10A.05 0.004724636 
TCGA.BH.A0B5.01A.11D.A12R.05 0.003378702 
TCGA.A2.A0YH.01A.11D.A10A.05 0.003620776 
TCGA.BH.A1EO.01A.11D.A138.05 0.005084574 
TCGA.A2.A0YM.01A.11D.A10A.05 0.005002952 
TCGA.AO.A125.01A.11D.A10N.05 0.004060624 
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TCGA.B6.A0RG.01A.11D.A10P.05 0.004096428 
TCGA.E2.A1B5.01A.21D.A12R.05 0.003066134 
TCGA.E2.A15I.01A.21D.A138.05 0.004353111 
TCGA.AO.A12G.01A.11D.A10N.05 0.006935495 
TCGA.BH.A0E0.01A.11D.A10P.05 0.00446237 
TCGA.B6.A0RL.01A.11D.A10P.05 0.004518183 
TCGA.BH.A0B9.01A.11D.A10P.05 0.003241087 
TCGA.B6.A0RM.01A.11D.A10P.05 0.004903756 
TCGA.BH.A0E2.01A.11D.A10P.05 0.006012318 
TCGA.A8.A0AD.01A.11D.A10P.05 0.007364535 
TCGA.AO.A124.01A.11D.A10N.05 0.004511424 
TCGA.A1.A0SP.01A.11D.A10P.05 0.004966359 
TCGA.A2.A0SW.01A.11D.A10P.05 0.005660729 
TCGA.E2.A1B4.01A.11D.A12R.05 0.007753176 
TCGA.E2.A1B6.01A.31D.A12R.05 0.007599778 
TCGA.AR.A1AV.01A.21D.A12R.05 0.004022035 
TCGA.AQ.A04L.01B.21D.A10N.05 0.003413629 
TCGA.BH.A1EU.01A.11D.A138.05 0.004626917 
TCGA.AR.A0U3.01A.11D.A10A.05 0.006910686 
TCGA.AO.A0JC.01A.11D.A10P.05 0.005461723 
TCGA.AO.A12C.01A.11D.A10N.05 0.004167172 
TCGA.AO.A03L.01A.41D.A10P.05 0.003697603 
TCGA.A7.A13F.01A.11D.A12R.05 0.005969587 
TCGA.A2.A0YT.01A.11D.A10A.05 0.009110358 
TCGA.A2.A0SY.01A.31D.A10P.05 0.004005739 
TCGA.BH.A0W5.01A.11D.A10A.05 0.004447155 
TCGA.E2.A15K.01A.11D.A12R.05 0.004870613 
TCGA.AR.A1AN.01A.11D.A12R.05 0.003574999 
TCGA.BH.A0RX.01A.21D.A10P.05 0.006190822 
TCGA.BH.A0GY.01A.11D.A10P.05 0.005845144 
TCGA.BH.A0HP.01A.12D.A10P.05 0.006096854 
TCGA.AR.A0TP.01A.11D.A10P.05 0.003715933 
TCGA.A8.A075.01A.11D.A10P.05 0.004878424 
TCGA.B6.A0WW.01A.11D.A10A.05 0.002731077 
TCGA.BH.A0HF.01A.11D.A10P.05 0.005386479 
TCGA.BH.A0BZ.01A.31D.A12R.05 0.006084875 
TCGA.E2.A10E.01A.21D.A10N.05 0.005778588 
TCGA.BH.A0BA.01A.11D.A10P.05 0.004877604 
TCGA.B6.A0RP.01A.21D.A10P.05 0.005880335 
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TCGA.BH.A0BT.01A.11D.A12R.05 0.006438997 
TCGA.C8.A1HG.01A.11D.A138.05 0.004488908 
TCGA.BH.A1EW.01A.11D.A138.05 0.007160813 
TCGA.A2.A0YC.01A.11D.A10A.05 0.00588259 
TCGA.AR.A0TV.01A.21D.A10P.05 0.005178542 
TCGA.AR.A1AS.01A.11D.A12R.05 0.004437695 
TCGA.E2.A109.01A.11D.A10N.05 0.006309665 
TCGA.E2.A1BD.01A.11D.A12R.05 0.004337178 
TCGA.BH.A1EV.01A.11D.A138.05 0.004000662 
TCGA.A7.A0D9.01A.31D.A10P.05 0.007665483 
TCGA.A1.A0SK.01A.12D.A10P.05 0.004793176 
TCGA.BH.A0HX.01A.21D.A10P.05 0.002482767 
TCGA.B6.A0WX.01A.11D.A10A.05 0.006908275 
TCGA.B6.A0RS.01A.11D.A10P.05 0.005189968 
TCGA.AR.A1AP.01A.11D.A12R.05 0.004688048 
TCGA.BH.A0WA.01A.11D.A10A.05 0.005583751 
TCGA.AR.A1AW.01A.21D.A12R.05 0.004727808 
TCGA.A2.A0T0.01A.22D.A10P.05 0.006525447 
TCGA.AR.A0TT.01A.31D.A10P.05 0.005134969 
TCGA.AR.A1AT.01A.11D.A12R.05 0.003636057 
TCGA.BH.A1ET.01A.11D.A138.05 0.003432473 
TCGA.BH.A0BS.01A.11D.A12R.05 0.004902988 
TCGA.E2.A108.01A.13D.A10N.05 0.008811121 
TCGA.AN.A0XN.01A.21D.A10A.05 0.002993314 
TCGA.AO.A0JL.01A.11D.A10P.05 0.003125091 
TCGA.BH.A0H0.01A.11D.A10P.05 0.003795048 
TCGA.AO.A03N.01B.11D.A10N.05 0.005665628 
TCGA.BH.A0E1.01A.11D.A10P.05 0.004028643 
TCGA.C8.A1HN.01A.11D.A138.05 0.003155995 
TCGA.AR.A1AL.01A.21D.A12R.05 0.004699683 
TCGA.A2.A0YI.01A.31D.A10N.05 0.004046469 
TCGA.AR.A1AX.01A.11D.A12R.05 0.005762302 
TCGA.AN.A0XV.01A.11D.A10A.05 0.003022781 
TCGA.E2.A14N.01A.31D.A138.05 0.005120922 
TCGA.AR.A0TX.01A.11D.A10P.05 0.003825255 
TCGA.BH.A0B8.01A.21D.A10P.05 0.00418056 
TCGA.E2.A10B.01A.11D.A10N.05 0.003445554 
TCGA.A1.A0SH.01A.11D.A10P.05 0.003631507 
TCGA.AR.A0U2.01A.11D.A10A.05 0.005529585 
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TCGA.BH.A0HY.01A.11D.A10P.05 0.007342597 
TCGA.A2.A0YF.01A.21D.A10A.05 0.004227783 
TCGA.AR.A0U0.01A.11D.A10A.05 0.004191931 
TCGA.B6.A0X4.01A.11D.A10A.05 0.00374443 
TCGA.A2.A0T5.01A.21D.A10P.05 0.006113399 
TCGA.AN.A0XR.01A.11D.A10A.05 0.004673885 
TCGA.AR.A0U4.01A.11D.A10A.05 0.003032262 
TCGA.E2.A15J.01A.11D.A12R.05 0.006701803 
TCGA.A2.A0EN.01A.13D.A10P.05 0.002829238 
TCGA.B6.A0WY.01A.11D.A10A.05 0.003345024 
TCGA.B6.A0X7.01A.11D.A10N.05 0.005120253 
TCGA.BH.A0C0.01A.21D.A10P.05 0.004245128 
TCGA.B6.A0RT.01A.21D.A10P.05 0.006201641 
TCGA.C8.A1HI.01A.11D.A138.05 0.00267761 
TCGA.BH.A0C3.01A.21D.A12R.05 0.00339262 
TCGA.AR.A0TZ.01A.12D.A10P.05 0.004080266 
TCGA.AQ.A04H.01B.11D.A10N.05 0.004255283 
TCGA.A2.A0T2.01A.11D.A10P.05 0.006398353 
TCGA.A2.A0T4.01A.31D.A10P.05 0.002009306 
TCGA.E2.A107.01A.11D.A10N.05 0.004936505 
TCGA.AO.A12E.01A.11D.A10N.05 0.004875582 
TCGA.AR.A1AJ.01A.21D.A12R.05 0.007370393 
TCGA.A7.A13D.01A.13D.A12R.05 0.004249298 
TCGA.BH.A0DH.01A.11D.A10P.05 0.004478194 
TCGA.A2.A0YK.01A.22D.A10A.05 0.002978679 
TCGA.AO.A0JI.01A.21D.A10P.05 0.006874959 
TCGA.A2.A0YD.01A.11D.A10A.05 0.003864627 
TCGA.A2.A0YL.01A.21D.A10A.05 0.005344285 
TCGA.B6.A0RO.01A.22D.A10P.05 0.00288861 
TCGA.BH.A0DQ.01A.11D.A10P.05 0.004703059 
TCGA.C8.A1HF.01A.11D.A138.05 0.004776993 
TCGA.BH.A0B3.01A.11D.A10P.05 0.003688105 
TCGA.AO.A126.01A.11D.A10N.05 0.005055207 
TCGA.AO.A129.01A.21D.A10N.05 0.004060163 
TCGA.BH.A0HI.01A.11D.A10P.05 0.005367915 
TCGA.BH.A0H9.01A.11D.A10P.05 0.004405858 
TCGA.B6.A0X5.01A.21D.A10A.05 0.006662572 
TCGA.AO.A03M.01B.11D.A10N.05 0.003466488 
TCGA.BH.A1ES.01A.11D.A138.05 0.007198607 
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TCGA.AR.A1AK.01A.21D.A12R.05 0.00622292 
TCGA.A2.A0YJ.01A.11D.A10A.05 0.004405081 
TCGA.BH.A0H7.01A.13D.A10P.05 0.004363733 
TCGA.A8.A0A6.01A.12D.A10P.05 0.006662677 
TCGA.A2.A0CT.01A.31D.A10P.05 0.003824759 
TCGA.BH.A0HB.01A.11D.A10P.05 0.004569775 
TCGA.AN.A0XL.01A.11D.A10N.05 0.005320296 
TCGA.AR.A1AI.01A.11D.A12R.05 0.005165608 
TCGA.AN.A0XT.01A.11D.A10A.05 0.005001892 
TCGA.B6.A0RU.01A.11D.A10P.05 0.002901868 
TCGA.AO.A0JB.01A.11D.A10P.05 0.006161489 
TCGA.A1.A0SE.01A.11D.A10P.05 0.002346617 
TCGA.B6.A0WT.01A.11D.A10A.05 0.003335766 
TCGA.BH.A0DS.01A.11D.A10P.05 0.004632027 
TCGA.BH.A0DP.01A.21D.A10P.05 0.00466949 
TCGA.AR.A1AR.01A.31D.A138.05 0.006912293 
TCGA.BH.A0BC.01A.22D.A10P.05 0.007133046 
TCGA.A2.A0SX.01A.12D.A10P.05 0.003857574 
TCGA.E2.A1AZ.01A.11D.A12R.05 0.00585069 
TCGA.AN.A0XP.01A.11D.A10A.05 0.006697218 
TCGA.B6.A0RI.01A.11D.A10P.05 0.003715878 
TCGA.BH.A0BF.01A.21D.A12R.05 0.00529479 
TCGA.B6.A0RV.01A.11D.A10P.05 0.003930334 
TCGA.BH.A0BM.01A.11D.A10P.05 0.004777698 
TCGA.AO.A0JM.01A.21D.A10P.05 0.004580386 
TCGA.E2.A1B1.01A.21D.A12R.05 0.005051534 
TCGA.A8.A08O.01A.21D.A10P.05 0.004327067 
TCGA.A2.A0T7.01A.21D.A10P.05 0.002922358 
TCGA.BH.A0GZ.01A.11D.A10P.05 0.003080986 
TCGA.BH.A0AU.01A.11D.A12R.05 0.004639711 
TCGA.AO.A03U.01B.21D.A10N.05 0.010458607 
TCGA.AR.A0TU.01A.31D.A10A.05 0.005393397 
TCGA.AO.A0JJ.01A.11D.A10P.05 0.006445223 
TCGA.BH.A0AZ.01A.21D.A12R.05 0.003726351 
TCGA.A2.A0ST.01A.12D.A10P.05 0.003166447 
TCGA.BH.A0DK.01A.21D.A10P.05 0.005643589 
TCGA.A2.A0T1.01A.21D.A10P.05 0.003999976 
TCGA.BH.A0DG.01A.21D.A12R.05 0.0060383 
TCGA.AR.A0TW.01A.11D.A10P.05 0.003189697 
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TCGA.AO.A12B.01A.11D.A10N.05 0.00385861 
TCGA.B6.A0X1.01A.11D.A10A.05 0.004289835 
TCGA.AO.A128.01A.11D.A10N.05 0.006181778 
TCGA.C8.A1HM.01A.12D.A138.05 0.004123266 
TCGA.AO.A0JD.01A.11D.A10P.05 0.00726664 
TCGA.B6.A0RE.01A.11D.A10P.05 0.005996137 
TCGA.A2.A0YG.01A.21D.A10A.05 0.005735151 
TCGA.AR.A0TQ.01A.11D.A10P.05 0.004657062 
TCGA.A2.A04R.01A.41D.A10A.05 0.003882034 
TCGA.A1.A0SJ.01A.11D.A10P.05 0.002366391 
TCGA.BH.A0DD.01A.31D.A12R.05 0.007568813 
TCGA.AR.A1AO.01A.11D.A12R.05 0.002465224 
TCGA.AR.A1AQ.01A.11D.A12R.05 0.005319799 
TCGA.AN.A0XU.01A.11D.A10A.05 0.004327784 
TCGA.BH.A0W4.01A.11D.A10A.05 0.004638693 
TCGA.AO.A0JF.01A.11D.A10P.05 0.007018679 
Supplementary Table 1 VPA methylation signature predictions in TCGA using 
unsmoothened data. 
VPA  predictions in Xenograft 
using unsmoothened data   
110p5_zeb1_2_h 0.003142682 
320p2_ck1_2_h 0.005681292 
110p5_zeb2_2_h 0.004249688 
320p2_ck2_2_h 0.003563555 
110p5_zeb3_2_h 0.002228956 
320p2_ck3_2_h 0.002642751 
110p5_zeb4_6_h 0.004919818 
320p2_ck4_6_h 0.004478486 
110p5_zeb5_6_h 0.004647055 
320p2_ck5_6_h 0.005093583 
110p5_zeb6_6_h 0.005998372 
320p2_ck6_6_h 0.004057624 
110p5_ck_2_h 0.002771826 
110p5_vpa1_2_h 0.003021936 
110p5_ck-1_2_h 0.003819968 
110p5_vpa2_2_h 0.003904431 
110p5_ck-2_2_h 0.004018917 
110p5_vpa3_2_h 0.005155175 
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110p5_ck4_6_h 0.002897108 
110p5_vpa4_6_h 0.006813395 
110p5_ck5_6_h 0.00622042 
110p5_vpa5_6_h 0.003069236 
110p5_ck6_6_h 0.003786031 
110p5_vpa6_6_h 0.005400175 
 
Supplementary Table 2: VPA methylation signature predictions in xenograft using 
unsmoothened data. 
Mouse Xenograft Untreated VPA treated 
110p5 0.531 0.171 
110p5 0.588 0.192 
110p5 0.721 0.211 
320p 0.382 0.313 
320p 0.355 0.231 
320p 0.251 0.153 
Supplementary Table 3: VPA methylation signature predictions in xenograft using 
smoothened data. 
 
SampleID Vpa-Methyltion Subtype 
TCGA.BH.A0HK 0.177861276 Normal 
TCGA.BH.A0BM 0.297027438 Normal 
TCGA.BH.A0B3 0.199414062 Normal 
TCGA.BH.A0DK 0.275537978 Normal 
TCGA.BH.A0BJ 0.228714749 Normal 
TCGA.BH.A0DP 0.241082695 Normal 
TCGA.BH.A0DQ 0.305635501 Normal 
TCGA.BH.A0B8 -0.002998578 Normal 
TCGA.BH.A0C0 0.244010022 Normal 
TCGA.BH.A0BA 0.141148947 Normal 
TCGA.BH.A0BC -0.002588531 Normal 
TCGA.BH.A0DH -0.002150998 Normal 
TCGA.BH.A0E1 0.334592326 Normal 
TCGA.BH.A0H9 0.006783576 Normal 
TCGA.A7.A0D9 -0.012001068 Normal 
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TCGA.BH.A0H7 0.266536221 Normal 
TCGA.BH.A0E0 0.191929465 Normal 
TCGA.BH.A0C3 0.235751954 Normal 
TCGA.BH.A0BS 0.283189544 Normal 
TCGA.A7.A13E -0.00279748 Normal 
TCGA.BH.A0BZ -0.000731403 Normal 
TCGA.A7.A13F 0.003086807 Normal 
TCGA.BH.A0AU 0.383914714 Normal 
TCGA.BH.A0DV 0.476444046 Normal 
TCGA.BH.A1F0 0.00082247 Normal 
TCGA.E2.A1BC -0.008094959 Normal 
TCGA.BH.A0HA 0.371101262 Normal 
TCGA.E2.A15I -0.012494082 Normal 
TCGA.BH.A1EW 0.034731748 Normal 
TCGA.BH.A1EU 0.130685593 Normal 
TCGA.BH.A1ET 0.007572001 Normal 
TCGA.BH.A1EO -0.011696776 Normal 
TCGA.BH.A1F0 0.456874713 Basal 
TCGA.E2.A14N 0.747414652 Basal 
TCGA.AR.A1AR 0.515505044 Basal 
TCGA.E2.A1B5 0.740726555 Basal 
TCGA.AR.A1AJ 0.559663291 Basal 
TCGA.AR.A1AI 0.891272538 Basal 
TCGA.E2.A1AZ 0.572295735 Basal 
TCGA.AR.A1AQ 0.771901279 Basal 
TCGA.AR.A1AY 0.709299424 Basal 
TCGA.A7.A13E 0.85564951 Basal 
TCGA.A7.A13D 0.836677295 Basal 
TCGA.A2.A0T2 0.824384414 Basal 
TCGA.AO.A129 0.770399733 Basal 
TCGA.AO.A128 0.807757505 Basal 
TCGA.AO.A124 0.813275467 Basal 
TCGA.AR.A0U0 0.897226956 Basal 
TCGA.AN.A0XU 0.801156733 Basal 
TCGA.BH.A0WA 0.737778075 Basal 
TCGA.AR.A0TU 0.788930993 Basal 
TCGA.B6.A0X1 0.936075946 Basal 
TCGA.AR.A0TP 0.809283065 Basal 
TCGA.B6.A0RT 0.601324135 Basal 
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TCGA.A2.A0SX 0.617503121 Basal 
TCGA.A1.A0SK 0.85981999 Basal 
TCGA.A1.A0SP 0.685958701 Basal 
TCGA.A2.A0T0 0.810894036 Basal 
TCGA.A1.A0SO 0.858262017 Basal 
TCGA.B6.A0RU 0.483529895 Basal 
TCGA.A2.A0ST 0.589245841 Basal 
TCGA.BH.A0RX 0.586593406 Basal 
TCGA.BH.A0B3 0.745922852 Basal 
TCGA.B6.A0RE 0.881400981 Basal 
TCGA.A2.A0YT 0.842818841 Basal 
TCGA.A2.A0YE 0.798503303 Basal 
TCGA.A2.A0YM 0.764301728 Basal 
TCGA.B6.A0WX 0.663657786 Basal 
TCGA.AR.A0U4 0.711073297 Basal 
TCGA.A2.A0YJ 0.956369104 Basal 
TCGA.AO.A0JL 0.708357432 Basal 
TCGA.BH.A0E0 0.828513839 Basal 
TCGA.BH.A0B9 0.814189964 Basal 
TCGA.BH.A1EV 0.76430659 her2 
TCGA.C8.A1HF 0.729375711 her2 
TCGA.AR.A1AT 0.813269175 her2 
TCGA.E2.A1B0 0.646896659 her2 
TCGA.AO.A03N 0.771988171 her2 
TCGA.B6.A0RS 0.643134017 her2 
TCGA.AR.A0TX 0.567342154 her2 
TCGA.A2.A0T1 0.618400456 her2 
TCGA.A8.A075 0.812847224 her2 
TCGA.AO.A0JE 0.674642586 her2 
TCGA.BH.A0AW 0.764838687 her2 
TCGA.BH.A0HY 0.774412431 her2 
TCGA.B6.A0IK 0.832604874 her2 
TCGA.AO.A03L 0.783774218 her2 
TCGA.BH.A1EO 0.383669803 Luminal-A 
TCGA.C8.A1HI 0.675608513 Luminal-A 
TCGA.BH.A1ET 0.659531992 Luminal-A 
TCGA.E2.A1B6 0.480084151 Luminal-A 
TCGA.E2.A15I 0.634288736 Luminal-A 
TCGA.BH.A1EU 0.35808825 Luminal-A 
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TCGA.BH.A1ES 0.812131434 Luminal-A 
TCGA.BH.A0HA 0.524291838 Luminal-A 
TCGA.BH.A0BT 0.781325489 Luminal-A 
TCGA.AR.A1AW 0.845638239 Luminal-A 
TCGA.AR.A1AN 0.501481666 Luminal-A 
TCGA.BH.A0H3 0.754089101 Luminal-A 
TCGA.BH.A0BS 0.77469838 Luminal-A 
TCGA.AR.A1AL 0.486224653 Luminal-A 
TCGA.E2.A1B4 0.708271519 Luminal-A 
TCGA.AR.A1AU 0.49364552 Luminal-A 
TCGA.AR.A1AK 0.553199565 Luminal-A 
TCGA.E2.A1B1 0.512108202 Luminal-A 
TCGA.BH.A0DI 0.575903308 Luminal-A 
TCGA.E2.A1BD 0.774097628 Luminal-A 
TCGA.BH.A0DG 0.532902117 Luminal-A 
TCGA.BH.A0AZ 0.670776504 Luminal-A 
TCGA.AR.A1AS 0.988305155 Luminal-A 
TCGA.AR.A1AP 0.660014888 Luminal-A 
TCGA.E2.A1BC 0.467983528 Luminal-A 
TCGA.E2.A15J 0.902061629 Luminal-A 
TCGA.AR.A1AX 0.531100013 Luminal-A 
TCGA.AN.A0XL 0.414014987 Luminal-A 
TCGA.E2.A10B 0.736867384 Luminal-A 
TCGA.B6.A0X7 0.543995824 Luminal-A 
TCGA.E2.A106 0.919593282 Luminal-A 
TCGA.AO.A12E 0.552630437 Luminal-A 
TCGA.E2.A10F 0.665649363 Luminal-A 
TCGA.E2.A105 0.895188978 Luminal-A 
TCGA.AO.A12C 0.724777364 Luminal-A 
TCGA.E2.A10E 0.797405506 Luminal-A 
TCGA.A2.A0YI 0.66835689 Luminal-A 
TCGA.AO.A03M 0.810796002 Luminal-A 
TCGA.AO.A126 0.671195199 Luminal-A 
TCGA.AQ.A04L 0.762415709 Luminal-A 
TCGA.AO.A125 0.962586905 Luminal-A 
TCGA.AO.A12G 0.627772413 Luminal-A 
TCGA.B6.A0X4 0.911088365 Luminal-A 
TCGA.AN.A0XT 0.616966219 Luminal-A 
TCGA.BH.A0W5 0.528683567 Luminal-A 
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TCGA.A2.A0SY 0.508649709 Luminal-A 
TCGA.BH.A0HP 0.570641879 Luminal-A 
TCGA.A2.A0T7 0.644728803 Luminal-A 
TCGA.A2.A0T6 0.340161859 Luminal-A 
TCGA.A1.A0SJ 0.492048241 Luminal-A 
TCGA.B6.A0RP 0.67405347 Luminal-A 
TCGA.AR.A0TW 0.910270055 Luminal-A 
TCGA.A2.A0T5 0.69455725 Luminal-A 
TCGA.A1.A0SH 0.63535049 Luminal-A 
TCGA.A2.A0SU 0.652552002 Luminal-A 
TCGA.A1.A0SE 0.651940289 Luminal-A 
TCGA.BH.A0HI 0.724835669 Luminal-A 
TCGA.B6.A0RO 0.800679189 Luminal-A 
TCGA.A2.A0EN 0.450153343 Luminal-A 
TCGA.B6.A0RN 0.644813374 Luminal-A 
TCGA.BH.A0DQ 0.494544735 Luminal-A 
TCGA.B6.A0RV 0.569516394 Luminal-A 
TCGA.BH.A0BC 0.645025026 Luminal-A 
TCGA.AO.A0JG 0.544877982 Luminal-A 
TCGA.B6.A0RM 0.743508857 Luminal-A 
TCGA.BH.A0DH 0.764958361 Luminal-A 
TCGA.AR.A0TR 0.925735915 Luminal-A 
TCGA.AO.A0JF 0.345305167 Luminal-A 
TCGA.BH.A0HX 0.761838782 Luminal-A 
TCGA.BH.A0GZ 0.71373769 Luminal-A 
TCGA.BH.A0DK 0.583747009 Luminal-A 
TCGA.BH.A0B8 0.763432239 Luminal-A 
TCGA.B6.A0RI 0.796833695 Luminal-A 
TCGA.BH.A0HK 0.534375068 Luminal-A 
TCGA.BH.A0GY 0.772745803 Luminal-A 
TCGA.A7.A0D9 0.733054427 Luminal-A 
TCGA.B6.A0RG 0.962635889 Luminal-A 
TCGA.BH.A0HF 0.55001884 Luminal-A 
TCGA.A2.A0EU 0.68967533 Luminal-A 
TCGA.BH.A0HB 0.724372084 Luminal-A 
TCGA.BH.A0E2 0.779178204 Luminal-A 
TCGA.BH.A0H9 0.810507509 Luminal-A 
TCGA.BH.A0E1 0.785243407 Luminal-A 
TCGA.BH.A0BM 0.484327111 Luminal-A 
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TCGA.A8.A0AD 0.743001833 Luminal-A 
TCGA.A2.A0YF 0.680844997 Luminal-A 
TCGA.AN.A0XS 0.57719717 Luminal-A 
TCGA.B6.A0WZ 0.849682089 Luminal-A 
TCGA.BH.A0W4 0.513141034 Luminal-A 
TCGA.B6.A0WY 0.684679418 Luminal-A 
TCGA.A2.A0YD 0.527672228 Luminal-A 
TCGA.AN.A0XP 0.890153476 Luminal-A 
TCGA.A2.A0YL 0.470823652 Luminal-A 
TCGA.A2.A0YC 0.688882145 Luminal-A 
TCGA.AN.A0XO 0.770012103 Luminal-A 
TCGA.AN.A0XN 0.683316164 Luminal-A 
TCGA.AN.A0XV 0.578511581 Luminal-A 
TCGA.B6.A0WT 0.771277993 Luminal-A 
TCGA.A8.A08O 0.6431514 Luminal-A 
TCGA.BH.A0DP 0.588334196 Luminal-A 
TCGA.AO.A0JA 0.717249027 Luminal-A 
TCGA.BH.A0H7 0.821382494 Luminal-A 
TCGA.BH.A0BJ 0.631923018 Luminal-A 
TCGA.A8.A0A6 0.683345276 Luminal-A 
TCGA.AO.A0JJ 0.48911757 Luminal-A 
TCGA.BH.A0H6 0.660273683 Luminal-A 
TCGA.BH.A0DS 0.446412012 Luminal-A 
TCGA.BH.A0BA 0.620265578 Luminal-A 
TCGA.C8.A1HL 0.828033771 Luminal-B 
TCGA.C8.A1HM 0.872594761 Luminal-B 
TCGA.C8.A1HN 0.866997109 Luminal-B 
TCGA.BH.A1EW 0.61044576 Luminal-B 
TCGA.C8.A1HG 0.753656183 Luminal-B 
TCGA.AR.A1AV 0.565799513 Luminal-B 
TCGA.BH.A0BF 0.664547423 Luminal-B 
TCGA.BH.A0B5 0.632276282 Luminal-B 
TCGA.BH.A0DD 0.648137099 Luminal-B 
TCGA.BH.A0AU 0.593182013 Luminal-B 
TCGA.A7.A13F 0.970253125 Luminal-B 
TCGA.E2.A15K 0.674571316 Luminal-B 
TCGA.BH.A0C3 0.317014377 Luminal-B 
TCGA.E2.A15K 0.990518207 Luminal-B 
TCGA.BH.A0BZ 0.943216756 Luminal-B 
	  	   108	  
TCGA.AO.A12B 0.79546023 Luminal-B 
TCGA.E2.A10C 0.808037942 Luminal-B 
TCGA.E2.A109 0.879756528 Luminal-B 
TCGA.E2.A107 0.797040696 Luminal-B 
TCGA.AQ.A04H 0.809115125 Luminal-B 
TCGA.A2.A0YH 0.776713973 Luminal-B 
TCGA.A2.A0YG 0.908883403 Luminal-B 
TCGA.A2.A04R 0.827100254 Luminal-B 
TCGA.A1.A0SM 0.775908008 Luminal-B 
TCGA.AR.A0TZ 0.91123373 Luminal-B 
TCGA.A2.A0SW 0.689215328 Luminal-B 
TCGA.A2.A0SV 0.774889526 Luminal-B 
TCGA.AR.A0TV 0.906447841 Luminal-B 
TCGA.A2.A0T4 0.390384981 Luminal-B 
TCGA.B6.A0RL 0.98948383 Luminal-B 
TCGA.AR.A0TQ 0.70020797 Luminal-B 
TCGA.AO.A0JD 0.870278639 Luminal-B 
TCGA.A2.A0CT 0.790272288 Luminal-B 
TCGA.AO.A0JC 0.517682442 Luminal-B 
TCGA.BH.A0C0 0.851300236 Luminal-B 
TCGA.AO.A0JM 0.808992636 Luminal-B 
TCGA.AN.A0XR 0.926826869 Luminal-B 
TCGA.BH.A0W3 0.949989675 Luminal-B 
TCGA.B6.A0WW 0.915963511 Luminal-B 
TCGA.AR.A0U3 0.818654827 Luminal-B 
TCGA.AN.A0XW 0.75577565 Luminal-B 
TCGA.B6.A0WV 0.899373443 Luminal-B 
TCGA.AR.A0U2 0.918460454 Luminal-B 
TCGA.B6.A0X5 0.877225386 Luminal-B 
TCGA.AR.A0TT 0.692832288 Luminal-B 
TCGA.AO.A0JI 0.524159333 Luminal-B 
TCGA.BH.A0H0 0.836738029 Luminal-B 
TCGA.AR.A1AO 0.415593174 normal-like 
TCGA.AO.A03U 0.556447737 normal-like 
TCGA.E2.A108 0.280397853 normal-like 
TCGA.AO.A0JB 0.74042582 normal-like 
TCGA.A2.A0YK 0.373149663 normal-like 
Supplementary Table 4: VPA methylation signature predictions in TCGA methylation  
using smoothened data. 
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Supplementary Table 5: Tumor size (mm3) of SUTI 110 and SUTI, mouse xenograft 
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measured after VPA treatment over four weeks. 
Sample ID VPA SAHA TSA Subtype 
TCGA-A7-A13E -0.002 0 0.001 Normal 
TCGA-BH-A0B3 0.0057 0.018 0 Normal 
TCGA-BH-A0E0 0.0124 0.102 0 Normal 
TCGA-BH-A1F0 0 0 0.002 Normal 
TCGA-A7-A0D9 -0.006 0 0 Normal 
TCGA-BH-A0B8 0 0 0 Normal 
TCGA-BH-A0BA 0.0913 0.01 0.115 Normal 
TCGA-BH-A0BC 0 0.149 0.003 Normal 
TCGA-BH-A0BJ 0.003 0.133 0.008 Normal 
TCGA-BH-A0BM 0.2135 0.141 0.003 Normal 
TCGA-BH-A0BS 0.0948 0.003 0.045 Normal 
TCGA-BH-A0DH -0.001 0.007 0 Normal 
TCGA-BH-A0DK 0.1227 0.227 0 Normal 
TCGA-BH-A0DP 0.0223 0.001 0 Normal 
TCGA-BH-A0DQ 0.1007 0.107 0 Normal 
TCGA-BH-A0E1 0.0503 0.012 0.001 Normal 
TCGA-BH-A0H7 0.0191 0.216 0.038 Normal 
TCGA-BH-A0H9 0.0333 0.001 0 Normal 
TCGA-BH-A0HA 0.1619 0 0.014 Normal 
TCGA-BH-A0HK 0.0012 0.02 0.002 Normal 
TCGA-BH-A1EO -0.005 0.017 0.013 Normal 
TCGA-BH-A1ET -0.002 0 0.001 Normal 
TCGA-BH-A1EU 0.0018 0 0.028 Normal 
TCGA-E2-A15I -0.005 0 0 Normal 
TCGA-E2-A1BC -0.003 0 0.006 Normal 
TCGA-A7-A13F -0.001 0 0.002 Normal 
TCGA-BH-A0AU 0.2246 0.003 0.033 Normal 
TCGA-BH-A0BZ 0 0 0.001 Normal 
TCGA-BH-A0C0 0.0157 0.001 0 Normal 
TCGA-BH-A0C3 0.0093 0.002 0.006 Normal 
TCGA-BH-A1EW -0.002 0.21 0 Normal 
TCGA-A1-A0SK 0.9427 0.988 0.902 Basal 
TCGA-A1-A0SO 0.8507 0.979 0.928 Basal 
TCGA-A2-A0ST 0.3972 0.65 0.692 Basal 
TCGA-A2-A0SX 0.4811 0.755 0.714 Basal 
TCGA-A2-A0T0 0.8342 0.82 0.929 Basal 
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TCGA-A2-A0T2 0.7511 0.664 0.828 Basal 
TCGA-A2-A0YE 0.8612 0.892 0.83 Basal 
TCGA-A2-A0YJ 0.9708 0.947 0.945 Basal 
TCGA-A2-A0YM 0.8756 0.96 0.964 Basal 
TCGA-A7-A13D 0.9228 0.802 0.973 Basal 
TCGA-A7-A13E -0.002 0.796 0.848 Basal 
TCGA-AN-A0XU 0.848 0.927 0.824 Basal 
TCGA-AO-A0JL 0.7632 0.703 0.901 Basal 
TCGA-AO-A124 0.7857 0.877 0.91 Basal 
TCGA-AO-A128 0.6784 0.723 0.754 Basal 
TCGA-AO-A129 0.727 0.866 0.953 Basal 
TCGA-AR-A0TP 0.8681 0.766 0.808 Basal 
TCGA-AR-A0TU 0.7303 0.991 0.969 Basal 
TCGA-AR-A0U0 0.9218 0.833 0.862 Basal 
TCGA-AR-A0U4 0.8031 0.853 0.878 Basal 
TCGA-AR-A1AI 0.8713 0.94 0.974 Basal 
TCGA-AR-A1AJ 0.4018 0.828 0.818 Basal 
TCGA-AR-A1AQ 0.7251 0.89 0.873 Basal 
TCGA-AR-A1AR 0.3942 0.801 0.833 Basal 
TCGA-AR-A1AY 0.6959 0.985 0.829 Basal 
TCGA-B6-A0RE 0.9009 0.897 0.938 Basal 
TCGA-B6-A0RT 0.3687 0.831 0.809 Basal 
TCGA-B6-A0RU 0.4107 0.837 0.776 Basal 
TCGA-B6-A0WX 0.572 0.544 0.531 Basal 
TCGA-B6-A0X1 0.934 0.973 0.949 Basal 
TCGA-BH-A0B3 0.0057 0.907 0.912 Basal 
TCGA-BH-A0B9 0.8106 0.881 0.905 Basal 
TCGA-BH-A0E0 0.0124 0.816 0.955 Basal 
TCGA-BH-A0RX 0.5186 0.822 0.876 Basal 
TCGA-BH-A0WA 0.7509 0.857 0.842 Basal 
TCGA-BH-A1F0 0 0.692 0.711 Basal 
TCGA-E2-A14N 0.8474 0.966 0.988 Basal 
TCGA-E2-A1AZ 0.3875 0.89 0.819 Basal 
TCGA-E2-A1B5 0.6882 0.69 0.879 Basal 
TCGA-A2-A0T1 0.4948 0.612 0.598 Her2 
TCGA-A8-A075 0.8556 0.704 0.54 Her2 
TCGA-AO-A03L 0.5373 0.715 0.446 Her2 
TCGA-AO-A03N 0.8171 0.55 0.48 Her2 
TCGA-AO-A0JE 0.6819 0.564 0.402 Her2 
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TCGA-AR-A0TX 0.3591 0.552 0.38 Her2 
TCGA-AR-A1AT 0.7207 0.581 0.541 Her2 
TCGA-B6-A0IK 0.8359 0.656 0.644 Her2 
TCGA-B6-A0RS 0.5849 0.645 0.475 Her2 
TCGA-BH-A0AW 0.6602 0.623 0.728 Her2 
TCGA-BH-A0HY 0.7816 0.587 0.561 Her2 
TCGA-BH-A1EV 0.7786 0.465 0.276 Her2 
TCGA-C8-A1HF 0.6966 0.775 0.628 Her2 
TCGA-E2-A1B0 0.6174 0.683 0.671 Her2 
TCGA-A1-A0SE 0.4612 0.465 0.222 Luminal-A 
TCGA-A1-A0SH 0.5042 0.313 0.224 Luminal-A 
TCGA-A1-A0SJ 0.2951 0.57 0.294 Luminal-A 
TCGA-A2-A0EN 0.2625 0.271 0.181 Luminal-A 
TCGA-A2-A0EU 0.6116 0.498 0.11 Luminal-A 
TCGA-A2-A0SU 0.5139 0.388 0.191 Luminal-A 
TCGA-A2-A0SY 0.2522 0.366 0.114 Luminal-A 
TCGA-A2-A0T5 0.6305 0.437 0.354 Luminal-A 
TCGA-A2-A0T6 0.0804 0.21 0.002 Luminal-A 
TCGA-A2-A0T7 0.4021 0.546 0.27 Luminal-A 
TCGA-A2-A0YC 0.5586 0.362 0.005 Luminal-A 
TCGA-A2-A0YD 0.3228 0.298 0.142 Luminal-A 
TCGA-A2-A0YF 0.5244 0.451 0.152 Luminal-A 
TCGA-A2-A0YI 0.4363 0.166 0.024 Luminal-A 
TCGA-A2-A0YL 0.2251 0.396 0.163 Luminal-A 
TCGA-A7-A0D9 -0.006 0.3 0.065 Luminal-A 
TCGA-A8-A08O 0.4096 0.46 0.24 Luminal-A 
TCGA-A8-A0A6 0.4726 0.283 0.214 Luminal-A 
TCGA-A8-A0AD 0.7602 0.388 0.153 Luminal-A 
TCGA-AN-A0XL 0.175 0.404 0.121 Luminal-A 
TCGA-AN-A0XN 0.6465 0.46 0.45 Luminal-A 
TCGA-AN-A0XO 0.7081 0.436 0.318 Luminal-A 
TCGA-AN-A0XP 0.8393 0.272 0.223 Luminal-A 
TCGA-AN-A0XS 0.4705 0.274 0.21 Luminal-A 
TCGA-AN-A0XT 0.4561 0.288 0.003 Luminal-A 
TCGA-AN-A0XV 0.3575 0.449 0.269 Luminal-A 
TCGA-AO-A03M 0.6837 0.62 0.525 Luminal-A 
TCGA-AO-A0JA 0.479 0.545 0.348 Luminal-A 
TCGA-AO-A0JF 0.0165 0.199 0.004 Luminal-A 
TCGA-AO-A0JG 0.285 0.202 0.002 Luminal-A 
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TCGA-AO-A0JJ 0.2919 0.352 0.256 Luminal-A 
TCGA-AO-A125 0.9514 0.258 0.257 Luminal-A 
TCGA-AO-A126 0.6146 0.291 0.283 Luminal-A 
TCGA-AO-A12C 0.5202 0.264 0.184 Luminal-A 
TCGA-AO-A12E 0.4566 0.491 0.164 Luminal-A 
TCGA-AO-A12G 0.5463 0.415 0.256 Luminal-A 
TCGA-AQ-A04L 0.8655 0.439 0.448 Luminal-A 
TCGA-AR-A0TR 0.767 0.274 0.001 Luminal-A 
TCGA-AR-A0TW 0.7865 0.524 0.342 Luminal-A 
TCGA-AR-A1AK 0.2305 0.402 0.188 Luminal-A 
TCGA-AR-A1AL 0.1862 0.34 0.307 Luminal-A 
TCGA-AR-A1AN 0.2718 0.206 0.11 Luminal-A 
TCGA-AR-A1AP 0.48 0.535 0.319 Luminal-A 
TCGA-AR-A1AS 0.9549 0.46 0.451 Luminal-A 
TCGA-AR-A1AU 0.301 0.418 0.26 Luminal-A 
TCGA-AR-A1AW 0.7259 0.374 0.157 Luminal-A 
TCGA-AR-A1AX 0.3906 0.494 0.375 Luminal-A 
TCGA-B6-A0RG 0.8457 0.528 0.298 Luminal-A 
TCGA-B6-A0RI 0.7625 0.532 0.284 Luminal-A 
TCGA-B6-A0RM 0.7114 0.467 0.199 Luminal-A 
TCGA-B6-A0RN 0.5156 0.153 0.004 Luminal-A 
TCGA-B6-A0RO 0.7314 0.331 0.073 Luminal-A 
TCGA-B6-A0RP 0.5785 0.237 0.024 Luminal-A 
TCGA-B6-A0RV 0.3516 0.442 0.244 Luminal-A 
TCGA-B6-A0WT 0.7299 0.483 0.243 Luminal-A 
TCGA-B6-A0WY 0.5568 0.413 0.35 Luminal-A 
TCGA-B6-A0WZ 0.7735 0.345 0.316 Luminal-A 
TCGA-B6-A0X4 0.915 0.251 0.169 Luminal-A 
TCGA-B6-A0X7 0.4728 0.257 0.153 Luminal-A 
TCGA-BH-A0AZ 0.4529 0.246 0.232 Luminal-A 
TCGA-BH-A0B8 0 0.401 0.131 Luminal-A 
TCGA-BH-A0BA 0.0913 0.278 0.249 Luminal-A 
TCGA-BH-A0BC 0 0.496 0.364 Luminal-A 
TCGA-BH-A0BJ 0.003 0.327 0.247 Luminal-A 
TCGA-BH-A0BM 0.2135 0.051 0.058 Luminal-A 
TCGA-BH-A0BS 0.0948 0.359 0.339 Luminal-A 
TCGA-BH-A0BT 0.8004 0.315 0.187 Luminal-A 
TCGA-BH-A0DG 0.3408 0.489 0.345 Luminal-A 
TCGA-BH-A0DH -0.001 0.454 0.096 Luminal-A 
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TCGA-BH-A0DI 0.3655 0.264 0.281 Luminal-A 
TCGA-BH-A0DK 0.1227 0.49 0.376 Luminal-A 
TCGA-BH-A0DP 0.0223 0.253 0.144 Luminal-A 
TCGA-BH-A0DQ 0.1007 0.462 0.173 Luminal-A 
TCGA-BH-A0DS 0.2837 0.389 0.107 Luminal-A 
TCGA-BH-A0E1 0.0503 0.598 0.377 Luminal-A 
TCGA-BH-A0E2 0.6698 0.611 0.436 Luminal-A 
TCGA-BH-A0GY 0.6457 0.627 0.553 Luminal-A 
TCGA-BH-A0GZ 0.66 0.378 0.165 Luminal-A 
TCGA-BH-A0H3 0.6604 0.323 0.36 Luminal-A 
TCGA-BH-A0H6 0.711 0.318 0.294 Luminal-A 
TCGA-BH-A0H7 0.0191 0.535 0.393 Luminal-A 
TCGA-BH-A0H9 0.0333 0.504 0.329 Luminal-A 
TCGA-BH-A0HA 0.1619 0.188 0.147 Luminal-A 
TCGA-BH-A0HB 0.6848 0.638 0.425 Luminal-A 
TCGA-BH-A0HF 0.3986 0.353 0.302 Luminal-A 
TCGA-BH-A0HI 0.6476 0.271 0.019 Luminal-A 
TCGA-BH-A0HK 0.0012 0.223 0.232 Luminal-A 
TCGA-BH-A0HP 0.3719 0.364 0.196 Luminal-A 
TCGA-BH-A0HX 0.64 0.473 0.231 Luminal-A 
TCGA-BH-A0W4 0.4219 0.335 0.15 Luminal-A 
TCGA-BH-A0W5 0.3522 0.342 0.036 Luminal-A 
TCGA-BH-A1EO -0.005 0.4 0.234 Luminal-A 
TCGA-BH-A1ES 0.6822 0.523 0.376 Luminal-A 
TCGA-BH-A1ET -0.002 0.162 0 Luminal-A 
TCGA-BH-A1EU 0.0018 0.222 0.005 Luminal-A 
TCGA-C8-A1HI 0.3081 0.373 0.138 Luminal-A 
TCGA-E2-A105 0.7837 0.582 0.359 Luminal-A 
TCGA-E2-A106 0.8388 0.356 0.106 Luminal-A 
TCGA-E2-A10B 0.6719 0.482 0.283 Luminal-A 
TCGA-E2-A10E 0.7066 0.383 0.201 Luminal-A 
TCGA-E2-A10F 0.471 0.431 0.282 Luminal-A 
TCGA-E2-A15I -0.005 0.064 0.001 Luminal-A 
TCGA-E2-A15J 0.9225 0.395 0.35 Luminal-A 
TCGA-E2-A1B1 0.2517 0.377 0.328 Luminal-A 
TCGA-E2-A1B4 0.6772 0.104 0.001 Luminal-A 
TCGA-E2-A1B6 0.3317 0.268 0.35 Luminal-A 
TCGA-E2-A1BC -0.003 0.001 0.001 Luminal-A 
TCGA-E2-A1BD 0.7334 0.364 0.19 Luminal-A 
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TCGA-A1-A0SM 0.6948 0.534 0.266 Luminal-B 
TCGA-A2-A04R 0.7295 0.651 0.336 Luminal-B 
TCGA-A2-A0CT 0.665 0.545 0.043 Luminal-B 
TCGA-A2-A0SV 0.6681 0.754 0.552 Luminal-B 
TCGA-A2-A0SW 0.5873 0.695 0.461 Luminal-B 
TCGA-A2-A0T4 0.0926 0.532 0.109 Luminal-B 
TCGA-A2-A0YG 0.7454 0.765 0.514 Luminal-B 
TCGA-A2-A0YH 0.6444 0.704 0.443 Luminal-B 
TCGA-A7-A13F -0.001 0.695 0.356 Luminal-B 
TCGA-AN-A0XR 0.9192 0.554 0.363 Luminal-B 
TCGA-AN-A0XW 0.698 0.614 0.354 Luminal-B 
TCGA-AO-A0JC 0.2298 0.338 0.398 Luminal-B 
TCGA-AO-A0JD 0.8212 0.819 0.424 Luminal-B 
TCGA-AO-A0JI 0.4005 0.538 0.001 Luminal-B 
TCGA-AO-A0JM 0.6861 0.683 0.486 Luminal-B 
TCGA-AO-A12B 0.7971 0.346 0.159 Luminal-B 
TCGA-AQ-A04H 0.5798 0.64 0.235 Luminal-B 
TCGA-AR-A0TQ 0.4484 0.774 0.485 Luminal-B 
TCGA-AR-A0TT 0.5423 0.571 0.409 Luminal-B 
TCGA-AR-A0TV 0.7725 0.673 0.287 Luminal-B 
TCGA-AR-A0TZ 0.7611 0.639 0.147 Luminal-B 
TCGA-AR-A0U2 0.8088 0.96 0.519 Luminal-B 
TCGA-AR-A0U3 0.7033 0.684 0.395 Luminal-B 
TCGA-AR-A1AV 0.2418 0.514 0.42 Luminal-B 
TCGA-B6-A0RL 0.9641 0.749 0.194 Luminal-B 
TCGA-B6-A0WV 0.7778 0.606 0.321 Luminal-B 
TCGA-B6-A0WW 0.8256 0.5 0.235 Luminal-B 
TCGA-B6-A0X5 0.8617 0.696 0.462 Luminal-B 
TCGA-BH-A0AU 0.2246 0.578 0.223 Luminal-B 
TCGA-BH-A0B5 0.4588 0.626 0.296 Luminal-B 
TCGA-BH-A0BF 0.4012 0.532 0.504 Luminal-B 
TCGA-BH-A0BZ 0 0.65 0.56 Luminal-B 
TCGA-BH-A0C0 0.0157 0.684 0.625 Luminal-B 
TCGA-BH-A0C3 0.0093 0.485 0.254 Luminal-B 
TCGA-BH-A0DD 0.4659 0.812 0.253 Luminal-B 
TCGA-BH-A0H0 0.7095 0.627 0.339 Luminal-B 
TCGA-BH-A0W3 0.8834 0.486 0.198 Luminal-B 
TCGA-BH-A1EW -0.002 0.55 0.382 Luminal-B 
TCGA-C8-A1HG 0.6573 0.712 0.473 Luminal-B 
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TCGA-C8-A1HL 0.6497 0.729 0.542 Luminal-B 
TCGA-C8-A1HM 0.6948 0.85 0.623 Luminal-B 
TCGA-C8-A1HN 0.7898 0.672 0.421 Luminal-B 
TCGA-E2-A107 0.6737 0.629 0.235 Luminal-B 
TCGA-E2-A109 0.773 0.779 0.497 Luminal-B 
TCGA-E2-A10C 0.7865 0.547 0.471 Luminal-B 
TCGA-E2-A15K 0.552 0.38 0.149 Luminal-B 
TCGA-E2-A15K 0.552 0.566 0.211 Luminal-B 
TCGA-A2-A0YK 0.0475 0.246 0.145 Normal-like 
TCGA-AO-A03U 0.4562 0.268 0.316 Normal-like 
TCGA-AO-A0JB 0.7577 0.472 0.8 Normal-like 
TCGA-AR-A1AO 0.253 0.509 0.538 Normal-like 
TCGA-E2-A108 0.0437 0.482 0.277 Normal-like 
Supplementary Table 6: ASSIGN expression signatures prediction for TSA, VPA, and 
SAHA into TCGA data with their respective subtypes. 
VPA SAHA TSA 
ABHD6 ABAT AACS 
ABTB2 ABCD3 ABAT 
ACOT2 ABHD6 ABCD3 
ACOT7 ABTB2 ABCE1 
ADHFE1 ACADSB ABHD6 
ADI1 ACSL1 ACAD8 
ADNP ACSL3 ACADSB 
AFF1 ACVR2A ACO1 
AFTPH ADHFE1 ACSL3 
AGTPBP1 ADNP ACTR10 
AKAP8 AFF1 ADHFE1 
ANG AFTPH AGTPBP1 
ANKMY2 AGTPBP1 AKAP10 
ANKRD27 AKAP8 AKAP8 
ANKRD46 ALAS1 ALAD 
ANKS1A ALDH3A2 ALAS1 
ANKZF1 AMOTL2 ANG 
ANP32B ANKMY2 ANGEL2 
AP4M1 ANKRD27 ANKRA2 
APAF1 ANKRD46 ANKRD27 
AREG ANP32B ANKRD46 
ARG2 APAF1 ANKS1A 
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ARHGAP19 ARF6 APAF1 
ARHGEF18 ASB1 ARHGAP12 
ARID1A ASXL1 ARHGAP19 
ARL8B ATF1 ARID1A 
ARMC6 ATF4 ARL3 
ASXL1 ATG2A ARMCX3 
ATF1 ATG4A ATF1 
ATF5 ATP2B4 ATF4 
ATG2B ATP6V1A ATF5 
ATG4A ATP6V1D ATG2B 
ATP11B AURKA ATP1B3 
ATP6V0D1 AVEN ATP6V1A 
ATP6V1A AVPI1 ATP6V1B2 
ATP6V1B1 BANP ATP6V1D 
ATP6V1H BCAR3 AURKA 
ATP9A BCL10 AVEN 
AURKA BCLAF1 AXIN1 
AVEN BCORL1 BACE1 
AVPI1 BICD2 BBS7 
BANP BNIP1 BCAR3 
BBS7 BPTF BICD2 
BCAR3 BRD1 BNIP1 
BCL10 BUB3 BPTF 
BCL3 C12orf44 BRCA2 
BCLAF1 C14orf132 BRD9 
BCORL1 C16orf80 BSPRY 
BICD2 C18orf8 BUD31 
BIN3 C19orf40 C12orf44 
BIRC5 C2orf44 C12orf49 
BNIP1 C7orf49 C16orf80 
BNIP3L C9orf156 C18orf8 
BPTF C9orf40 C19orf40 
BRD2 C9orf91 C1orf174 
BRD9 CALCOCO1 C2orf47 
BTAF1 CAMLG C7orf49 
C1orf134 CBFA2T2 CAMLG 
C16orf80 CCDC28A CARD8 
C18orf8 CCDC47 CASD1 
C1orf123 CCDC51 CCDC101 
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C1orf174 CCDC59 CCDC47 
C2orf44 CCDC94 CCDC87 
C7orf49 CCNA2 CCDC94 
C8orf33 CCNB1 CCNA2 
C9orf156 CCNB2 CCNB2 
C9orf91 CCND1 CCND1 
CALCOCO2 CDC16 CDC42EP3 
CALM1 CDC25A CDIPT 
CBX7 CDC42EP1 CDKN1A 
CBY1 CDC7 CDKN1C 
CCDC101 CDK2AP2 CDT1 
CCDC28A CDKN1A CEP68 
CCDC94 CDKN2D CEP70 
CCNA2 CEBPD CETN2 
CCNB1 CEBPG CFLAR 
CCNB2 CENPA CGRRF1 
CCND1 CFLAR CHERP 
CDC7 CGGBP1 CHST12 
CDK10 CGRRF1 CLK4 
CDK2 CHCHD7 CLPX 
CDKN2D CHKA CMTM6 
CENPN CHST12 CNNM4 
CGGBP1 CLCN3 COPS3 
CHMP1B CLP1 CORO1A 
CHRNA5 CMTM6 COTL1 
CHST12 CNBP CPD 
CNOT2 CNOT2 CREB3L2 
CNOT8 COIL CREBL2 
COIL COPS3 CRISPLD2 
COQ7 COQ7 CROT 
COQ9 COQ9 CSNK1D 
CORO1A CORO1A CTBP2 
CREBBP COX10 CTCF 
CRY1 CREBBP CTDSP1 
CTCF CRY1 CTR9 
CTR9 CSK CYB5B 
CYB5R1 CSNK2A1 CYFIP2 
CYC1 CSRP1 CYP1B1 
CYP1B1 CTCF CYP20A1 
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CYP20A1 CTR9 DAAM1 
DAAM1 CUL1 DCTD 
DARS CYB5R1 DDX1 
DAZAP2 CYFIP2 DDX11 
DCPS CYP20A1 DDX17 
DCTD DAAM1 DDX56 
DCTN4 DAZAP2 DEAF1 
DDX17 DCTD DGCR8 
DDX24 DCTN4 DHX16 
DDX54 DCTN6 DHX30 
DDX56 DDX23 DNAJB12 
DGCR8 DDX28 DNAJB4 
DHRS1 DDX54 DNAJC11 
DHX16 DEPDC1 DNAJC12 
DHX57 DHX15 DOLPP1 
DIDO1 DHX16 DYRK1A 
DIXDC1 DIDO1 DYRK3 
DKC1 DKC1 EFHC1 
DLEU1 DNAJB12 EFNA3 
DNAJB12 DNAJC12 EFNA4 
DNAJC12 DOCK4 EHD1 
DOLPP1 DOLPP1 EIF2B5 
DOPEY1 DUSP10 EIF3A 
DUSP10 DUSP12 EIF4E 
DUSP12 DYRK3 EIF4ENIF1 
DYRK1A EDEM3 EIF5 
DYRK3 EFNA3 ELOVL4 
EAF2 EHD1 ENPP4 
EDEM3 EIF4A3 EP300 
EFNA3 EIF5 ERBB2IP 
EFNA4 ELF2 ETHE1 
EIF2AK3 ELF4 EXOSC10 
EIF3A ELP3 EXOSC4 
EIF5 EMG1 EXOSC8 
EMG1 EML4 EXT2 
EPOR ENOX1 F2RL1 
ERGIC2 EPAS1 FADS3 
ETHE1 EPM2A FAM117A 
EXOSC10 ERO1LB FAM134C 
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EXTL2 EXOSC10 FAM136A 
FAIM EXOSC4 FAM46C 
FAM117A EXOSC8 FBXL2 
FAM131A EXTL2 FBXO3 
FAM53C F11R FDFT1 
FAM8A1 FADD FNBP4 
FANCE FAIM FSCN1 
FASTKD2 FAM117A FUCA1 
FBXL2 FAM134C GAB2 
FBXO3 FAM136A GABARAPL1 
FIS1 FAM35A GABARAPL2 
FKRP FAM53C GABPA 
FLVCR2 FAM89B GEMIN4 
FNTB FANCE GFPT1 
FOXA1 FASTKD2 GINS3 
FXN FBXO3 GLCE 
FYN FDFT1 GLRX 
FZD8 FGD6 GLS 
GAB2 FKRP GLUL 
GABARAPL2 FLVCR2 GMEB1 
GABPA FNTB GMEB2 
GAPVD1 FUCA1 GMPR 
GEMIN4 GABARAPL2 GNS 
GFOD1 GABPA GOLGA1 
GFPT1 GAPVD1 GPR137B 
GINS3 GEMIN4 GRAMD1C 
GLCE GFOD1 GRWD1 
GLRX GINS3 GTF2B 
GLRX5 GLCE GTF2E2 
GLS GLRX GTF3C2 
GMCL1 GLRX5 GTPBP8 
GMEB1 GLTSCR2 GUK1 
GMEB2 GMCL1 HEBP1 
GMPR GMEB2 HMGB2 
GNAZ GMPR HMGB3 
GNB1 GNAI2 HNRNPR 
GOSR1 GNS HNRNPU 
GPR137B GOLGA7 HRSP12 
GRB2 GOSR1 HS2ST1 
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GRK5 GPR137B HSDL2 
GRWD1 GRK5 HSPA1A 
GTF2B GRWD1 IMPA1 
GTF3C2 GTF2B INPP5A 
HBEGF GTF3C2 INPP5E 
HDAC3 GTPBP4 INPP5F 
HEBP1 H1F0 INSIG1 
HECA HBEGF INTS7 
HLTF HDAC3 IRF6 
HMGB2 HEBP1 ITM2C 
HN1 HECA ITPA 
HNRNPR HECTD3 JAK1 
HS2ST1 HNRNPR JRKL 
HSDL2 HS1BP3 KBTBD2 
HSF2 HSDL2 KDELC1 
HSPA1A HSPA1A KEAP1 
IFT20 IDH1 KIAA0355 
IFT52 IDI1 KIAA0513 
INPP5F IL1RAP KIF13B 
INSIG2 INPP5A KIF15 
INTS7 INPP5F KIF3A 
IRAK1 IRF6 KIF3B 
ITFG2 JAK1 KIF3C 
JAK1 JRK KIF4A 
JRK KBTBD2 KLF11 
KATNA1 KCTD15 KLHL24 
KATNB1 KEAP1 KPNB1 
KBTBD4 KIAA0247 L2HGDH 
KCTD15 KIAA0368 LCMT1 
KDELC1 KIAA0513 LEPRE1 
KEAP1 KIDINS220 LIG3 
KIAA0141 KIF3A LIMA1 
KIAA0226 KLHL26 LIN37 
KIAA0368 LANCL2 LIPA 
KIAA0513 LARP6 LMNB1 
KIAA0895 LARP7 LPHN2 
KIAA1009 LIPA LRRC1 
KIF13B LMBR1L LRRC20 
KIF1B LMNB1 LRRC41 
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KIF3A LRRC1 LSM14B 
KIF3C LSM12 LTA4H 
KIF4A LTA4H MAGEH1 
KIFAP3 LTBR MAN1A2 
KLHL24 LUC7L2 MANBA 
KPNB1 MAK MAP1LC3B 
KRAS MAP1LC3B MAP3K8 
LANCL2 MAP2K1 MAX 
LARP6 MAP2K3 MBD3 
LARP7 MAP3K3 MCM2 
LCMT1 MAP3K9 MCM3 
LCMT2 MARK4 MCM7 
LIPT1 MBD4 MCM9 
LMBR1L MCM7 MECP2 
LMNB1 MCM9 MEPCE 
LRRC1 MCPH1 METTL1 
LRRC20 MDFIC METTL8 
LTA4H MEGF9 MGAT2 
LUC7L2 MEPCE MGST3 
LYRM4 METTL1 MICB 
LYST METTL4 MKI67 
MAGEH1 MID1IP1 MLF1 
MAK MINA MLF2 
MAP1LC3B MITF MLLT3 
MAP2K3 MKNK2 MMD 
MAP3K13 MLF1 MNAT1 
MAPK8IP1 MLXIP MOSPD3 
MARK4 MMD MPV17 
MAST3 MNAT1 MRPS2 
MAX MOSPD1 MRTO4 
MBD3 MPV17 MTIF2 
MCM2 MPZL1 MTMR1 
MCM5 MRPL12 MUS81 
MCM7 MRPL15 MUT 
MCM9 MRPS18B MXI1 
MCRS1 MRPS22 MXRA7 
MEGF9 MRTO4 MYH10 
MEIS1 MTHFS MYNN 
MEPCE MTIF2 NARF 
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METTL1 MTMR1 NARFL 
MFN1 MXD1 NCBP2 
MINA MXI1 NCOA3 
MITF MYBL1 NDRG4 
MKNK1 MYH10 NEDD9 
MKNK2 NBPF1 NEU1 
MLF1 NBPF15 NFE2L3 
MMD NBPF20 NFIL3 
MNAT1 NBPF3 NFKB1 
MOSPD1 NCBP2 NFYC 
MOSPD2 NCOA3 NIF3L1 
MPDU1 NEDD9 NLE1 
MPV17 NEU1 NME7 
MPZL1 NFIC NOL11 
MRPL15 NFIL3 NOL3 
MRPL46 NFKB1 NR1H2 
MRPL9 NFKBIA NR2F6 
MRPS18B NFYC NSD1 
MTG1 NGDN NSUN5 
MTIF2 NIT1 NUBP1 
MTM1 NME6 NUDT15 
MTMR6 NMI NUP153 
MTSS1 NOL3 NUP62 
MXD1 NPAT OCEL1 
MXI1 NR3C2 OPA3 
MYH10 NRGN ORMDL2 
NARFL NSD1 OSBPL11 
NBN NSMAF OSBPL8 
NCAPH NSUN5 PAIP2B 
NCOA3 NUBP1 PALLD 
NFIL3 NUDT15 PAPSS1 
NFKBIE NUP43 PAQR5 
NFYC NUP62 PARP2 
NHEJ1 OAZ2 PATZ1 
NIF3L1 OPA3 PBXIP1 
NIT1 OSBPL8 PCBP1 
NME6 PAIP2B PCNT 
NMT1 PAPSS1 PCYOX1 
NOL3 PAXIP1 PCYOX1L 
	  	   125	  
NOSIP PCBP1 PDGFRL 
NPAT PCNT PDK3 
NUBP1 PDCD2 PDPK1 
NUDT15 PDE6D PDS5B 
NUP62 PDPK1 PEF1 
OPA3 PELI1 PELI1 
OSBPL8 PEX3 PEX14 
PAPSS1 PHF2 PHIP 
PARP2 PI4K2A PIP4K2A 
PCBP1 PIGH PKP2 
PCNT PITPNA PLAG1 
PCYOX1L PLEKHB2 PLK4 
PDCL3 PLK1 PLLP 
PELI1 PLK4 PLS1 
PES1 PLXNA3 PMM2 
PEX1 PMM2 POLDIP3 
PEX11B PNN POLR2B 
PEX14 POGK POLR3E 
PEX3 POLDIP3 PPCS 
PGAP1 POLR2B PPL 
PHF2 POLR3E PPP1R8 
PI4K2A POR PPRC1 
PIGA PPP1R2 PQLC1 
PIGH PPP1R2P3 PRC1 
PIM2 PPP1R8 PREPL 
PIP4K2A PPP2R5B PRKACB 
PISD PPRC1 PRKAR2B 
PITPNA PQLC1 PRPF18 
PJA2 PRC1 PRPF38B 
PKNOX1 PRDM10 PRPH 
PLEKHB2 PRKAR2B PRR13 
PLK4 PSMB5 PSMB9 
PLS1 PSMD11 PTPN1 
POGK PSMD7 PTPN13 
POLDIP3 PTPN1 PTPN2 
POLR2B PTS PTTG1IP 
POLR3B PUF60 PUM2 
POLR3E PUM2 PUS1 
PPARD QRICH1 QRICH1 
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PPIF RAB11FIP1 RAB22A 
PPM1B RAB11FIP2 RAB7L1 
PPP1R2 RAB33B RABEP2 
PPP1R2P3 RAB8B RABIF 
PPP1R8 RAD9A RABL3 
PPP2R5B RAP2A RABL5 
PPRC1 RB1CC1 RAD17 
PRDM10 RBM22 RAP2A 
PREPL RBM23 RB1CC1 
PRKACB RBM39 RBM10 
PRKAR2B RBM5 RBM23 
PRMT2 RBMX RBM28 
PTPN1 REPIN1 RBM5 
PTS REV1 RBMX 
PUF60 RGS19 RCBTB1 
QRICH1 RIMS3 RCC1 
RAB11FIP1 RIOK3 RCHY1 
RAB3A RMND5A RECQL 
RAB40B RNF7 REEP1 
RAB7L1 RPP40 REPS2 
RAB8B RRS1 REXO2 
RABGGTA RTF1 RHBDD3 
RABIF RTN3 RIOK3 
RAD17 RYBP RNASE4 
RAP2A SAFB RNF24 
RB1CC1 SAMHD1 RNF41 
RBM14 SAP30 RNF6 
RBM22 SARS2 RPS6KA1 
RBM23 SEMA4C RPS6KC1 
RBM39 SENP6 RRAGD 
RBM5 SEPHS1 RRS1 
RBMX SERTAD2 RXRA 
RCC1 SETDB1 SAFB 
RIMS3 SFMBT1 SAMHD1 
RIOK3 SGPP1 SBNO2 
RIPK2 SH3BP5 SCPEP1 
RMND5A SHQ1 SDCCAG3 
RNF41 SLC20A1 SDF2 
RPP40 SLC25A44 SEC14L1 
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RPS6KA5 SLC31A1 SEH1L 
RRAGD SLC31A2 SENP2 
RRS1 SLC36A1 SENP6 
RSRC2 SLC9A1 SERPINB8 
RTF1 SLTM SERTAD2 
RUNDC3B SMAD1 SETD5 
SAMHD1 SMARCE1 SFMBT1 
SAP30 SMEK1 SH2B3 
SARS2 SMG5 SH2D4A 
SDCCAG3 SMYD5 SH3BP5 
SENP2 SNAPC1 SIRT4 
SENP6 SNN SLC19A1 
SEPHS1 SNUPN SLC23A2 
SETD3 SNW1 SLC25A38 
SETDB1 SNX2 SLC25A44 
SH3BP5 SOCS6 SLC26A2 
SHQ1 SORT1 SLC31A1 
SLC9A3R1 SP2 SLC31A2 
SLC20A1 SPAG7 SLC36A1 
SLC23A2 SPAG9 SLC7A1 
SLC25A44 SPIN1 SLTM 
SLC31A2 SQLE SMARCB1 
SLC36A1 SRPK2 SMCR7L 
SLC7A1 SSBP2 SMEK1 
SLC9A6 ST3GAL5 SMNDC1 
SMYD5 STAG1 SMYD5 
SNAP23 STK17A SNAPC1 
SNAPC1 STK38 SNAPC5 
SNN STX12 SNN 
SNX2 STXBP1 SNW1 
SON SUV39H1 SOAT1 
SP2 SUV420H1 SP3 
SPAG7 SYNCRIP SPAG9 
SPAST TACC1 SPATA5L1 
SPATA7 TAF5L SPATA7 
SPIN1 TAOK3 SPSB1 
SRPK2 TBPL1 SQLE 
SRRM2 TCERG1 SRP54 
SSBP2 TDRD3 SRRM1 
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ST3GAL5 TEAD4 ST3GAL2 
STAG1 TEX2 ST7 
STK4 TFDP1 STAG1 
STX12 THAP1 STK17A 
STX6 THAP10 STK38 
STXBP1 THAP7 STX2 
SUMO3 THG1L STXBP1 
SUV39H1 TIAL1 SUSD4 
SUV420H1 TIPARP SUV39H1 
SYNCRIP TMED1 SYNCRIP 
TACC1 TMEM11 TACC1 
TAOK3 TMEM168 TAF4 
TARBP2 TMEM39B TAF7 
TBPL1 TMEM41B TAOK3 
TCERG1 TMEM87A TARDBP 
TCF25 TMPO TCERG1 
TCFL5 TNFRSF12A TCF12 
TDRD3 TNS3 TEAD4 
TEX2 TOE1 TFDP2 
TFDP1 TPST2 THAP10 
TFDP2 TRAPPC4 THG1L 
THAP10 TRIM13 THOC6 
THG1L TRIM27 TMED1 
THOC6 TRIM44 TMEM185B 
TMED1 TSPAN5 TMEM30A 
TMEM185B TSPYL2 TMEM30B 
TMEM39B TSSC4 TMEM39B 
TMEM41B TUBGCP3 TMEM41B 
TMEM87A TUFT1 TMEM87A 
TNFRSF12A TXNIP TMPO 
TOE1 UAP1L1 TOE1 
TPMT UBE2C TOR1A 
TPST1 UBE2H TOR1AIP2 
TPST2 UBE3A TOR1B 
TRAFD1 UBE4A TOR3A 
TRAPPC4 UBTF TOX4 
TRIM13 UCK2 TPST1 
TRIM36 UCP2 TRAFD1 
TSEN34 ULBP2 TRAM2 
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TSPAN5 UMPS TRIM27 
TSSC4 UNC119 TRIM36 
TTLL7 USE1 TRIM8 
TUBA4A USP13 TRIP11 
TUBGCP3 USP15 TRIP6 
TUFT1 USP16 TRMT11 
TUSC2 USP33 TSSC4 
UBE2C UTP18 TTBK2 
UBE2H VPS26A TTLL7 
UBE2Z VPS37C TUFT1 
ULBP2 VPS54 TYMS 
UNC119 WAC U2AF2 
USE1 WARS2 UBE2H 
USP15 WASF1 UBE2Z 
USP16 WBSCR16 UBE3A 
USP22 WDR19 UBE4A 
USP33 WDR47 UBTF 
USP9X WDR73 UMPS 
UST WDR74 UNC119 
VDR WDR82 USE1 
VPS37C WDR91 USP1 
VPS52 WEE1 USP13 
WARS2 WFS1 USP15 
WASF1 XPO1 USP16 
WBSCR16 YAP1 USP22 
WDR19 YARS2 UTP11L 
WDR4 ZBED5 WARS2 
WDR47 ZBTB1 WBSCR16 
WDR82 ZC3H7A WDR19 
WDR91 ZCCHC10 WDR4 
WFS1 ZFP64 WDR47 
YARS2 ZFX WDR74 
ZBTB1 ZFY WDR82 
ZBTB3 ZMAT3 WFS1 
ZCCHC10 ZMYND11 WRB 
ZFX ZMYND8 XPO1 
ZFY ZNF146 YIPF1 
ZMAT3 ZNF148 YPEL1 
ZNF14 ZNF24 ZFX 
	  	   130	  
ZNF167 ZNF324 ZFY 
ZNF207 ZNF335 ZMAT3 
ZNF224 ZNF33B ZMYND8 
ZNF24 ZNF384 ZNF142 
ZNF335 ZNF562 ZNF20 
ZNF33B ZNF668 ZNF202 
ZNF384 ZNF710 ZNF250 
ZNF668 ZNF768 ZNF335 
ZNF692 ZNF787 ZNF692 
ZNF710 ZNHIT2 ZNF787 
ZNF787 ZZZ3 ZNHIT2 
Supplementary Table 7: Top differentially expressed gene list extracted from breast 
cancer cell lines treated by VPA, SAHA, and TSA. ASSIGN model was used for 
signature prediction. 
 
Genes Genes Genes Genes 
MITF MNAT1 TMED1 SETDB1 
GMEB2 CCDC28A KIFAP3 MCM2 
KEAP1 GAPVD1 DHX16 
ARHGEF1
8 
RAB11FIP1 PI4K2A COQ7 EXOSC10 
MEPCE PRDM10 SEPHS1 ATF5 
MAX TDRD3 MMD NOL3 
TCERG1 ST3GAL5 MCM7 MFN1 
PELI1 HNRNPR ABTB2 CHST12 
DCTN4 SSBP2 PTPN1 VPS37C 
ANKRD27 MRPL15 ATP6V1A RABIF 
SLC31A2 SNN CCNB1 GRK5 
POLR3B ZNF668 ZCCHC10 MAST3 
WARS2 DNAJB12 CYB5R1 STK4 
SP2 THAP10 STX12 ASXL1 
ABHD6 USP16 EPOR SRRM2 
GMEB1 INPP5F OPA3 SUV39H1 
PCNT EXTL2 APAF1 LRRC1 
SUV420H1 SH3BP5 PIGA TFDP2 
YARS2 SLC25A44 BRD9 MINA 
FAM117A KATNA1 TPMT GABARAP
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L2 
CCDC94 SLC23A2 ATF1 ETHE1 
USE1 FZD4 C12orf44 GLS 
TRAFD1 LUC7L2 CDKN2D RBM5 
ATG2B KLHL24 PIGH ATP6V1B2 
CREBBP RPS6KA5 BBS7 SDCCAG3 
SARS2 WDR47 RMND5A FBXO3 
LARP7 RIOK3 DNAJC12 LMBR1L 
NUP62 ZFX QRICH1 USP15 
PUF60 RIMS3 MYH10 FKRP 
NUDT15 GLRX CORO1A ADNP 
LANCL2 ZBTB1 TPST1 PKNOX1 
CRY1 METTL1 PPRC1 ARID1A 
GEMIN4 MPV17 TCF25 NME6 
TMEM87A SMYD5 CDK2 IFT20 
RBM23 GOSR1 BTAF1 KIF3A 
GAB2 ZNF335 AURKA LMNB1 
WDR19 WASF1 BANP NIF3L1 
FXN EIF5 NFIL3 NIT1 
FLVCR2 MAP1LC3B CYP20A1 ZMAT3 
C18orf8 HN1 ZBTB3 ZNF10 
RAB8B TUBGCP3 AVEN CCDC101 
KIAA0513 AFTPH SPAG7 JRK 
AKAP8 SLC20A1 TAOK3 USP33 
MOSPD1 RB1CC1 PPM1B TFDP1 
ANKMY2 HECA CYP1B1 SPIN1 
TUBA4A THG1L DUSP12 PRKACB 
RAP2A MLF1 PEX3 TMEM41B 
TMEM39B PRKAR2B ATP6V0D1 LRRC20 
AP4M1 GTF3C2 DKC1 C7orf49 
CTCF NUBP1 LTA4H SLC9A6 
 
Supplementary Table 8: Top 200 differentially methylated genes extracted from breast 
cancer cell lines treated with VPA. 
TP63 PPP2R2D LEPR EHMT1 
ZNF490 RPA1 SNRPC ZNF358 
SHCBP1L TM4SF20 TSSC1 PARD6G 
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REEP5 SLC6A9 ARID1B C6orf136 
ADCY9 RPS6KA4 SVIL TAF7L 
ATP2A2 PLEKHA5 OSBPL9 TBC1D4 
CMTM1 NCOA5 FER C11orf30 
AFAP1 ZNF438 PITX2 ARHGEF10 
SOD3 PITPNA ZNF236 STAT1 
PRDM15 HERC2 ZBTB2 HIVEP2 
DDX23 SSU72 KLF17 EPHX3 
ZNF843 WDR37 PCGF3 KDM2B 
RALGPS1 COPE MRPS27 PNLDC1 
PCCA BZW2 NEB NAMPT 
DIP2C FCHO2 CCNJL RBM23 
MLLT4 LOH12CR1 ZNF605 EHD3 
LIPH VIM NOTCH3 ZADH2 
SPTBN1 WIPI2 FAM20C AFG3L1P 
IPO5 SMAD6 PIK3R5 SETBP1 
SDCCAG8 GTF2IRD1 TULP4 NPHP4 
RBPMS EPB41L1 NUB1 CTSC 
WDR45B TAOK1 
MPHOSP
H8 LRRC8A 
ZNF461 PTGFRN FUCA2 C17orf85 
AUTS2 MAD1L1 BCORL1 MACROD1 
ANKRD30B SLC39A14 TBC1D2B NF1 
NOXRED1 CTBP1 FOXK1 MYO10 
NHLRC1 SERP2 SYCP3 UBE3C 
BDH2 CASP3 RNF39 ATXN7L1 
SYNJ1 CHTF18 TUBGCP2 KIAA0930 
TRIO NUP88 UBE2J2 ALDH1A3 
GLIS1 CCDC79 TMEM182 CATSPER2 
LGR4 NAA60 ARF6 CYTH2 
FARP1 TET3 WAPAL H2AFY2 
TET1 FRMD4A IMP4 GNG4 
TEX12 CLYBL MON1A MANBA 
FAM86EP RPTOR TACC2 DNAJC6 
PRX SETD1B SFT2D1 C8orf76 
GAK QRICH2 WDR52 SFSWAP 
MICALL2 U2AF1 MBD3 SH3BGRL2 
RAB42 PIK3R3 RALBP1 TCF12 
GRWD1 LONRF1 ANKRD11 DAZAP1 
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TRAPPC12 TFDP1 ZNF787 LMNB2 
GLI3 MAPKAP1 UBE4B DNAJC1 
NEK1 CAMSAP2 P4HTM KDM4B 
WDR81 ZNF74 SNCA ALYREF 
THADA SMG6 HDAC4 GALNT11 
SCRN1 GRB10 AGAP1 USP36 
COPG2 AP2A2 CSNK2A2 CUL1 
GPR107 OPTN PITX1 CERKL 
ERICH1 MEIS1 EIF3A GNAS 
Supplementary Table 9: Top 500 differentially methylated genes extracted from mouse 
xenografts treated with VPA. 
Sample ID Expression Methylation 
TCGA.BH.A0HK.11A.11R.A089.07 0.16307845 0.484408548 
TCGA.BH.A0BM.11A.12R.A089.07 0.289180705 0.575862553 
TCGA.BH.A0B3.11B.21R.A089.07 0.189135115 0.561916266 
TCGA.BH.A0DK.11A.13R.A089.07 0.255491079 0.201020389 
TCGA.BH.A0BJ.11A.23R.A089.07 0.214103446 0.479183777 
TCGA.BH.A0DP.11A.12R.A089.07 0.239081555 0.389324911 
TCGA.BH.A0DQ.11A.12R.A089.07 0.296277163 0.413135439 
TCGA.BH.A0B8.11A.41R.A089.07 -0.002431002 0 
TCGA.BH.A0C0.11A.21R.A089.07 0.231360728 0.242237467 
TCGA.BH.A0BA.11A.22R.A089.07 0.150709615 0.194761572 
TCGA.BH.A0BC.11A.22R.A089.07 -0.003125995 0.28815791 
TCGA.BH.A0DH.11A.31R.A089.07 -0.002821413 0.302516794 
TCGA.BH.A0E1.11A.13R.A089.07 0.33490227 0.256737608 
TCGA.BH.A0H9.11A.22R.A089.07 0.007819269 0.447229046 
TCGA.A7.A0D9.11A.53R.A089.07 -0.011976084 0.284737154 
TCGA.BH.A0H7.11A.13R.A089.07 0.262325366 0.247123665 
TCGA.BH.A0E0.11A.13R.A089.07 0.185494599 0.522729535 
TCGA.BH.A0C3.11A.23R.A12P.07 0.218956356 1.75E-05 
TCGA.BH.A0BS.11A.11R.A12P.07 0.293045777 0.444986783 
TCGA.A7.A13E.11A.61R.A12P.07 -0.002429591 0.430651494 
TCGA.BH.A0BZ.11A.61R.A12P.07 0.000221418 0.19674319 
TCGA.A7.A13F.11A.42R.A12P.07 0.003171634 0.190119905 
TCGA.BH.A0AU.11A.11R.A12P.07 0.39265999 0.251302448 
TCGA.BH.A0DV.11A.22R.A12P.07 0.491312374 0.549614888 
TCGA.BH.A1F0.11B.23R.A137.07 -0.000610402 0.453359707 
TCGA.E2.A1BC.11A.32R.A12P.07 -0.007030514 0.26001225 
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TCGA.BH.A0HA.11A.31R.A12P.07 0.37812894 0.502467288 
TCGA.E2.A15I.11A.32R.A137.07 -0.01176794 0.237820453 
TCGA.BH.A1EW.11B.33R.A137.07 0.019025606 0.592257294 
TCGA.BH.A1EU.11A.23R.A137.07 0.120930772 0.228448852 
TCGA.BH.A1ET.11B.23R.A137.07 0.009711435 0.08121846 
TCGA.BH.A1EO.11A.31R.A137.07 -0.010899112 0.465913219 
TCGA.BH.A1EO.01A.11R.A137.07 0.367901467 0.517965114 
TCGA.BH.A1F0.01A.11R.A137.07 0.437651014 0.567691068 
TCGA.C8.A1HI.01A.11R.A137.07 0.679045864 0.782724769 
TCGA.BH.A1EV.01A.11R.A137.07 0.768175398 0.667717029 
TCGA.C8.A1HL.01A.11R.A137.07 0.824245821 0.465535716 
TCGA.BH.A1ET.01A.11R.A137.07 0.661789631 0.387192645 
TCGA.E2.A14N.01A.31R.A137.07 0.717533887 0.502605054 
TCGA.E2.A1B6.01A.31R.A12P.07 0.483762081 0.598559705 
TCGA.C8.A1HM.01A.12R.A137.07 0.860822639 0.733348778 
TCGA.E2.A15I.01A.21R.A137.07 0.645402925 0.294087329 
TCGA.C8.A1HN.01A.11R.A137.07 0.854393455 0.733326529 
TCGA.C8.A1HF.01A.11R.A137.07 0.721093375 0.513400152 
TCGA.BH.A1EW.01A.11R.A137.07 0.599147981 0.745906754 
TCGA.BH.A1EU.01A.11R.A137.07 0.350740702 0.518867315 
TCGA.AR.A1AR.01A.31R.A137.07 0.4905772 0.577479396 
TCGA.BH.A1ES.01A.11R.A137.07 0.802777975 0.767282585 
TCGA.C8.A1HG.01A.11R.A137.07 0.742856981 0.297828046 
TCGA.BH.A0HA.01A.11R.A12P.07 0.526419629 0.57152585 
TCGA.BH.A0BT.01A.11R.A12P.07 0.789481794 0.743462339 
TCGA.AR.A1AW.01A.21R.A12P.07 0.853614979 0.279236085 
TCGA.AR.A1AN.01A.11R.A12P.07 0.500134061 0.27408711 
TCGA.E2.A1B5.01A.21R.A12P.07 0.732401671 0.316083946 
TCGA.BH.A0H3.01A.11R.A12P.07 0.76173366 0.71114084 
TCGA.BH.A0BS.01A.11R.A12P.07 0.784061432 0.334031876 
TCGA.AR.A1AV.01A.21R.A12P.07 0.563515729 0.574305908 
TCGA.AR.A1AL.01A.21R.A12P.07 0.473878303 0.708808491 
TCGA.E2.A1B4.01A.11R.A12P.07 0.712618175 0.785226945 
TCGA.BH.A0BF.01A.21R.A12P.07 0.656475336 0.486282085 
TCGA.AR.A1AU.01A.11R.A12P.07 0.491837691 0.316163408 
TCGA.AR.A1AK.01A.21R.A12P.07 0.549511559 0.725754108 
TCGA.E2.A1B1.01A.21R.A12P.07 0.510442733 0.704990153 
TCGA.BH.A0DI.01A.21R.A12P.07 0.573176954 0.755734091 
TCGA.BH.A0B5.01A.11R.A12P.07 0.627084046 0.266935513 
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TCGA.AR.A1AT.01A.11R.A12P.07 0.830442136 0.572242501 
TCGA.AR.A1AJ.01A.21R.A12P.07 0.539408394 0.743787888 
TCGA.E2.A1BD.01A.11R.A12P.07 0.791377433 0.487428302 
TCGA.E2.A1B0.01A.11R.A12P.07 0.616825581 0.91307932 
TCGA.BH.A0DG.01A.21R.A12P.07 0.513757795 0.712223063 
TCGA.BH.A0AZ.01A.21R.A12P.07 0.665981472 0.575175869 
TCGA.AR.A1AS.01A.11R.A12P.07 0.988853658 0.415654391 
TCGA.AR.A1AI.01A.11R.A12P.07 0.861575609 0.637517073 
TCGA.E2.A1AZ.01A.11R.A12P.07 0.548761139 0.665498189 
TCGA.BH.A0DD.01A.31R.A12P.07 0.633702575 0.993797326 
TCGA.BH.A0AU.01A.11R.A12P.07 0.582751342 0.694973155 
TCGA.AR.A1AQ.01A.11R.A12P.07 0.749142856 0.536384052 
TCGA.A7.A13F.01A.11R.A12P.07 0.971842066 0.225694093 
TCGA.E2.A15K.01A.11R.A12P.07 0.664323531 0.811071432 
TCGA.BH.A0C3.01A.21R.A12P.07 0.305084026 0.680137959 
TCGA.AR.A1AY.01A.21R.A12P.07 0.704205622 0.695819385 
TCGA.AR.A1AP.01A.11R.A12P.07 0.645664562 0.639367264 
TCGA.A7.A13E.01A.11R.A12P.07 0.81820832 0.785477633 
TCGA.E2.A15K.06A.11R.A12P.07 0.99059166 0.627386341 
TCGA.E2.A1BC.01A.11R.A12P.07 0.460006946 0.698758453 
TCGA.E2.A15J.01A.11R.A12P.07 0.930094384 0.155431656 
TCGA.BH.A0BZ.01A.31R.A12P.07 0.931868728 0.344739342 
TCGA.AR.A1AX.01A.11R.A12P.07 0.541423107 0.362425232 
TCGA.AR.A1AO.01A.11R.A12P.07 0.39976669 0.638010033 
TCGA.A7.A13D.01A.13R.A12P.07 0.807705793 0.461480519 
TCGA.A2.A0T2.01A.11R.A084.07 0.795384299 0.431526735 
TCGA.AO.A12B.01A.11R.A10J.07 0.793776447 0.842931787 
TCGA.E2.A10C.01A.21R.A10J.07 0.816695469 0.492747692 
TCGA.AN.A0XL.01A.11R.A10J.07 0.407395037 0.740055066 
TCGA.AO.A129.01A.21R.A10J.07 0.752510299 0.825527692 
TCGA.E2.A10B.01A.11R.A10J.07 0.738419047 0.82536417 
TCGA.B6.A0X7.01A.11R.A10J.07 0.542623161 0.648266732 
TCGA.AO.A128.01A.11R.A10J.07 0.809112139 0.657258369 
TCGA.AO.A124.01A.11R.A10J.07 0.775572534 0.476365881 
TCGA.E2.A106.01A.11R.A10J.07 0.92349226 0.642919486 
TCGA.AO.A03U.01B.21R.A10J.07 0.571338531 0.503506233 
TCGA.AO.A12E.01A.11R.A10J.07 0.547826704 0.459214025 
TCGA.E2.A10F.01A.11R.A10J.07 0.657831905 0.294638885 
TCGA.E2.A105.01A.11R.A10J.07 0.894948197 0.483419043 
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TCGA.AO.A03N.01B.11R.A10J.07 0.79148619 0.776189087 
TCGA.AO.A12C.01A.11R.A10J.07 0.723685258 0.476972419 
TCGA.E2.A10E.01A.21R.A10J.07 0.788069774 0.6103378 
TCGA.A2.A0YI.01A.31R.A10J.07 0.671055789 0 
TCGA.AO.A03M.01B.11R.A10J.07 0.813760288 0.73726027 
TCGA.E2.A109.01A.11R.A10J.07 0.880708117 0.4921055 
TCGA.AO.A126.01A.11R.A10J.07 0.678332712 0.383364801 
TCGA.E2.A108.01A.13R.A10J.07 0.273724091 0.861263223 
TCGA.AQ.A04L.01B.21R.A10J.07 0.764590273 0.950569109 
TCGA.AO.A125.01A.11R.A10J.07 0.968138639 0.781758426 
TCGA.E2.A107.01A.11R.A10J.07 0.798625799 0.535671686 
TCGA.AQ.A04H.01B.11R.A10J.07 0.79430812 0.002030998 
TCGA.AO.A12G.01A.11R.A10J.07 0.637288488 0.526262142 
TCGA.AR.A0U0.01A.11R.A109.07 0.854721848 0.651376487 
TCGA.A2.A0YH.01A.11R.A109.07 0.781104909 0.815798324 
TCGA.AN.A0XU.01A.11R.A109.07 0.779914011 0.669490374 
TCGA.B6.A0X4.01A.11R.A109.07 0.900017334 0.544304774 
TCGA.BH.A0WA.01A.11R.A109.07 0.71769386 0.651606894 
TCGA.AR.A0TU.01A.31R.A109.07 0.743859946 0.626471468 
TCGA.A2.A0YG.01A.21R.A109.07 0.913617622 0.871443331 
TCGA.AN.A0XT.01A.11R.A109.07 0.613103181 0 
TCGA.B6.A0X1.01A.11R.A109.07 0.920444986 0.658421292 
TCGA.BH.A0W5.01A.11R.A109.07 0.520023232 0.513982773 
TCGA.A2.A04R.01A.41R.A109.07 0.829108361 0.30097022 
TCGA.AR.A0TP.01A.11R.A084.07 0.809267621 0.563079677 
TCGA.A2.A0SY.01A.31R.A084.07 0.508717597 0.516653853 
TCGA.A1.A0SM.01A.11R.A084.07 0.762637501 0.562048815 
TCGA.B6.A0RT.01A.21R.A084.07 0.579686549 0.202440752 
TCGA.BH.A0HP.01A.12R.A084.07 0.574380806 0.534256074 
TCGA.AR.A0TZ.01A.12R.A084.07 0.908792847 0.30296762 
TCGA.A2.A0T7.01A.21R.A084.07 0.638630112 0.484038964 
TCGA.A2.A0SX.01A.12R.A084.07 0.587560114 0.389889958 
TCGA.A1.A0SK.01A.12R.A084.07 0.826258623 0.705060542 
TCGA.B6.A0RS.01A.11R.A084.07 0.619592882 0.668344927 
TCGA.A2.A0T6.01A.11R.A084.07 0.327721398 0.740285891 
TCGA.A2.A0SW.01A.11R.A084.07 0.68549319 0.80260648 
TCGA.A1.A0SJ.01A.11R.A084.07 0.468229066 0.656938874 
TCGA.B6.A0RP.01A.21R.A084.07 0.66751663 0.924793175 
TCGA.AR.A0TW.01A.11R.A084.07 0.914903483 0.246054841 
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TCGA.A2.A0T5.01A.21R.A084.07 0.726949987 0.490522959 
TCGA.A2.A0SV.01A.11R.A084.07 0.760051118 0.806276656 
TCGA.A1.A0SH.01A.11R.A084.07 0.647078647 0.451273202 
TCGA.A2.A0SU.01A.11R.A084.07 0.659254689 0.700900247 
TCGA.A1.A0SE.01A.11R.A084.07 0.65487954 0.374722309 
TCGA.AR.A0TX.01A.11R.A084.07 0.539408424 0.364464486 
TCGA.BH.A0HI.01A.11R.A084.07 0.719622714 0.70053158 
TCGA.B6.A0RO.01A.22R.A084.07 0.789735434 0.914483809 
TCGA.A2.A0EN.01A.13R.A084.07 0.434903152 0.418398345 
TCGA.AR.A0TV.01A.21R.A084.07 0.891245531 0.22554554 
TCGA.A2.A0T4.01A.31R.A084.07 0.382601384 0.68119497 
TCGA.B6.A0RN.01A.12R.A084.07 0.633323725 0.733102778 
TCGA.BH.A0DQ.01A.11R.A084.07 0.480960407 0.571532706 
TCGA.A2.A0T1.01A.21R.A084.07 0.607381286 0.701907698 
TCGA.A1.A0SP.01A.11R.A084.07 0.661783258 0.421143511 
TCGA.B6.A0RV.01A.11R.A084.07 0.569927991 0.988965606 
TCGA.B6.A0RL.01A.11R.A084.07 0.988398854 0.542773892 
TCGA.BH.A0BC.01A.22R.A084.07 0.644747875 0.810578305 
TCGA.AR.A0TQ.01A.11R.A084.07 0.699810892 0.618490139 
TCGA.A2.A0T0.01A.22R.A084.07 0.777541465 0.444419707 
TCGA.A1.A0SO.01A.22R.A084.07 0.840467021 0.746345052 
TCGA.B6.A0RU.01A.11R.A084.07 0.469556046 0.671813779 
TCGA.AO.A0JG.01A.31R.A084.07 0.546322561 0.539268984 
TCGA.A8.A075.01A.11R.A084.07 0.803431265 0.292286894 
TCGA.A2.A0ST.01A.12R.A084.07 0.58328199 0.446303299 
TCGA.BH.A0RX.01A.21R.A084.07 0.574970779 0.785070387 
TCGA.B6.A0RM.01A.11R.A084.07 0.75929955 0.879051159 
TCGA.BH.A0DH.01A.11R.A084.07 0.759011536 0.299816107 
TCGA.AR.A0TR.01A.11R.A084.07 0.929735152 0.552780356 
TCGA.AO.A0JF.01A.11R.A056.07 0.332784397 0.829280912 
TCGA.BH.A0HX.01A.21R.A056.07 0.75987531 0.72755421 
TCGA.BH.A0GZ.01A.11R.A056.07 0.707572469 0.309468064 
TCGA.BH.A0DK.01A.21R.A056.07 0.575375452 0.403901256 
TCGA.BH.A0B8.01A.21R.A056.07 0.76477622 0.774058489 
TCGA.B6.A0RI.01A.11R.A056.07 0.795452526 0.504377661 
TCGA.AO.A0JE.01A.11R.A056.07 0.681158595 0.950098481 
TCGA.BH.A0HK.01A.11R.A056.07 0.545843918 0.748455585 
TCGA.BH.A0GY.01A.11R.A056.07 0.755555722 0.353070906 
TCGA.A7.A0D9.01A.31R.A056.07 0.703045397 0.591482869 
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TCGA.BH.A0B3.01A.11R.A056.07 0.724239604 0.415231337 
TCGA.B6.A0RG.01A.11R.A056.07 0.966149072 0.38610066 
TCGA.AO.A0JD.01A.11R.A056.07 0.850978062 0.698597642 
TCGA.BH.A0HF.01A.11R.A056.07 0.547543005 0.950186897 
TCGA.A2.A0EU.01A.22R.A056.07 0.681514 0.718395325 
TCGA.A2.A0CT.01A.31R.A056.07 0.794917123 0.719059261 
TCGA.B6.A0RE.01A.11R.A056.07 0.850651091 0.246560216 
TCGA.AO.A0JC.01A.11R.A056.07 0.506609729 0.406983812 
TCGA.BH.A0HB.01A.11R.A056.07 0.718410484 0.481501293 
TCGA.BH.A0E2.01A.11R.A056.07 0.780737638 0.472086193 
TCGA.BH.A0C0.01A.21R.A056.07 0.847280672 0.52565254 
TCGA.BH.A0AW.01A.11R.A056.07 0.756903784 0.401104652 
TCGA.AO.A0JM.01A.21R.A056.07 0.802596862 0.711714877 
TCGA.AO.A0JB.01A.11R.A056.07 0.777778936 0.683616087 
TCGA.BH.A0H9.01A.11R.A056.07 0.804649517 0.994726127 
TCGA.BH.A0E1.01A.11R.A056.07 0.789061513 0.74481005 
TCGA.BH.A0BM.01A.11R.A056.07 0.474390427 0.529100678 
TCGA.A8.A0AD.01A.11R.A056.07 0.766564984 0.275762209 
TCGA.A2.A0YF.01A.21R.A109.07 0.685234608 0.427627875 
TCGA.AN.A0XS.01A.22R.A109.07 0.577912809 0.177304777 
TCGA.B6.A0WZ.01A.11R.A109.07 0.852879784 0.515056513 
TCGA.BH.A0W4.01A.11R.A109.07 0.508608004 0.529123705 
TCGA.A2.A0YT.01A.11R.A109.07 0.846737816 0.53558681 
TCGA.A2.A0YE.01A.11R.A109.07 0.778526443 0.914412949 
TCGA.AN.A0XR.01A.11R.A109.07 0.932982083 0.70887986 
TCGA.B6.A0WY.01A.11R.A109.07 0.70007558 0.251503579 
TCGA.BH.A0W3.01A.11R.A109.07 0.951244288 0.64198024 
TCGA.A2.A0YM.01A.11R.A109.07 0.73799703 0.340412761 
TCGA.A2.A0YD.01A.11R.A109.07 0.52359801 0.337840916 
TCGA.AN.A0XP.01A.11R.A109.07 0.889047299 0.7789148 
TCGA.B6.A0WX.01A.11R.A109.07 0.649154497 0.721781533 
TCGA.AR.A0U4.01A.11R.A109.07 0.69383058 0.372382934 
TCGA.A2.A0YL.01A.21R.A109.07 0.470074504 0.459159877 
TCGA.A2.A0YC.01A.11R.A109.07 0.679147999 0.69049216 
TCGA.AN.A0XO.01A.11R.A109.07 0.761564237 0.571612962 
TCGA.B6.A0WW.01A.11R.A109.07 0.915815586 0.315012572 
TCGA.AR.A0U3.01A.11R.A109.07 0.801465243 0.544053971 
TCGA.A2.A0YK.01A.22R.A109.07 0.360103617 0.473881541 
TCGA.AN.A0XW.01A.11R.A109.07 0.762067096 0.923906099 
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TCGA.AN.A0XN.01A.21R.A109.07 0.67260251 0.525033688 
TCGA.B6.A0WV.01A.11R.A109.07 0.880978985 0.71143261 
TCGA.AR.A0U2.01A.11R.A109.07 0.909631081 0.746863955 
TCGA.A2.A0YJ.01A.11R.A109.07 0.924693196 0.684435556 
TCGA.AN.A0XV.01A.11R.A109.07 0.581525776 0.407619671 
TCGA.B6.A0X5.01A.21R.A109.07 0.893515763 0.437580284 
TCGA.B6.A0WT.01A.11R.A109.07 0.776899993 0.592551762 
TCGA.AR.A0TT.01A.31R.A084.07 0.697567281 0.548505838 
TCGA.A8.A08O.01A.21R.A056.07 0.624728968 0.453362203 
TCGA.AO.A0JI.01A.21R.A056.07 0.527639355 0.452571064 
TCGA.BH.A0HY.01A.11R.A056.07 0.77389102 0.865696602 
TCGA.BH.A0H0.01A.11R.A056.07 0.856510408 0.521369766 
TCGA.BH.A0DP.01A.21R.A056.07 0.586322673 0.703994412 
TCGA.AO.A0JL.01A.11R.A056.07 0.704061635 0.563899499 
TCGA.AO.A0JA.01A.11R.A056.07 0.714706387 0.626669889 
TCGA.BH.A0H7.01A.13R.A056.07 0.818635776 0.571610753 
TCGA.BH.A0E0.01A.11R.A056.07 0.786320427 0.780014391 
TCGA.BH.A0BJ.01A.11R.A056.07 0.618348343 0.657364819 
TCGA.A8.A0A6.01A.12R.A056.07 0.682629695 0.808363263 
TCGA.AO.A0JJ.01A.11R.A056.07 0.503623378 0.640057096 
TCGA.B6.A0IK.01A.12R.A056.07 0.833295992 0.414509316 
TCGA.BH.A0H6.01A.21R.A056.07 0.660629104 0.389997125 
TCGA.BH.A0DS.01A.11R.A056.07 0.445027982 0.314607081 
TCGA.BH.A0BA.01A.11R.A056.07 0.628517636 0.568043339 
TCGA.BH.A0B9.01A.11R.A056.07 0.837495767 0.603982933 
TCGA.AO.A03L.01A.41R.A056.07 0.771771339 0.558143271 
Supplementary Table 10: VPA Expression and methylation ASSIGN signatures 
prediction for TCGA using LIMMA selected 200 genes as training set. 
Column1 Column2 Column3 
TCGA.BH.A0HK.11A.11R.A089.07 0.001284271 0.177861276 
TCGA.BH.A0BM.11A.12R.A089.07 0.213552453 0.297027438 
TCGA.BH.A0B3.11B.21R.A089.07 0.005760424 0.199414062 
TCGA.BH.A0DK.11A.13R.A089.07 0.122790723 0.275537978 
TCGA.BH.A0BJ.11A.23R.A089.07 0.003073921 0.228714749 
TCGA.BH.A0DP.11A.12R.A089.07 0.022332927 0.241082695 
TCGA.BH.A0DQ.11A.12R.A089.07 0.100775075 0.305635501 
TCGA.BH.A0B8.11A.41R.A089.07 -0.0005942 -0.002998578 
TCGA.BH.A0C0.11A.21R.A089.07 0.015753195 0.244010022 
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TCGA.BH.A0BA.11A.22R.A089.07 0.091384779 0.141148947 
TCGA.BH.A0BC.11A.22R.A089.07 -0.00062563 -0.002588531 
TCGA.BH.A0DH.11A.31R.A089.07 -0.001695199 -0.002150998 
TCGA.BH.A0E1.11A.13R.A089.07 0.05037374 0.334592326 
TCGA.BH.A0H9.11A.22R.A089.07 0.033398861 0.006783576 
TCGA.A7.A0D9.11A.53R.A089.07 -0.006440307 -0.012001068 
TCGA.BH.A0H7.11A.13R.A089.07 0.019148548 0.266536221 
TCGA.BH.A0E0.11A.13R.A089.07 0.012481986 0.191929465 
TCGA.BH.A0C3.11A.23R.A12P.07 0.009392939 0.235751954 
TCGA.BH.A0BS.11A.11R.A12P.07 0.094841656 0.283189544 
TCGA.A7.A13E.11A.61R.A12P.07 -0.002183355 -0.00279748 
TCGA.BH.A0BZ.11A.61R.A12P.07 -0.000786117 -0.000731403 
TCGA.A7.A13F.11A.42R.A12P.07 -0.001330597 0.003086807 
TCGA.BH.A0AU.11A.11R.A12P.07 0.224665964 0.383914714 
TCGA.BH.A0DV.11A.22R.A12P.07 0.364598015 0.476444046 
TCGA.BH.A1F0.11B.23R.A137.07 -0.00087191 0.00082247 
TCGA.E2.A1BC.11A.32R.A12P.07 -0.0034703 -0.008094959 
TCGA.BH.A0HA.11A.31R.A12P.07 0.161998423 0.371101262 
TCGA.E2.A15I.11A.32R.A137.07 -0.005549262 -0.012494082 
TCGA.BH.A1EW.11B.33R.A137.07 -0.002205924 0.034731748 
TCGA.BH.A1EU.11A.23R.A137.07 0.00187594 0.130685593 
TCGA.BH.A1ET.11B.23R.A137.07 -0.00202301 0.007572001 
TCGA.BH.A1EO.11A.31R.A137.07 -0.005885485 -0.011696776 
TCGA.BH.A1EO.01A.11R.A137.07 0.065368128 0.383669803 
TCGA.BH.A1F0.01A.11R.A137.07 0.29415786 0.456874713 
TCGA.C8.A1HI.01A.11R.A137.07 0.308158738 0.675608513 
TCGA.BH.A1EV.01A.11R.A137.07 0.778686934 0.76430659 
TCGA.C8.A1HL.01A.11R.A137.07 0.649781808 0.828033771 
TCGA.BH.A1ET.01A.11R.A137.07 0.487822639 0.659531992 
TCGA.E2.A14N.01A.31R.A137.07 0.847486638 0.747414652 
TCGA.E2.A1B6.01A.31R.A12P.07 0.331787106 0.480084151 
TCGA.C8.A1HM.01A.12R.A137.07 0.694818039 0.872594761 
TCGA.E2.A15I.01A.21R.A137.07 0.471101543 0.634288736 
TCGA.C8.A1HN.01A.11R.A137.07 0.789870503 0.866997109 
TCGA.C8.A1HF.01A.11R.A137.07 0.696649454 0.729375711 
TCGA.BH.A1EW.01A.11R.A137.07 0.3474136 0.61044576 
TCGA.BH.A1EU.01A.11R.A137.07 0.020117186 0.35808825 
TCGA.AR.A1AR.01A.31R.A137.07 0.394295762 0.515505044 
TCGA.BH.A1ES.01A.11R.A137.07 0.682248681 0.812131434 
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TCGA.C8.A1HG.01A.11R.A137.07 0.657369515 0.753656183 
TCGA.BH.A0HA.01A.11R.A12P.07 0.23146016 0.524291838 
TCGA.BH.A0BT.01A.11R.A12P.07 0.800455222 0.781325489 
TCGA.AR.A1AW.01A.21R.A12P.07 0.725937622 0.845638239 
TCGA.AR.A1AN.01A.11R.A12P.07 0.271801038 0.501481666 
TCGA.E2.A1B5.01A.21R.A12P.07 0.688274318 0.740726555 
TCGA.BH.A0H3.01A.11R.A12P.07 0.660406247 0.754089101 
TCGA.BH.A0BS.01A.11R.A12P.07 0.758380931 0.77469838 
TCGA.AR.A1AV.01A.21R.A12P.07 0.241877775 0.565799513 
TCGA.AR.A1AL.01A.21R.A12P.07 0.186228256 0.486224653 
TCGA.E2.A1B4.01A.11R.A12P.07 0.677285489 0.708271519 
TCGA.BH.A0BF.01A.21R.A12P.07 0.401259411 0.664547423 
TCGA.AR.A1AU.01A.11R.A12P.07 0.301037073 0.49364552 
TCGA.AR.A1AK.01A.21R.A12P.07 0.230584151 0.553199565 
TCGA.E2.A1B1.01A.21R.A12P.07 0.251781766 0.512108202 
TCGA.BH.A0DI.01A.21R.A12P.07 0.365524392 0.575903308 
TCGA.BH.A0B5.01A.11R.A12P.07 0.45883153 0.632276282 
TCGA.AR.A1AT.01A.11R.A12P.07 0.720767115 0.813269175 
TCGA.AR.A1AJ.01A.21R.A12P.07 0.401837838 0.559663291 
TCGA.E2.A1BD.01A.11R.A12P.07 0.733400974 0.774097628 
TCGA.E2.A1B0.01A.11R.A12P.07 0.617419171 0.646896659 
TCGA.BH.A0DG.01A.21R.A12P.07 0.340860966 0.532902117 
TCGA.BH.A0AZ.01A.21R.A12P.07 0.452912561 0.670776504 
TCGA.AR.A1AS.01A.11R.A12P.07 0.954917435 0.988305155 
TCGA.AR.A1AI.01A.11R.A12P.07 0.871329633 0.891272538 
TCGA.E2.A1AZ.01A.11R.A12P.07 0.387510578 0.572295735 
TCGA.BH.A0DD.01A.31R.A12P.07 0.465917217 0.648137099 
TCGA.BH.A0AU.01A.11R.A12P.07 0.411474043 0.593182013 
TCGA.AR.A1AQ.01A.11R.A12P.07 0.725194032 0.771901279 
TCGA.A7.A13F.01A.11R.A12P.07 0.882477538 0.970253125 
TCGA.E2.A15K.01A.11R.A12P.07 0.552060106 0.674571316 
TCGA.BH.A0C3.01A.21R.A12P.07 0.010687105 0.317014377 
TCGA.AR.A1AY.01A.21R.A12P.07 0.695975999 0.709299424 
TCGA.AR.A1AP.01A.11R.A12P.07 0.480027144 0.660014888 
TCGA.A7.A13E.01A.11R.A12P.07 0.918672492 0.85564951 
TCGA.E2.A15K.06A.11R.A12P.07 0.952859386 0.990518207 
TCGA.E2.A1BC.01A.11R.A12P.07 0.30627562 0.467983528 
TCGA.E2.A15J.01A.11R.A12P.07 0.922588824 0.902061629 
TCGA.BH.A0BZ.01A.31R.A12P.07 0.733089211 0.943216756 
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TCGA.AR.A1AX.01A.11R.A12P.07 0.390678754 0.531100013 
TCGA.AR.A1AO.01A.11R.A12P.07 0.253047563 0.415593174 
TCGA.A7.A13D.01A.13R.A12P.07 0.922817673 0.836677295 
TCGA.A2.A0T2.01A.11R.A084.07 0.75119683 0.824384414 
TCGA.AO.A12B.01A.11R.A10J.07 0.797153813 0.79546023 
TCGA.E2.A10C.01A.21R.A10J.07 0.786508801 0.808037942 
TCGA.AN.A0XL.01A.11R.A10J.07 0.175045098 0.414014987 
TCGA.AO.A129.01A.21R.A10J.07 0.727010718 0.770399733 
TCGA.E2.A10B.01A.11R.A10J.07 
0.6719287720000
0000000 0.736867384 
TCGA.B6.A0X7.01A.11R.A10J.07 0.472882577 0.543995824 
TCGA.AO.A128.01A.11R.A10J.07 0.678443631 0.807757505 
TCGA.AO.A124.01A.11R.A10J.07 0.78571905 0.813275467 
TCGA.E2.A106.01A.11R.A10J.07 0.838870875 0.919593282 
TCGA.AO.A03U.01B.21R.A10J.07 0.456264268 0.556447737 
TCGA.AO.A12E.01A.11R.A10J.07 0.456688326 0.552630437 
TCGA.E2.A10F.01A.11R.A10J.07 0.471097452 0.665649363 
TCGA.E2.A105.01A.11R.A10J.07 0.783783703 0.895188978 
TCGA.AO.A03N.01B.11R.A10J.07 0.817176201 0.771988171 
TCGA.AO.A12C.01A.11R.A10J.07 0.520273524 0.724777364 
TCGA.E2.A10E.01A.21R.A10J.07 0.706691892 0.797405506 
TCGA.A2.A0YI.01A.31R.A10J.07 0.436302438 0.66835689 
TCGA.AO.A03M.01B.11R.A10J.07 0.683706742 0.810796002 
TCGA.E2.A109.01A.11R.A10J.07 0.773097213 0.879756528 
TCGA.AO.A126.01A.11R.A10J.07 0.614660438 0.671195199 
TCGA.E2.A108.01A.13R.A10J.07 0.043740493 0.280397853 
TCGA.AQ.A04L.01B.21R.A10J.07 0.865578215 0.762415709 
TCGA.AO.A125.01A.11R.A10J.07 0.951473863 0.962586905 
TCGA.E2.A107.01A.11R.A10J.07 0.673731055 0.797040696 
TCGA.AQ.A04H.01B.11R.A10J.07 0.579823662 0.809115125 
TCGA.AO.A12G.01A.11R.A10J.07 0.546372186 0.627772413 
TCGA.AR.A0U0.01A.11R.A109.07 0.921867396 0.897226956 
TCGA.A2.A0YH.01A.11R.A109.07 0.644447136 0.776713973 
TCGA.AN.A0XU.01A.11R.A109.07 0.848008268 0.801156733 
TCGA.B6.A0X4.01A.11R.A109.07 0.915038375 0.911088365 
TCGA.BH.A0WA.01A.11R.A109.07 0.750903879 0.737778075 
TCGA.AR.A0TU.01A.31R.A109.07 0.730362971 0.788930993 
TCGA.A2.A0YG.01A.21R.A109.07 0.745402005 0.908883403 
TCGA.AN.A0XT.01A.11R.A109.07 0.456110937 0.616966219 
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TCGA.B6.A0X1.01A.11R.A109.07 0.934050337 0.936075946 
TCGA.BH.A0W5.01A.11R.A109.07 0.352215168 0.528683567 
TCGA.A2.A04R.01A.41R.A109.07 0.729586511 0.827100254 
TCGA.AR.A0TP.01A.11R.A084.07 0.868141599 0.809283065 
TCGA.A2.A0SY.01A.31R.A084.07 0.252277314 0.508649709 
TCGA.A1.A0SM.01A.11R.A084.07 0.694852225 0.775908008 
TCGA.B6.A0RT.01A.21R.A084.07 0.368769673 0.601324135 
TCGA.BH.A0HP.01A.12R.A084.07 0.371957111 0.570641879 
TCGA.AR.A0TZ.01A.12R.A084.07 0.761141256 0.91123373 
TCGA.A2.A0T7.01A.21R.A084.07 0.402199423 0.644728803 
TCGA.A2.A0SX.01A.12R.A084.07 0.481191377 0.617503121 
TCGA.A1.A0SK.01A.12R.A084.07 0.942783006 0.85981999 
TCGA.B6.A0RS.01A.11R.A084.07 0.584921662 0.643134017 
TCGA.A2.A0T6.01A.11R.A084.07 0.080422375 0.340161859 
TCGA.A2.A0SW.01A.11R.A084.07 0.587328174 0.689215328 
TCGA.A1.A0SJ.01A.11R.A084.07 0.295145792 0.492048241 
TCGA.B6.A0RP.01A.21R.A084.07 0.578533415 0.67405347 
TCGA.AR.A0TW.01A.11R.A084.07 0.786530858 0.910270055 
TCGA.A2.A0T5.01A.21R.A084.07 0.630579408 0.69455725 
TCGA.A2.A0SV.01A.11R.A084.07 0.66819118 0.774889526 
TCGA.A1.A0SH.01A.11R.A084.07 0.504269223 0.63535049 
TCGA.A2.A0SU.01A.11R.A084.07 0.513992375 0.652552002 
TCGA.A1.A0SE.01A.11R.A084.07 0.461221127 0.651940289 
TCGA.AR.A0TX.01A.11R.A084.07 0.359167967 0.567342154 
TCGA.BH.A0HI.01A.11R.A084.07 0.647630396 0.724835669 
TCGA.B6.A0RO.01A.22R.A084.07 0.731447043 0.800679189 
TCGA.A2.A0EN.01A.13R.A084.07 0.262556128 0.450153343 
TCGA.AR.A0TV.01A.21R.A084.07 0.772531992 0.906447841 
TCGA.A2.A0T4.01A.31R.A084.07 0.092653401 0.390384981 
TCGA.B6.A0RN.01A.12R.A084.07 0.515655219 0.644813374 
TCGA.BH.A0DQ.01A.11R.A084.07 0.297740254 0.494544735 
TCGA.A2.A0T1.01A.21R.A084.07 0.494877428 0.618400456 
TCGA.A1.A0SP.01A.11R.A084.07 0.682187285 0.685958701 
TCGA.B6.A0RV.01A.11R.A084.07 0.351647916 0.569516394 
TCGA.B6.A0RL.01A.11R.A084.07 0.964130003 0.98948383 
TCGA.BH.A0BC.01A.22R.A084.07 0.462570822 0.645025026 
TCGA.AR.A0TQ.01A.11R.A084.07 0.448408422 0.70020797 
TCGA.A2.A0T0.01A.22R.A084.07 0.834240171 0.810894036 
TCGA.A1.A0SO.01A.22R.A084.07 0.850758288 0.858262017 
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TCGA.B6.A0RU.01A.11R.A084.07 0.410764675 0.483529895 
TCGA.AO.A0JG.01A.31R.A084.07 0.285011874 0.544877982 
TCGA.A8.A075.01A.11R.A084.07 0.855697836 0.812847224 
TCGA.A2.A0ST.01A.12R.A084.07 0.39725499 0.589245841 
TCGA.BH.A0RX.01A.21R.A084.07 0.518638374 0.586593406 
TCGA.B6.A0RM.01A.11R.A084.07 0.711429926 0.743508857 
TCGA.BH.A0DH.01A.11R.A084.07 0.681894578 0.764958361 
TCGA.AR.A0TR.01A.11R.A084.07 0.767054963 0.925735915 
TCGA.AO.A0JF.01A.11R.A056.07 0.016550046 0.345305167 
TCGA.BH.A0HX.01A.21R.A056.07 0.64009736 0.761838782 
TCGA.BH.A0GZ.01A.11R.A056.07 0.660024081 0.71373769 
TCGA.BH.A0DK.01A.21R.A056.07 0.282285727 0.583747009 
TCGA.BH.A0B8.01A.21R.A056.07 0.631931019 0.763432239 
TCGA.B6.A0RI.01A.11R.A056.07 0.762548427 0.796833695 
TCGA.AO.A0JE.01A.11R.A056.07 0.681917766 0.674642586 
TCGA.BH.A0HK.01A.11R.A056.07 0.373538196 0.534375068 
TCGA.BH.A0GY.01A.11R.A056.07 0.645766181 0.772745803 
TCGA.A7.A0D9.01A.31R.A056.07 0.563589558 0.733054427 
TCGA.BH.A0B3.01A.11R.A056.07 0.752190678 0.745922852 
TCGA.B6.A0RG.01A.11R.A056.07 0.845704684 0.962635889 
TCGA.AO.A0JD.01A.11R.A056.07 0.821210613 0.870278639 
TCGA.BH.A0HF.01A.11R.A056.07 0.398625662 0.55001884 
TCGA.A2.A0EU.01A.22R.A056.07 0.611637543 0.68967533 
TCGA.A2.A0CT.01A.31R.A056.07 0.665046668 0.790272288 
TCGA.B6.A0RE.01A.11R.A056.07 0.900990438 0.881400981 
TCGA.AO.A0JC.01A.11R.A056.07 0.229896793 0.517682442 
TCGA.BH.A0HB.01A.11R.A056.07 0.684820515 0.724372084 
TCGA.BH.A0E2.01A.11R.A056.07 0.66980905 0.779178204 
TCGA.BH.A0C0.01A.21R.A056.07 0.691625275 0.851300236 
TCGA.BH.A0AW.01A.11R.A056.07 0.660209908 0.764838687 
TCGA.AO.A0JM.01A.21R.A056.07 0.686106094 0.808992636 
TCGA.AO.A0JB.01A.11R.A056.07 0.757728516 0.74042582 
TCGA.BH.A0H9.01A.11R.A056.07 0.749195757 0.810507509 
TCGA.BH.A0E1.01A.11R.A056.07 0.632648846 0.785243407 
TCGA.BH.A0BM.01A.11R.A056.07 0.31119882 0.484327111 
TCGA.A8.A0AD.01A.11R.A056.07 0.760275929 0.743001833 
TCGA.A2.A0YF.01A.21R.A109.07 0.524446613 0.680844997 
TCGA.AN.A0XS.01A.22R.A109.07 0.470539207 0.57719717 
TCGA.B6.A0WZ.01A.11R.A109.07 0.773568485 0.849682089 
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TCGA.BH.A0W4.01A.11R.A109.07 0.421968884 0.513141034 
TCGA.A2.A0YT.01A.11R.A109.07 0.664018119 0.842818841 
TCGA.A2.A0YE.01A.11R.A109.07 0.86123673 0.798503303 
TCGA.AN.A0XR.01A.11R.A109.07 0.919224844 0.926826869 
TCGA.B6.A0WY.01A.11R.A109.07 0.556840618 0.684679418 
TCGA.BH.A0W3.01A.11R.A109.07 0.883418343 0.949989675 
TCGA.A2.A0YM.01A.11R.A109.07 0.875696101 0.764301728 
TCGA.A2.A0YD.01A.11R.A109.07 0.322818437 0.527672228 
TCGA.AN.A0XP.01A.11R.A109.07 0.839384095 0.890153476 
TCGA.B6.A0WX.01A.11R.A109.07 0.572092185 0.663657786 
TCGA.AR.A0U4.01A.11R.A109.07 0.803142647 0.711073297 
TCGA.A2.A0YL.01A.21R.A109.07 0.225102121 0.470823652 
TCGA.A2.A0YC.01A.11R.A109.07 0.55868395 0.688882145 
TCGA.AN.A0XO.01A.11R.A109.07 0.708115356 0.770012103 
TCGA.B6.A0WW.01A.11R.A109.07 0.825682205 0.915963511 
TCGA.AR.A0U3.01A.11R.A109.07 0.703316295 0.818654827 
TCGA.A2.A0YK.01A.22R.A109.07 0.047584318 0.373149663 
TCGA.AN.A0XW.01A.11R.A109.07 0.698004909 0.75577565 
TCGA.AN.A0XN.01A.21R.A109.07 0.646556232 0.683316164 
TCGA.B6.A0WV.01A.11R.A109.07 0.777848083 0.899373443 
TCGA.AR.A0U2.01A.11R.A109.07 0.808855454 0.918460454 
TCGA.A2.A0YJ.01A.11R.A109.07 0.970820473 0.956369104 
TCGA.AN.A0XV.01A.11R.A109.07 0.357579077 0.578511581 
TCGA.B6.A0X5.01A.21R.A109.07 0.861745135 0.877225386 
TCGA.B6.A0WT.01A.11R.A109.07 0.729976248 0.771277993 
TCGA.AR.A0TT.01A.31R.A084.07 0.54238151 0.692832288 
TCGA.A8.A08O.01A.21R.A056.07 0.409644408 0.6431514 
TCGA.AO.A0JI.01A.21R.A056.07 0.400537903 0.524159333 
TCGA.BH.A0HY.01A.11R.A056.07 0.781673984 0.774412431 
TCGA.BH.A0H0.01A.11R.A056.07 0.709505943 0.836738029 
TCGA.BH.A0DP.01A.21R.A056.07 0.464639482 0.588334196 
TCGA.AO.A0JL.01A.11R.A056.07 0.763250368 0.708357432 
TCGA.AO.A0JA.01A.11R.A056.07 0.479018696 0.717249027 
TCGA.BH.A0H7.01A.13R.A056.07 0.728396731 0.821382494 
TCGA.BH.A0E0.01A.11R.A056.07 0.720493166 0.828513839 
TCGA.BH.A0BJ.01A.11R.A056.07 0.319247063 0.631923018 
TCGA.A8.A0A6.01A.12R.A056.07 0.472615787 0.683345276 
TCGA.AO.A0JJ.01A.11R.A056.07 0.291926518 0.48911757 
TCGA.B6.A0IK.01A.12R.A056.07 0.835939948 0.832604874 
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TCGA.BH.A0H6.01A.21R.A056.07 0.711035608 0.660273683 
TCGA.BH.A0DS.01A.11R.A056.07 0.283711503 0.446412012 
TCGA.BH.A0BA.01A.11R.A056.07 0.476076638 0.620265578 
TCGA.BH.A0B9.01A.11R.A056.07 0.810637481 0.814189964 
TCGA.AO.A03L.01A.41R.A056.07 0.537312648 0.783774218 
Supplementary Table 11: VPA expression and methylation ASSIGN signatures 
generated using 40 negatively correlated topcor genes as training set. 
Category Term Genes p-value 
SP_PIR_KEYWORDS phosphoprotein 122 4.6E-09 
SP_PIR_KEYWORDS acetylation 57 0.000000052 
GOTERM_CC_FAT 
intracellular organelle 
lumen 39 0.000005 
SP_PIR_KEYWORDS nucleus 72 0.0000085 
GOTERM_CC_FAT organelle lumen 39 0.0000086 
GOTERM_CC_FAT membrane-enclosed lumen 39 0.000014 
GOTERM_CC_FAT nuclear lumen 33 0.000019 
SP_PIR_KEYWORDS cell cycle 16 0.00009 
SP_PIR_KEYWORDS Transcription 40 0.00014 
SP_PIR_KEYWORDS transcription regulation 38 0.00039 
UP_SEQ_FEATURE mutagenesis site 38 0.00052 
KEGG_PATHWAY Cell cycle 8 0.00089 
SP_PIR_KEYWORDS nucleotide-binding 32 0.0011 
SP_PIR_KEYWORDS transferase 28 0.0011 
GOTERM_BP_FAT transcription 41 0.0014 
Supplementary Table 12: Functional annotation categories for VPA expression ASSIGN 
signatures using the DAVID analysis 
Category Term Genes p-value 
GOTERM_CC_FAT intracellular organelle lumen 46 
0.00000005
1 
GOTERM_CC_FAT organelle lumen 46 0.0000001 
GOTERM_CC_FAT nuclear lumen 40 0.00000011 
GOTERM_CC_FAT membrane-enclosed lumen 46 0.00000018 
SP_PIR_KEYWORDS phosphoprotein 110 0.00000073 
SP_PIR_KEYWORDS acetylation 53 0.0000022 
SP_PIR_KEYWORDS nucleus 72 0.00001 
GOTERM_CC_FAT nucleolus 20 0.00028 
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PIR_SUPERFAMILY 
PIRSF002317:kinesin-like 
protein KIF3 3 0.00034 
KEGG_PATHWAY Prostate cancer 7 0.00039 
UP_SEQ_FEATURE region of interest:Globular 4 0.00046 
UP_SEQ_FEATURE 
short sequence motif:Nuclear 
localization signal 12 0.00062 
SP_PIR_KEYWORDS cytoplasm 54 0.00063 
SP_PIR_KEYWORDS cell cycle 14 0.0011 
GOTERM_BP_FAT cell cycle 19 0.0027 
GOTERM_BP_FAT response to organic substance 18 0.003 
GOTERM_CC_FAT nucleoplasm 20 
0.0044 
 
GOTERM_BP_FAT cell cycle process 15 0.0046 
GOTERM_BP_FAT 
response to endogenous 
stimulus 12 0.006 
GOTERM_BP_FAT cell cycle phase 12 0.0071 
GOTERM_BP_FAT response to hormone stimulus 11 0.0085 
SP_PIR_KEYWORDS chromosomal rearrangement 9 0.0087 
GOTERM_BP_FAT mitotic cell cycle 11 0.009 
UP_SEQ_FEATURE domain:Kinesin-motor 4 0.01 
GOTERM_CC_FAT 
non-membrane-bounded 
organelle 42 0.01 
GOTERM_CC_FAT 
intracellular non-membrane-
bounded organelle 42 0.01 
GOTERM_BP_FAT 
regulation of translational 
initiation 4 0.011 
UP_SEQ_FEATURE repeat:WD 5 8 0.011 
GOTERM_BP_FAT cellular response to stress 14 0.011 
INTERPRO Kinesin, motor region 4 0.011 
Supplementary Table 13: Functional annotation categories for TSA expression ASSIGN 
signatures using the DAVID analysis. 
Category Term Genes p-value 
SP_PIR_KEYWORDS phosphoprotein 124 4.4E-12 
GOTERM_CC_FAT intracellular organelle lumen 47 1.2E-09 
GOTERM_CC_FAT organelle lumen 47 2.6E-09 
GOTERM_CC_FAT nuclear lumen 41 3.7E-09 
GOTERM_CC_FAT membrane-enclosed lumen 47 
0.0000000
05 
SP_PIR_KEYWORDS nucleus 79 
0.0000000
48 
GOTERM_CC_FAT nucleolus 22 0.00001 
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SP_PIR_KEYWORDS acetylation 48 0.0001 
GOTERM_CC_FAT nucleoplasm 23 0.00011 
SP_PIR_KEYWORDS activator 17 0.00011 
SP_PIR_KEYWORDS Transcription 39 0.00032 
SP_PIR_KEYWORDS transferase 29 0.00055 
SP_PIR_KEYWORDS repressor 14 0.00062 
GOTERM_CC_FAT nucleoplasm part 16 0.00065 
GOTERM_CC_FAT 
non-membrane-bounded 
organelle 44 0.00072 
GOTERM_CC_FAT 
intracellular non-membrane-
bounded organelle 44 0.00072 
GOTERM_BP_FAT transcription 41 0.0012 
SP_PIR_KEYWORDS transcription regulation 36 0.0017 
GOTERM_CC_FAT mitochondrion 23 0.0018 
GOTERM_BP_FAT chromosome segregation 6 0.0027 
GOTERM_CC_FAT ribonucleoprotein complex 14 0.0027 
SP_PIR_KEYWORDS cell cycle 13 0.0032 
GOTERM_MF_FAT protein kinase activity 16 0.0032 
KEGG_PATHWAY Cell cycle 7 0.0042 
Supplementary Table 14: Functional annotation categories for SAHA expression 
ASSIGN signatures using the DAVID analysis. 
Basal VPA SAHA TSA Luminal VPA SAHA TSA 
HCC15
69 
0.78654
0664 
0.65919
7098 
0.53241
5588 
SUM52P
E 
0.55416
6664 
0.60805
658 
0.51734
9245 
HCC18
06 
0.63536
4926 
0.73304
3416 
0.88328
2005 T47D 
0.61665
7268 
0.43808
5628 
0.41621
0667 
HCC19
37 
0.55920
4644 
0.62028
7978 
0.85244
3502 
T47D.Kbl
uc 
0.44373
7847 
0.49828
1088 
0.60047
2279 
HCC19
54 
0.79832
9828 
0.78746
4452 
0.63849
0005 
UACC81
2 
0.44597
035 
0.08381
2105 
0.39812
0773 
HCC31
53 
0.87590
9098 
0.86375
6822 
0.64580
0222 ZR751 
0.68665
4976 
0.27755
074 
0.29567
1955 
HCC70 
0.76963
4675 
0.69352
5791 
0.47190
3536 ZR75B 
0.48561
38 
0.29364
2784 
0.47042
7488 
MX1 
0.48854
7298 
0.57652
8165 
0.85003
2766 
SUM225
CWN 
0.47819
1775 
0.03701
0883 
0.30307
91 
SUM14
9PT 
0.62389
729 
0.77819
7675 
0.91891
8411 SKBR3 
0.58534
986 
0.43402
5059 
0.40412
1566 
HCC11
43 
0.60992
7976 
0.73350
24 
0.88011
8232 
MDAMB3
61 
0.98018
9351 
0.58863
6709 
0.24599
37 
SUM22
9PE 
0.22685
2354 
0.44002
8677 
0.88209
4025 MCF7 
0.74851
0065 
0.37241
1297 
0.39172
9507 
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Supplementary Table 15: Multi-Drug Signature validation in ICBP Breast Cancer Cell 
line (subtypes) Drug Response Data for VPA, SAHA, and TSA 
 
DDX11L1 CELA2B KLHL21 PDPN TNFRSF14 
5S_rRNA CEP104 LINC00115 PER3 TNFRSF18 
AADACL3 CHD5 
LOC10012953
4 PEX10 TNFRSF1B 
AADACL4 CLCN6 
LOC10013041
7 PEX14 TNFRSF25 
ACAP3 CLCNKA 
LOC10013206
2 PGD TNFRSF4 
ACOT7 CLCNKB 
LOC10013333
1 PHF13 TNFRSF8 
ACTL8 CLSTN1 
LOC10013344
5 PIK3CD TNFRSF9 
ACTRT2 CORT 
LOC10013361
2 PLA2G2A TP73 
AGMAT CPSF3L 
LOC10028806
9 PLA2G2E TP73-AS1 
AGRN CROCC 
LOC10050673
0 PLA2G5 TPRG1L 
AGTRAP CROCCP2 LOC115110 PLCH2 TRNA_Asn 
AJAP1 CROCCP3 LOC148413 PLEKHG5 TRNA_Gly 
AK054708 CTNNBIP1 LOC254099 PLEKHM2 TRNA_Pseudo 
AK055853 CTRC LOC284661 PLEKHN1 TRNA_Val 
AK056486 DDI2 LOC388312 PLOD1 TTC34 
AK094692 DFFA LOC440563 PQLC2 TTLL10 
NA NA NA NA 
MDAMB1
34VI 
0.89059
3114 
0.54633
1601 
0.31119
1425 
Normal-
Like VPA8 SAHA9 TSA10 LY2 
0.45751
7462 
0.05304
1747 
0.68521
2345 
MCF10
A 
0.41040
1511 
0.14873
3037 
0.66509
1989 HCC1419 
0.91194
2493 
0.34337
5249 
0.12656
4952 
MCF10
F 
0.50463
938 
0.24569
6936 
0.37745
2694 HCC1428 
0.74491
1917 
0.30297
4078 
0.37195
1205 
MCF12
A 
0.18953
5328 
0.53368
2651 
0.18212
6999 AU565 
0.19272
848 
0.01669
4354 
0.53183
5407 
NA NA NA NA BT474 
0.95778
2858 
0.42494
9477 
0.23063
1795 
NA NA NA NA BT483 
0.87689
9239 
0.33059
6065 
0.29634
1002 
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AK097814 DFFB LOC643837 PRAMEF1 UBE2J2 
AK124197 DHRS3 LOC649330 PRAMEF10 UBE4B 
AK125078 DL489931 LOC728716 PRAMEF11 UBIAD1 
AK125437 DNAJC11 LOC729737 PRAMEF12 UBR4 
AK125737 DNAJC16 LRRC38 PRAMEF13 UQCRHL 
AK128833 DQ573015 LRRC47 PRAMEF16 UTS2 
AK310350 DQ575786 LZIC PRAMEF17 VAMP3 
AK310751 DQ576383 M37726 PRAMEF19 VPS13D 
AKR7A2 DQ597235 MAD2L2 PRAMEF2 VWA1 
AKR7A3 DQ599768 MASP2 PRAMEF20 WASH7P 
AKR7L DQ599872 MEGF6 PRAMEF22 WRAP73 
AL832937 DRAXIN Metazoa_SRP PRAMEF3 ZBTB17 
ALDH4A1 DVL1 MFAP2 PRAMEF4 ZBTB48 
ANGPTL7 EFHD2 MFN2 PRAMEF5 SZRD1 
ANKRD65 EMC1 MIB2 PRAMEF6 TARDBP 
APITD1 ENO1 MIIP PRAMEF8 TAS1R1 
APITD1-
CORT ENO1-AS1 MINOS1 PRAMEF9 TAS1R2 
ARHGEF10
L EPHA2 MINOS1-NBL1 PRDM16 TAS1R3 
ARHGEF16 ERRFI1 Mir_584 PRDM2 THAP3 
ARHGEF19 ESPN mir-34 PRKCZ TMCO4 
ATAD3A ESPNP MIR200A PTCHD2 TMEM201 
ATAD3B EXOSC10 MIR200B PUSL1 TMEM240 
ATAD3C FAM131C MIR34A RBP7 TMEM51 
ATP13A2 FAM132A MIR3675 RCC2 TMEM51-AS1 
AURKAIP1 FAM138F MIR4251 RER1 TMEM52 
AX747125 FAM213B MIR4252 RERE TMEM82 
AX747516 FAM41C MIR429 RNF186 TMEM88B 
AX747530 FBLIM1 MIR4417 RNF207 NPPA 
AX747631 FBXO2 MIR4632 RNF223 NPPA-AS1 
AX747755 FBXO42 MIR4689 RPL22 NPPB 
AX747988 FBXO44 MIR4695 RPS14P3 OR4F29 
AX748283 FBXO6 MIR551A RSC1A1 OR4F5 
B3GALT6 FHAD1 MMEL1 RSG1 OTUD3 
BC015342 FLJ00313 MMP23A SAMD11 PADI1 
BC018779 FLJ37453 MMP23B SCNN1D PADI2 
BC033949 FLJ42875 MORN1 SDF4 PADI3 
BC036251 GABRD MRPL20 SDHB PADI4 
BC036435 GLTPD1 MRTO4 SKI PADI6 
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BC037321 GNB1 MST1L SLC25A33 PANK4 
BC038541 GPR153 MST1P2 SLC25A34 PARK7 
BC070363 GPR157 MTHFR SLC2A5 PAX7 
BC113958 H6PD MTOR SLC2A7 IGSF21 
C1orf127 HES2 MTOR-AS1 SLC35E2 ISG15 
C1orf158 HES3 MXRA8 SLC35E2B JA429830 
C1orf159 HES4 NADK SLC45A1 JA429831 
C1orf167 HES5 NBL1 SMIM1 JA715134 
C1orf170 HNRNPCL1 NBPF1 SNORA59B JA715143 
C1orf174 HP08716 NECAP2 SPATA21 JB137814 
C1orf200 HSPB7 NMNAT1 SPEN KAZN 
C1orf211 HTR6 NOC2L SPSB1 KCNAB2 
C1orf222 ICMT NOL9 SRM KIAA1751 
C1orf233 IFFO2 NPHP4 SSU72 KIAA2013 
CDK11B C1orf64 CAMTA1 CCNL2 KIF1B 
CELA2A C1orf86 CAPZB CDC2L1 KLHDC7A 
 
Supplementary Table 16: 353 genes extracted from NIH roadmap epigenomics 
consortium across five tissues (with UPC > 0.5 for mRNA in atleast more than one 
tissue. 
 
	  	   152	  
Supplementary Table 17: Gene list with a variety of miRNA genes, uncategorized genes, 
and multiple genes from one family lost in transition from NIH Raodmap Epigenomics 
Consortium to Cell line perturbation experiment. 
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